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Abstract 
 
Myofibroblasts are recognised to play an important role in wound healing and the 
maintenance of tissue integrity. In addition, they are increasingly recognised to 
provide a supporting microenvironment for cancer cells. They secrete a variety of 
chemokines, cytokines, growth factors and proteases that collectively regulate cell 
proliferation, migration and invasion. Specific chemokines are known to recruit 
mesenchymal stromal cells (MSCs) to both tumours and normal tissue which may 
then give rise to myofibroblasts. Proteomic studies by Holmberg and Varro 
(unpublished observations) identified chemerin as an upregulated chemokine in 
conditioned media (CM) from oesophageal cancer associated myofibroblasts 
(CAMs) compared to adjacent tissue myofibroblasts (ATMs). Chemerin is potent 
chemo-attractant for immune and inflammatory cells. The objectives of this thesis 
were (a) to functionally characterise the oesophageal myofibroblasts,(b) validate 
the findings of previous proteomic studies and (c) determine  the role of chemerin 
in MSC migration. 
Oesophageal CAMs from both squamous and adenocarcinoma tumours were 
shown to be more proliferative than their paired ATMs, or normal tissue 
myofibroblasts (NTMs). In addition, CAM conditioned media increased the 
proliferation and migration of two oesophageal cancer cell lines (OE21 and OE33) 
and stimulated MSC migration compared to ATM CM.  The data suggest 
oesophageal CAMs promote an aggressive tumour microenvironment. 
Western blotting and ELISA confirmed increased chemerin secretion by squamous 
carcinoma CAMs. Chemerin and conditioned media from squamous carcinoma 
CAMs, stimulated MSC and OE21 cell migration; Chemerin neutralizing antibody 
reversed these effects and siRNA knockdown of chemerin in CAMs, or of its 
cognate receptor ChemR23 in MSCs, decreased migratory responses. Studies 
xviii 
 
using pharmacological inhibitors or Western blot of cellular proteins indicated that 
chemerin stimulated MSCs via PKC, and p42/44, p38 MAP and JNK kinases.  
Macrophage Inhibitory Factor (MIF) was identified as a putative chemerin target in 
MSCs and validated by ELISA and Western blot of MSC media and cell extracts. 
MIF inhibited MSC migration in response to low or moderate concentrations of 
chemerin, indicating that it might restrain MSC migration in normal tissues but not 
in cancers where chemerin is elevated. 
Finally, confirmation of chemerin-chemR23 interactions was obtained using a 
chemR23 antagonist, CCX832. Chemerin induced MSC and OE21 cell migration 
was inhibited by CCX832. Moreover, transendothelial migration of MSCs in 
response to chemerin or CAM conditioned media was reversed by CCX832. 
Transendothelial migration was also shown to depend on chemerin-stimulated 
MMP-2 secretion. These findings indicate a molecular mechanism by which MSCs 
are recruited to tumours.  
Taken as a whole, this work indicates that myofibroblasts derived from 
oesophageal cancers differ from those in adjacent or normal tissue. The finding of 
increased chemerin in these cells is novel and may be relevant to MSC 
recruitment. Since it is possible to inhibit the effects of chemerin on MSCs using 
CCX832, there is the potential for a novel therapeutic approach to prevent cancer 
progression. 
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Introduction
Introduction 
 
2 
 
1.1 Overview 
In multicellular organisms there are evolutionary advantages conferred by the 
differentiation of cells into different types with specialised functions. Coordinated 
cell-cell interactions then become vital in maintaining the organisation and 
function of tissues containing multiple cells types, both in development and in 
tissue repair. In the gastrointestinal tract, for example, interactions between 
epithelial cells and stromal cells control cell proliferation, differentiation and 
apoptosis. These interactions are disrupted in a variety of diseases including 
inflammatory conditions and, most strikingly, in cancer. Since inflammation is 
recognised as a driver of cancer progression (Balkwill and Mantovani 2001) there 
has been a growing appreciation of the role that cellular microenvironments play 
in carcinogenesis. In particular work by several groups over the last decades has 
led to the idea of a specific niche that determines the fate of mutated cancer cells 
(Bissell, Radisky et al. 2002) and is one of the  hallmarks of cancer (Hanahan and 
Weinberg 2011) as well as being a potential target for therapy (Hainaut and 
Plymoth 2013).  
Amongst the various cells contributing to the tumour niche, myofibroblasts have 
been highlighted by many studies. These cells normally play an important role in 
the maintenance of tissue architecture and wound healing (Roland 1976; 
Tomasek, Gabbiani et al. 2002; Radisky, Kenny et al. 2007; Klingberg, Hinz et al. 
2013). They are a rich source of growth factors, cytokines, chemokines, 
extracellular matrix (ECM) proteins, proteases and their inhibitors (Powell, Mifflin 
et al. 1999a). Disrupted autocrine and paracrine signalling by myofibroblasts 
influences cancer cell proliferation, metastasis, infiltration of immune cells and 
recruitment of mesenchymal stromal cells (MSCs) (Powell, Mifflin et al. 1999a; 
Direkze, Hodivala-Dilke et al. 2004). The latter are of interest because they are 
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thought to be myofibroblast progenitors and as well as potentially exerting other 
effects that determine tumour progression (Klopp, Gupta et al. 2011). 
In spite of recent progress, the functional role of myofibroblasts in many cancers, 
including those of the oesophagus, is not well understood. In this thesis, the 
overall aim was to investigate novel signalling pathways that are altered in 
cancer-derived myofibroblasts and their influence on other cell types including 
cancer cells and the recruitment of MSCs. 
  
1.2 The Organisation of the Gastrointestinal Tract 
1.2.1 The basic pattern of organisation 
The wall of the gastrointestinal tract is divided into layers: i) there is an outer 
muscle layer and ii) within this a mucosal layer consisting of epithelial cells that 
continuously line the luminal surface and an underlying stromal layer, the lamina 
propria consisting of blood vessels, ECM, lymphatics, inflammatory and immune 
cells, fibroblasts and myofibroblasts (Wu, Jackson et al. 1999). One of the ECM 
components, basement membrane, provides the anchorage for epithelial cells. 
Between these two layers, there is a submucosal layer of connective tissue 
(Streuli, Bailey et al. 1991). Nerve plexuses are found between the circular and 
longitudinal muscle (myenteric plexus) and in the submucosa (submucosal 
plexus). There are marked differences in mucosal organisation in different regions 
of the gut; the present studies focus on the upper gastrointestinal tract. 
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1.2.2 Oesophagus 
The mucosal organisation of the oesophagus is relatively simple compared with 
many other regions of the gut. In particular, the lining consists of squamous type 
stratified epithelial cells that lack absorptive and secretory functions. The 
oesophageal submucosa includes seromucous glands. This pattern of 
organisation is changed dramatically in preneoplastic conditions e.g. Barrett’s 
oesophagus.  
 
1.2.3 Stomach  
In the stomach, the epithelium is folded into gastric glands that are of two main 
types: in the body of stomach there are corpus or acid-secreting gastric glands 
while distally there are pyloric antral glands that do not release acid but do 
contain G-cells releasing the hormone gastrin.  Mucus-secreting surface epithelial 
cells that have a protective role are found in both cases, as are pepsinogen-
secreting chief cells. Acid is released by parietal cells in corpus glands in 
response to histamine secreted by enterochromaffin-like (ECL) cells. The latter 
are stimulated by gastrin released from antral G-cells.  Other endocrine cells 
include D-cells producing somatostatin in both regions of the stomach, and X-
cells producing ghrelin in the corpus. 
 
The maintenance of glandular organisation is achieved by cellular proliferation 
and differentiation, and the migration of differentiating cells to their final 
destination. In the corpus, proliferating cells occur in the isthmus region that also 
includes pluripotent gastric stem cells (Figure 1.1). The precursor cells exhibit bi-
directional movement from this region towards the surface or towards the base of 
the glands (Barker, Huch et al. 2010). Cells moving up to the pit region 
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differentiate into mucus-secreting cells, whereas cells migrating in the opposite 
direction differentiate into pepsinogen cells, parietal cells, or endocrine cells 
(Yang, Tsuyama et al. 1997; Karam 1999). Epithelial cell populations survive for 
varying periods of time: mucus cells are reproduced every 2-6 days compared 
with >3 weeks for parietal and chief cells (Karam 1993; Kirton, Wang et al. 2002). 
There is a tight network of myofibroblasts around the gastric glands that are 
thought to determine organisation and function of the epithelial cells. 
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Figure.1.1     Gastric gland cell organisations. 
Diagrammatic representation of different cell types: proliferating cells, mucous neck 
cells, parietal cells, ECL cells and chief cells. The bi- directional migration of cells 
leaving the cell-cycle occurs from isthmus region to gastric pits and to the fundus 
region generating the differentiated cell types. 
 
 
1.3 Tissue Remodelling and Repair 
The events that characterise wound healing in the gut include (a) restitution and 
haemostasis after tissue damage, (b) inflammation, (c) neo-vascularisation and 
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re-epithelisation and (d) resolution or tissue remodelling (Shaw and Martin 2009).  
In some tissues e.g. liver and pancreas there are stellate cells which resemble 
myofibroblasts but in general myofibroblasts are sparse in healthy tissue (Omary, 
Lugea et al. 2007). In the gastrointestinal tract, however, myofibroblasts are 
normally relatively abundant and their numbers increase still further in wound 
healing. 
 
1.3.1 Restitution and Haemostasis: Blood Platelets and Fibrin   
Restitution is an epithelial migratory response to superficial damage in the gut by 
which a protective layer of epithelial cells forms over exposed basement 
membrane. This is characterised by initial epithelial cell migration about 30 
minutes after tissue damage and does not involve proliferation (Lacy and Ito 
1984).  The initial step in healing upon more substantial damage is formation of a 
blood clot and platelet aggregation. In conjunction with blood clotting factors, 
anaphylatoxin, C3a and C5a in the matrix (Ghebrehiwet, Silverberg et al. 1981) 
aggregate platelets  on fibrin  (Clark 2001). In damaged tissue, fibrin forms a 
provisional ECM (Clark, Lanigan et al. 1982; Clark 2001) that embeds platelets 
which are an early source of growth factors and chemokines e.g. platelet derived 
growth factor (PDGF) and monocyte chemotactic protein-1 (MCP-1) required to 
further drive coordinated wound healing (Gawaz, Neumann et al. 1998; Kim, 
Gittes et al. 1998). 
 
1.3.2 Inflammation: Infiltration of inflammatory cells 
Inflammatory cells/leucocytes including macrophages, neutrophils, natural killer 
cells and eosinophils circulate in largely undifferentiated forms that are recruited 
to damaged tissue. The release of anaphylatoxins and histamine from mast cells 
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act as vasodilators (Fernandez, Henson et al. 1978). This facilitates successful 
infiltration of inflammatory cells in response to growth factors such as PDGF and 
MCP-1 (Deuel, Senior et al. 1982; Gross, Leavell et al. 1997; Gawaz, Neumann 
et al. 1998). The first to migrate into wounds are neutrophils which release matrix 
degrading enzymes such as collagenase (matrix metalloproteinase-8, MMP-8) 
(Nwomeh, Liang et al. 1999; Dovi, Szpaderska et al. 2004) and shield against 
further infection as well as removing dead cells via phagocytosis. 
 
Monocytes infiltrate the tissue microenvironment and differentiate into 
macrophages in response to TGF-β (Turley, Falk et al. 1996). Resident 
macrophages act as anti-inflammatory agents by phagocytosing microbes and 
secreting IL-10 (Monteleone, Platt et al. 2008). The modification of ECM by 
macrophage-secreted proteins including MMPs and plasmin also provokes the 
activation and release of ECM-stored angiogenic factors e.g. vascular endothelial 
growth factor (VEGF), PDGF and TGF- β (Cordon-Cardo, Vlodavsky et al. 1990).  
 
1.3.3 Proliferation: Vascularisation and Re-epithelialisation 
1.3.3.1 Vascularisation  
Neoangiogenesis is required to meet the oxygen requirements of healing tissues. 
Oxygen stress induces the transcription factor, hypoxia inducible factor (HIF) in 
endothelial cells which enhances the expression of VEGF (Gerber, Condorelli et 
al. 1997). Fibroblast growth factor (FGF) (Gospodarowicz, Bialecki et al. 1978) 
and endothelial cell growth factors (ECGF) (Maciag, Cerundolo et al. 1979) also 
increase the proliferation of endothelial cells. In addition, other growth factors e.g. 
FGF-2, insulin growth factor (IGF)-I and IGF-II also support neoangiogenesis 
(Chang, Garcia-Cardena et al. 2004; Bjorndahl, Cao et al. 2005). Increased 
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endothelial cell proliferation is followed by initiation of collagen deposition 
(Prockop, Kivirikko et al. 1979). 
 
1.3.3.2 Re-epithelialisation 
Re-epithelisation is the process of epithelial cell proliferation and migration in 
damaged tissue. In gastric inflammation, macrophage or platelet derived TGF-β 
stimulates interleukin-1β (IL-1β), interferon-γ (IFN- γ) and EGF expression which 
promote epithelial cell proliferation (Dignass and Podolsky 1993). The increased 
expression of integrin (Gailit, Welch et al. 1994) and IGF-I, EGF and FGF 
facilitates cell adhesion and pro-migratory roles in re-epithelialisation (Giancotti 
and Ruoslahti 1999; Eslami, Gallant-Behm et al. 2009).  
 
1.3.4 Matrix Deposition and Tissue Remodelling  
The concluding event in wound healing involves scar maturation and crosslinking 
of collagen fibrils. Simultaneously, there is removal of blood clots, inhibition of 
platelet driven signalling events and remodelling of tissue architecture.  
 
1.3.4.1 Fibroblasts 
In the final stages, mechanical force is required for closure of wounds and matrix 
deposition. The vital cell types in this process are derived from fibroblast lineages. 
Fibroblasts are activated in response to TGF- to become “activated fibroblasts” 
also called myofibroblasts. The expression of α-smooth muscle actin (α-SMA) and 
other actin filaments in myofibroblasts provides the capacity for contractile tension 
for wound closure (Hinz 2007). These cells are also an important source of ECM 
proteins e.g. collagens. In addition, they secrete proteases such as MMPs to 
maintain a balance in ECM deposition and degradation (Hinz 2007).  
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1.3.4.2 ECM Proteins 
The adhesion of infiltrated cells occurs via integrin receptors and interactions with 
fibronectin, collagen, vitronectin or other ECM molecules (Schwartz, Schaller et 
al. 1995). Adhesion, migration and proliferation are mediated by increased 
expression of integrin and fibronectin in tissue repair (George, Georges-
Labouesse et al. 1993; Wijelath, Murray et al. 2002). In tissue remodelling all 
types of collagen contribute to tissue strength and elasticity. The intestinal 
submucosa demands elasticity and is predominantly constituted of Type III and V 
collagen (Graham, Diegelmann et al. 1988).  However, fibrous collagens, type I 
and type IV, are the primary structural unit in ECM and basement membrane, 
respectively, of all tissues (Timpl, Wiedemann et al. 1981; Prockop and Kivirikko 
1995). Other vital players in the ECM are glycosaminoglycans (GAG) e.g. 
hyaluronan (Chen and Abatangelo 1999; Trabucchi, Pallotta et al. 2002). In 
addition, other GAG molecules e.g. heparin sulphate regulates cell proliferation 
and angiogenesis (Andres, DeFalcis et al. 1992; Iozzo 1998). Proteolytic 
cleavage of sydencan, laminin and elastin releases bioactive fragments known as 
matrikines (Maquart, Bellon et al. 2005). They are equally important in 
proliferation, adhesion and signalling in completion of  wound repair (Adair-Kirk 
and Senior 2008). 
 
1.3.5 Failure in Tissue Remodelling and Repair 
Failure of the normal wound healing processes to restore tissue architecture may 
lead to the development of conditions such as fibrosis and chronic inflammation.  
1.3.5.1 Fibrosis 
Fibrosis is the result of excessive deposition of ECM proteins often with loss of 
some resident cell types, but increased numbers of myofibroblasts and related 
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cells. Early in wound healing, fibrin and other scar matrix proteins provide a 
favourable scaffold for adhesion, migration and proliferation of cells. However, 
subsequent inefficient removal of fibrin, and further matrix protein deposition, 
leads to fibrosis (Olman, Mackman et al. 1995). The role of plasminogen activator 
inhibitor-1 (PAI-1), for example, is well studied in this case. Thus PAI-1 is an 
inhibitor of tissue plasminogen activator (tPA) and urokinase-type plasminogen 
activator (uPA). Plasmin abundance is regulated by uPA which determines the 
degradation of fibrin and ECM proteins; these enzymes also play a role in 
activating MMPs (Madlener, Parks et al. 1998). The mouse bleomycin induced-
lung fibrosis model illustrates some of the relevant issues: in bleomycin-treated 
mice there is upregulation of TGF-β and procollagen I and III (Gurujeyalakshmi 
and Giri 1995); TGF-β enhances PAI-1 expression (Kutz, Hordines et al. 2001; 
Vayalil, Olman et al. 2005) and PAI-1 in turn contributes to pulmonary fibrosis by 
inhibiting proteases that degrade ECM proteins (Olman, Mackman et al. 1995). 
Similar evidence is available for other systems including liver and kidney fibrosis, 
but less is understood of the stomach. Even so, however, there is evidence of 
increased PAI-1 in epithelial cells in conditions associated with atrophy e.g 
H.pylori infection (Kenny, Duval et al. 2008). Interestingly, in some clinical 
situations fibrosis might develop from cancer cell-secreted growth factors. For 
example, the fibrosis of the peritoneum in scirrhous gastric cancer (Yashiro, 
Chung et al. 1996) is characterised by extensive growth of fibroblasts possibly 
due to TGF-β1 secretion from scirrhous gastric cancer cells (Mahara, Kato et al. 
1994).  
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1.3.5.2 Chronic Inflammation 
One characteristic of chronic inflammation is the continuous reiteration of 
inflammation steps in wound healing. An excess of cytokines and MMP’s due to 
continuous infiltration of inflammatory cells causes increased degradation of ECM 
(Wysocki, Staiano-Coico et al. 1993; Widgerow 2011). Proteases also cleave 
laminin and elastin triggering further inflammatory responses (Adair-Kirk and 
Senior 2008; He, Turino et al. 2010). These phenomena cause repetition of repair 
events (Adair-Kirk and Senior 2008; He, Turino et al. 2010) resulting in deformed 
tissue architecture, a loose bed of ECM proteins, damaged basement membrane 
and infiltrated macrophages and fibroblasts or resident activated myofibroblasts. 
Chronic inflammation leads to a state in which wounds never heal and 
predisposes to cancer (Figure 1.2). 
 
1.4 Chronic inflammation in the gastrointestinal tract 
The gastrointestinal tract is normally exposed to many different potentially 
damaging agents including acid, ingested toxins, resident and ingested 
microbiota. In the upper gastrointestinal tract, failure of the normal protective 
mechanisms is a feature of several common conditions including pathology 
associated with gastric infection with H.pylori, and reflux of gastroduodenal 
contents into the oesophagus. In both cases chronic inflammation is associated 
with increased risk of cancer. 
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Figure 1.2     Changes in tissue intergrity and microenvironment components. 
Schematic representation of changes in epithelial cell organisation and cellular 
microenvironments A. in normal tissue, B. inflammed and C. in cancer. The loss of 
basement memebrane and increased stromal cell population, particulary 
myofibroblasts, contributes to the development of cancer on a background on chronic 
inflammation. 
 
 
1.4.1 Chronic Inflammation and Gastric cancer 
H.pylori infection is associated with chronic gastritis (Fox and Wang 2007). The 
cascade of events initiated by H. pylori in the stomach triggers immune responses 
involving secretion of cytokines and chemokines (Bodger and Crabtree 1998). 
Subsequently infiltration of neutrophils and monocytes enhances the secretion of 
proinflammatory cytokines like TNF-α and chemokines from epithelial cells 
(Bodger and Crabtree 1998). In some patients this leads to chronic inflammation 
that is associated with a sequence of pre-neoplastic changes including atrophy, 
metaplasia and dysplasia (Correa, Piazuelo et al. 2010). In other patients there is 
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an increased risk of duodenal ulcer (McColl 2012). It seems that antrum-
predominant infection leads to increased acid secretion by parietal cells which are 
associated with duodenal ulcer. In contrast, infection in the antrum and the corpus 
is associated with development of the pre-neoplastic progression leading to 
gastric cancer (Fox and Wang 2007). There is also some evidence of increased 
fibrosis in atrophy (Truong, Farhood et al. 1992; Kang, Hughes et al. 2001).  
 
1.4.2 Barrett’s oesophagus  
Barrett’s oesophagus results from persistent gastro-oesophageal reflux (GORD) 
by which the oesophagus is continuously exposed to gastric acid and bile salts 
(Souza, Krishnan et al. 2008). The resulting chronic inflammation can lead in 
some patients to a transition from squamous to columnar epithelia characterised 
by the presence of increased goblet cells i.e. intestinal metaplasia, and known as 
Barrett’s oesophagus (Naef, Savary et al. 1975; Nicholson, Graham et al. 2012). 
The condition is important because it may lead to oesophageal adenocarcinoma 
(AC). Interestingly, infection of the gastric corpus with H. pylori may decrease acid 
secretion and mitigate the effects of gastric acid reflux thereby decreasing the risk 
for developing Barrett’s oesophagus (Chow, Blaser et al. 1998).  
 
1.4.3 Oesophagitis and Oesophageal Squamous Cell Carcinoma 
Other states of oesophageal inflammation are recognised including excess 
eosinophil infiltration. Eosinophil oesophagitis is defined as an increase in 
eosinophils ( >20 /high power field) (Rothenberg, Mishra et al. 2001) in the mid 
and upper oesophagus (Noffsinger 2009). The condition may progress to involve 
basal cell hyperplasia (BCH), with >15% epithelial thickness and extended lamina 
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propria papillae, leading to squamous dysplasia and squamous carcinoma of the 
oesophagus (Wang, Abnet et al. 2005). 
 
1.5 Cancer  
Modern theories of oncogenesis are based on observations that go back well over 
a century. The “Tissue Organisation Field Theory” (TOFT) of cancer development 
(Soto and Sonnenschein 2011) originated with Franz Boll in 1876 who considered 
cancer to be a self-sustaining entity with enhanced cellular proliferation (Garrison 
1926). The concept of “false embryo” was put forward by Thiersch, Cohnheim in 
1876, i.e. displaced embryonic rest, by which a portion of undifferentiated 
embryonic cells in adult tissue initiate cancer; this was later also called the theory 
of “displaced embryonic cell in space and time” (Garrison 1926).  Modern ideas 
are based on the observation of genetic and somatic mutations in epithelial cells 
determining the cancer phenotype (Knudson 2001).  
 
Over the last decade or so, however, it has become clear that genetic changes in 
cancer cells do not, alone, account for cancer progression. Instead there are 
important tumour-promoting changes in the microenvironment. The term niche is 
sometimes used to define the combination of stromal cells such as myofibroblasts 
and ECM proteins that together interact with cancer cells to provide the conditions 
for tumour growth (Hanahan and Weinberg 2000; Coussens and Werb 2002; 
Hanahan and Weinberg 2011).  
 
1.5.1 Cancer Niche 
The idea of a cancer-promoting microenvironment is an extension of an old 
question which is “why do certain organs support cancer metastasis?” i.e. provide 
an appropriate microenvironment that nurtures cancer cells. The question was 
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posed by Stephen Paget in 1889, who suggested the “seed (cancer) and soil 
(microenvironment)” theory of cancer progression. Later, the idea of a cancer- 
specialised niche emerged that sustains mutated epithelial cell capacities for 
tumorigenicity (Weaver, Fischer et al. 1996; Bissell 2007). 
 
The cancer niche depends on stromal cells that include resident and inwardly 
migrating non-malignant cells. The non-malignant cells can be from local or 
healthy neighbouring tissue, e.g. myofibroblasts, or can migrate in from distant 
source e.g. MSCs and inflammatory cells (Wels, Kaplan et al. 2008). A reactive 
stroma encourages tumour growth through multiple mechanisms. For instance, 
extensive neo-vascularisation results from enhanced endothelial cell proliferation. 
In such cases upregulation of MT1-MMP and VEGF in stromal cells have been 
identified (Sounni, Janssen et al. 2003). In addition, vascularisation facilitates 
metastasis, i.e. cancer cell migration and invasion of other tissues. Abnormal 
basement membrane facilitates the motility of cancer cells in solid tumours of the 
gut (Ozzello 1959; Li, Chen et al. 2001). This includes basement membrane 
degradation and imbalances between collagen deposition, hyaluoran GAGs, 
laminin, vitronectin and fibronectin (Noble, McKee et al. 1996; Kalluri 2003).  
 
However, in addition to interactions with ECM proteins, various stromal cells in 
the niche determine cancer cell proliferation, survival and metastatic properties 
(Weaver, Petersen et al. 1997). Stromal cells progressively increase in cancer 
either by inward migration or transdifferentiation from other cells as well as by 
proliferation. For example, in response to signalling molecules such as TGF-β, 
fibroblasts and infiltrated monocytes differentiate to myofibroblasts and 
macrophages, respectively (Roberts and Sporn 1993). In addition, recruitment of 
bone marrow derived MSCs to tumour sites is increasingly recognised (Kidd, 
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Spaeth et al. 2009). These pluripotent cells infiltrate in response to multiple 
signalling molecules including chemokines, VEGF and IL-10 (Serafini, Borrello et 
al. 2006); they may differentiate into various stromal cells including myofibroblasts 
(Spaeth, Dembinski et al. 2009; Quante, Tu et al. 2011). In addition they have 
their own signalling systems that influence the microenvironment and cancer cell 
function (Whiteside 2008). 
 
1.6 Myofibroblasts  
Myofibroblasts are activated fibroblasts; they are dynamic, spindle-like cells 
sharing the functional characteristics of both fibrocytes and smooth muscle cells 
(Hinz, Phan et al. 2007). They are rare in most tissues, but in the gastrointestinal 
tract they are relatively abundant where they are localized in a subepithelial 
compartment (in the lamina propria mucosae). Myofibroblasts express alpha-
smooth muscle actin (α-SMA) and vimentin, which are specific histopathological 
markers of these cells. A variety of different origins of these cells has been 
discussed (Figure. 1.3), including (a) rapid stimulation of local fibroblasts to 
differentiate into myofibroblasts (Serini, Bochaton-Piallat et al. 1998), (b) epithelial 
cell transdifferentiation into myofibroblasts via epithelial mesenchymal transition 
(EMT) (Radisky, Kenny et al. 2007), (c) local or bone-marrow-derived 
mesenchymal stem cells transformation into myofibroblasts (Spaeth, Dembinski 
et al. 2009; Quante, Tu et al. 2011). 
The dynamic secretory profile of myofibroblasts includes growth factors, MMPs, 
and tissue inhibitor of metalloproteinase (TIMPs) that regulate tissue remodelling 
and influence cancer progression (Figure 1.3).  In case of H. pylori gastritis, 
gastric epithelial cells secrete matrix metalloproteinase-7 which cleaves insulin-
like growth factor binding protein-5 (IGFBP-5) secreted by myofibroblasts leading 
Introduction 
 
17 
 
to release of IGF-II which stimulates both epithelial and myofibroblast proliferation 
(McCaig, Duval et al. 2006).  In breast cancer, stromal derived factor-1 (SDF-1), 
HIF-1 and VEGF are highly expressed by CAMs and promote cancer cell 
proliferation and angiogenesis (Orimo, Tomioka et al. 2001; Orimo, Gupta et al. 
2005).  The profound effect of CAMs can be shown in xenografts where they 
increase tumour growth when co-injected with cancer cells compared to cancer 
cell alone (Gleave, Hsieh et al. 1991; Quante, Tu et al. 2011; Holmberg, Quante 
et al. 2012). 
 
1.6.1 Myofibroblasts Associated With Cancers 
Fibroblasts residing in the cancer niche are known as peritumoural fibroblasts. 
Their activated forms express α-SMA, vimentin, P4H and are negative for 
cytokeratin; they are designated “cancer associated myofibroblasts” (CAMs) (De 
Wever and Mareel 2003). Differences in gene expression (Boussioutas, Li et al. 
2003; Farmer, Bonnefoi et al. 2009) and changes at the epigenetic level have 
been detected in CAMs from gastric cancer compared with myofibroblasts derived 
from normal tissues (Jiang, Gonda et al. 2008). The differential expression of 
genes is not only involved in classifying myofibroblast associated with tumour 
tissue (CAMs/CAFs) or non-tumour/normal tissue (NTMs) but also, relates to 
various cellular functions such as cancer cell proliferation, migration and invasion 
(Bhowmick, Neilson et al. 2004; Singer, Gschwantler-Kaulich et al. 2008; Grugan, 
Miller et al. 2010). It has been demonstrated that CAMs exhibit increased 
migration and/ or proliferation compared to myofibroblasts from non-cancerous 
stroma (Schor, Schor et al. 1988; Holmberg, Quante et al. 2012).   
Tumour myofibroblasts have been shown to have decreased sensitivity to 
chemotherapy at least partly due to CpG DNA hypermethylation and reduced 
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expression of caspase and STAT-1 resulting in escape from apoptosis of cancer 
cells (Muerkoster, Werbing et al. 2008). 
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Bone marrow derived
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Figure 1.3 Myofibroblasts: single cell with multiple, origins and functional roles. 
Schematic representation of origin of myofibroblasts from multiple progenitors 
(fibroblasts, mesenchymal stromal cells orepithelial cells). Myofibroblasts secrete 
various growth factors e.g. EGF, IGF, HGF; chemokines e.g. CXCL12, TGF-β; 
preoteases, MMPs; and protease inhibitors, TIMPs that regulate cell proliferation, 
migration, and infiltration of immune cells and stromal cells, e.g. MSCs, cell 
differentiation, as well as  ECM remodelling.  
 
1.6.2 Myofibroblast Secretomes in Cancer  
Differential secretome analysis has suggested upregulated stromal-derived factor-
1α and Rantes in CAFs associated with colon cancer compared to bone marrow 
derived MSCs (De Boeck, Hendrix et al. 2013).  Moreover secretome analysis of 
CAMs in gastric cancer compared to ATMs showed decreased transforming 
growth factor-β-induced gene-h3 (TGFβig-h3) in advanced disease. A role for this 
protein in suppression of cancer cell proliferation and migration was shown 
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indicating that myofibroblasts may also release tumour suppressors (Holmberg, 
Quante et al. 2012).  
 
Myofibroblast are a prime source of extracellular MMP’s that have potential as 
prognostic markers in cancer (Vihinen and Kahari 2002) as well as promoting 
cancer progression (Holmberg, Ghesquiere et al. 2013). Also, secretome analysis 
has provided a potential marker, collagen type XII, for differentiating myofibroblast 
in colon cancer (Karagiannis, Petraki et al. 2012). These studies highlight the 
value of protein profiling of myofibroblasts in understanding cancer growth and 
treatment.  
 
However, there are still large gaps in knowledge and, for example, myofibroblasts 
in oesophageal cancers have been largely ignored to date. Unpublished studies 
in our group have shown differentially upregulated secretory proteins in CAMs vs 
ATMs from oesophageal squamous cell carcinoma (ESCC) and adenocarcinoma 
(AC) (Holmberg & Varro, unpublished data). The data have provided a potential 
candidate, namely the chemokine chemerin, as differentially upregulated in CAMs 
vs ATMs and this provides the starting point for the present experimental work.  
 
1.7 Mesenchymal Stromal Cells  
Bone marrow-derived MSCs have shown to populate the gastrointestinal tract and 
in bone transplant patients there is evidence of differentiation into epithelial cells 
(Ferrand, Noel et al. 2011). In Barrett’s adenocarcinoma, X/Y fluorescence in situ 
hybridization (FISH), indicates MSC homing and differentiation to stromal and 
epithelial cells (Sarosi, Brown et al. 2008; Hutchinson, Stenstrom et al. 2011). 
Moreover, in mice with H. felis-induced gastric cancer, 20% of CAMs have been 
shown to originate from bone marrow-derived MSCs (Quante, Tu et al. 2011). In 
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other studies, sublethally irradiated severe combined immunodeficient (SCID) 
mouse (H-2d) tumours were shown to harbour bone marrow derived 
myofibroblasts: 12.7 % on day 14 and 39.8 % on day 28 (Ishii, Sangai et al. 
2003). The infiltrated bone marrow derived MSCs differentiate into myofibroblasts 
in response to osteopontin (OPN) or TGF-β secreted by cancer cells or stroma 
(Popova, Bozyk et al. 2010; Mi, Bhattacharya et al. 2011). Moreover, TGF-β1-
stimulated MSCs shared 16 proteins with CAFs in colon cancer, including 
stromal-derived factor-1α and Rantes (De Boeck, Hendrix et al. 2013), suggesting 
that in the presence of TGF-β1 MSCs might potentially give rise to CAFs. In other 
studies, IGF-1 transactivation of CXCR4 increased MSC migration in response to 
growth factor SDF-1 (Li, Yu et al. 2007).  Recruited MSCs secrete CCL5 which 
interacts with its cognate receptor CCLR5 to increase breast cancer cell motility 
(Karnoub, Dash et al. 2007). While, on the other hand, MSCs have also been 
ascribed anti-tumorigenic properties (Kidd, Spaeth et al. 2008). In Kaposi’s 
sarcoma, recruited MSCs inhibited tumour growth perhaps via moderation of Akt 
signalling (Khakoo, Pati et al. 2006).  
 
Collectively the data suggest that the homing of bone marrow derived MSCs to 
cancer involves multiple ligands eg EGF, HGF, MCP-1, and ligand-receptor 
interactions, SDF-1α/CXCR4 and CXCL5/CXCR2 (Karnoub, Dash et al. 2007; 
Yang, Huang et al. 2008; Feng and Chen 2009; Quante, Tu et al. 2011). 
Nevertheless many aspects of the relationships between MSCs and tumour 
stroma remain uncertain, including mechanisms of homing in oesophageal 
cancer. 
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1.8 Mechanisms of inter-cellular signalling  
Cell-cell signalling is mediated by various substances including hormones, growth 
factors, cytokines and chemokines. In each case, a ligand activates receptors on 
target cells. Where ligands are released in close proximity to target cells the 
mechanisms are collectively known as paracrine signalling. Where they are 
carried in the blood stream to their targets the mechanisms are known as 
hormonal signalling; in some cases, ligands may even act on their cell of origin, 
known as autocrine signalling. Within a tissue, there are frequently interactions 
that are two-way, for example epithelial-stromal cell interactions where both cell 
types can be the source of signalling ligands and can respond to them by 
paracrine mechanisms. 
 
1.8.1 Humoral transmission 
The idea of chemical messengers mediating cell-cell interactions originated with 
the discovery of the first hormone, secretin, in 1902 by Bayliss and Starling 
(Bayliss and Starling 1902). Many gut hormones were subsequently discovered 
and shown to be involved in regulating gut secretion, motility and growth (Dockray 
2006). It was only much later that the cell surface receptors at which these 
hormones act were discovered. The well characterized gut hormones include 
gastrin, cholecystokinin (CCK), secretin, gastric inhibitory polypeptide (GIP), 
peptide YY (PYY), glucagon-like peptide (GLP)-1, and somatostatin (SST); their 
respective receptors are CCK-2 (gastrin/CCK-B), CCK-1,  human secretin 
receptor (SCTR), GIP-R , Y-2 receptor, GLP-1 and the SSTR1-5 receptors 
(Konturek, Konturek et al. 2004; Murphy and Bloom 2006). 
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1.8.2 Growth factors 
Growth factors (GFs) are polypeptides which are secreted and act in relatively 
close proximity to their cells of origin. Like polypeptide hormones they bind 
specific membrane receptors. However, while hormones typically act via GPCRs 
(Walsh 1993), growth factors typically act at receptor tyrosine kinases (Lemmon 
and Schlessinger 2010). There are multiple classes of growth factors including 
the families of EGF, IGF, VEGF, TGF-β, HGF, FGF, PDGF, Wnt, Hedgehog, 
Notch; each of these act at their cognate receptors and most play a role in 
gastrointestinal mucosal regeneration (Jones, Tomikawa et al. 1999). Cancer 
cells (Sporn and Roberts 1985), stromal cells e.g. myofibroblasts, bone marrow-
derived MSCs and epithelial cells are all potential sources of growth factors 
(Sporn and Roberts 1985; Orimo, Tomioka et al. 2001; Chen, Tredget et al. 2008) 
 
EGF family. The EGF family consists of EGF, heparin-binding EGF (HB-EGF), 
TGFα, amphiregulin, epiregulin, βcellulin, and neuregulin-1 to -4. The expression 
of TGFα, and HB-EGF in gastric parietal cells (Murayama, Miyagawa et al. 1995)  
may induce mitogenic signals within the epithelium regulating tissue integrity 
(Wang, Dangler et al. 2000). Members of the family may also influence stromal 
cells to enhance healing for example of gastroduodenal ulcers (Schultz, Rotatori 
et al. 1991). The exocrine secretion of EGF from salivary gland may stimulate 
proliferation of gastrointestinal epithelial cells and plays a role in the healing of 
gastric ulcers (Olsen, Poulsen et al. 1984; Konturek, Dembinski et al. 1988).  
 
IGF family. As its name suggests, members of the IGF family of growth factors 
are related in structure to insulin; however, the two members of this family, IGF-I 
and IGF-II, each consist of a single peptide chain which is homologous to the 
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single chain of pro-insulin prior to its cleavage to generate the A and B chains of 
mature insulin (Rinderknecht and Humbel 1978). Both IGF-I and –II act at the 
IGF-1 receptor to stimulate cell proliferation and migration; there is also an IGF-II 
receptor which is not functional. In the extracellular space, IGFs are sequestered 
by binding to IGF-binding proteins (IGFBPs1-6). In the upper gastrointestinal 
tract, IGF-II has been shown to be produced by myofibroblasts and to act on both 
epithelial cells and myofibroblasts to stimulate proliferation and migration 
(McCaig, Duval et al. 2006).  It has been shown that MMP-7 released by epithelial 
cells cleaves IGFBP-5 released by myofibroblasts to liberate the active growth 
factor (Hemers, Duval et al. 2005).   
 
TGF/activins. The TGF-β family comprises five members, TGF-β1-5 of which 
TGF-β1-3 are expressed in mammals. The release of TGF-β is attributed to 
cleavage by plasmin of latent TGF-β (Sato and Rifkin 1989); TGF-β1, TGF-β2 and 
TGF-β3 are mainly expressed by mesenchymal, epithelial and connective tissue 
cells respectively (Massague 1990). TGF-β acts via two receptors, TGF-β 
receptors type I and II. The binding of ligand to a type II receptor dimer, recruits a 
type I receptor dimer forming a hetero-tetrameric complex in which both receptors 
are required for the transduction of signal (Wrana, Attisano et al. 1992). Receptor 
type-III does not transduce signals; however, binding of type I and II is catalysed 
by type III receptors (Wrana, Attisano et al. 1994). In gastric cancer, cell 
invasiveness and migration may be mediated by TGF-β1 (Fu, Hu et al. 2009). As 
already noted, TGF- stimulates conversion of fibroblasts to myofibroblasts and 
consistent with this increased TGF-β in scirrhous gastric carcinoma cells 
increases the number of myofibroblasts associated with the tumour (Fuyuhiro, 
Yashiro et al. 2011). 
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FGF Family. There are 23 mammalian forms of FGF, including FGF-1 (acidic 
FGF), FGF-2 (basic FGF) and FGF-7/keratinocyte growth factor (KGF) which 
interact with FGFRs to influence cellular growth and differentiation. FGF-2/bFGF 
is secreted by fibroblasts and immobilised by binding to heparin and heparan 
sulphate in the ECM. The binding of FGF-2 to ECM proteins may confer 
protection from proteases and regulate activity and binding affinity to the receptor, 
FGFR2 (Guimond, Maccarana et al. 1993). FGF-7 is expressed in mesenchymal 
cells (Finch, Rubin et al. 1989) and studies have shown it signals via FGFR2 
expressed on epithelial cells (Mason, Fuller-Pace et al. 1994). There is increased 
expression of FGF-7 in gastric ulcer (Hull, Brough et al. 1998) which in turn 
stimulates epithelial cell proliferation and migration (Cordon-Cardo, Vlodavsky et 
al. 1990). 
 
PDGF Family. This is a family of dimeric glycoproteins with isoforms e.g. PDGFA, 
PDGFB acting through two different receptors, PDGFRA, PDGFRB. In gastric 
ulcer PDGF has been shown to be a potent mitogen for fibroblasts (Piazuelo, 
Lanas et al. 1998). Other studies have shown that gastric cancer cells (MKN-1) 
secrete PDGF which interacts with PDGFRA to increase the proliferation of 
gastric fibroblasts (Wada, Sakamoto et al. 1998). The isoform PDGF-B regulates 
the expression of other growth factors, e.g. VEGF and HGF by stromal cells; it 
increases the proliferation of epithelial cells and myofibroblasts in epithelial 
cancers (Lederle, Stark et al. 2006). 
 
HGF Family. Inactive HGF produced by stromal cells is cleaved by serine 
proteases to release the active form that acts on the protoncogene c-Met 
receptor. CAF-derived HGF has been shown to act at c-Met expressed on ESCC 
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to increase cell invasion (Grugan, Miller et al. 2010). Other studies have shown 
increased c-Met in TE-1 and TE-4 cells (ESCC lines) that depends on the level of 
Ets-1 transcription factor (Saeki, Oda et al. 2002). Further, these cells show 
increased motility in response to HGF.  
 
VEGF Family. As the name suggests, VEGF is a growth factor for endothelial 
cells and is vital in angiogenesis. The family consist of the isoforms, VEGF-A, 
VEGF-B, VEGF-C and VEGF-D. VEGF-A regulates cell proliferation and 
migration via VEGFR-1 and VEGFR-2. The expression of VEGF depends upon 
enhanced HIP-1 expression in an oxygen-stressed environment and has been 
observed in ESCC (Kimura, Kitadai et al. 2004). Further, VEGFs are extensively 
studied in gastrointestinal tract injury (Milani and Calabro 2001) and they have 
been shown to have relevance in carcinogenesis (Hyodo, Doi et al. 1998). 
 
Wnt Family. These are a family of cysteine rich glycoproteins comprised of 19 
members in humans. There are distinct intracellular signalling pathways for 
different Wnt proteins. For example Wnt3a, binds to cognate receptors of the 
Frizzled (Fz) family and a low-density lipoprotein receptor-related (LRP) protein to 
activate the so-called canonical pathway mediated by -catenin; while Wnt5a 
activates the non-canonical pathway (Cong, Schweizer et al. 2004). Collectively, 
Wnt molecules act as growth factors for stem cells and maintain the stemness of 
epithelial cells (Willert, Brown et al. 2003). Increased accumulation of β-catenin as 
a result of canonical pathway activation is seen in a majority of upper 
gastrointestinal cancers (Woo, Kim et al. 2001). Moreover, Wnt2 derived from 
tumour fibroblasts increases oesophageal cancer cell proliferation and migration 
via increased cyclin D and c-Myc expression and via Wnt/β catenin signalling (Fu, 
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Zhang et al. 2011). In contrast, both gastric epithelial and myofibroblasts-derived 
Wnt-5a mediates a β-catenin-independent pathway to enhance the gastric cancer 
cell migration (Kurayoshi, Oue et al. 2006; Wang 2013).   
 
Hedgehog Family. There are three hedgehog (Hh) homologues, Desert 
hedgehog homolog (DHH), Indian hedgehog homolog (IHH), and sonic hedgehog 
(SHH) of which SHH is widely studied in mammals. SHH undergoes processing to 
yield the active form by a mechanism involving translocation to the endoplasmic 
reticulum and autocatalytic processing to produce an active N-terminal domain. 
The activation of Patched (PTCH), a cell-surface transmembrane protein, by Hh 
increases the level of a 7-transmembrane spanning receptor, Smoothened (SMO) 
which in turn is coupled to activation of GLI transcription factors (Brink, 
Peppelenbosch et al. 2006). In gastric glands SHH is expressed in neck cells (van 
den Brink, Hardwick et al. 2001) while IHH is expressed by pit epithelial cells 
(Fukaya, Isohata et al. 2006). Sonic hedgehog plays a vital role in cell 
differentiation and is lost in atrophic gastritis (Zavros 2008). The loss of SHH in 
parietal cells increases the expression of E-cadherin, nuclear localisation of β-
catenin, the transcription factor GIi1, and activation of Wnt pathways. In addition, 
the expression of IHH was shown to regulate the events occurring in the absence 
of SHH in gastric epithelium. Thus Hh and related molecules might play an 
important role in maintaining gastric epithelial architecture (Xiao, Ogle et al. 
2010). Overexpression of sonic hedgehog (SHH) and abnormal hedgehog 
signalling has been shown to increase proliferation of both gastric and 
oesophageal cancer cells (Berman, Karhadkar et al. 2003). 
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Notch Family. Notch proteins are of 4 types, Notch1-Notch4, and possess 
transmembrane domains. The activation of notch receptors occurs mostly via the 
transmembrane ligands, delta and jagged, thus cell-cell contact is essential. 
Increased notch-1 activity and increased jagged expression are associated with 
Barrett’s adenocarcinoma (Mendelson, Song et al. 2011) and inhibition of notch-1 
activation increases the colony formation in oesophageal cancer cells 
(Subramaniam, Ponnurangam et al. 2012).  
 
1.8.3 Cytokines 
Cytokines are small cell signalling molecules found in both extracellular and 
membrane-bound forms. Many cytokines are upregulated in cancer. They are 
named on the basis of their ability to stimulate growth, differentiation and 
activation of immune cells and can be grouped into immunoregulatory cytokines 
e.g. IL-2 and pro-inflammatory cytokines, e.g. TNF-α. 
 
Immunoregulatory cytokines.  Immunoregulatory cytokines regulate various 
aspects of inflammation, and modulate the biological impact of pro-inflammatory 
cytokines. The expression of some cytokine receptors such as IL1R, IL-4R in 
resting immune cells is constitutive providing for readily responsive cells. In 
addition, activating stimuli may increase expression and activation of cytokine 
receptors e.g. IL 2R, (Ozaki, Kikly et al. 2000; Dumoutier, Lejeune et al. 2003). 
The interaction of activated cytokine receptors and upregulated cytokines 
regulates the migration and proliferation not just of the immune cells, but also of 
stromal and epithelial cells (Trinchieri and Scott 1995). Gastric cancer cells show 
increase expression of IL 2Rβ and in response to IL-2 exhibit enhanced cell 
proliferation (Lin, Yasumura et al. 1995). Some cytokines also regulate immune 
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responses via induced secretion of other cytokines. Thus increased IL-10 in 
oesophageal cancer regulates cell proliferation (Gholamin, Moaven et al. 2009) 
and secretion of IL-8 and IL-12 (Buelens, Verhasselt et al. 1997).  
 
Proinflammatory Cytokines. These cytokine are generally not expressed until 
an external stress stimulus triggers their expression. Infection with H. pylori 
provides an example, and is associated for instance with increased the secretion 
of IL-1β (Jung, Kim et al. 1997).  As the name suggests, the main function of this 
class of cytokine is to enhance inflammation. In the case of gastric cells, co-
culture of cancer cells (MKN45) with H. pylori caused increased IL-8 which was 
attributed to activation of NF-kB and regulated proinflammatory cytokine 
transcription (Aihara, Tsuchimoto et al. 1997). Moreover, increased IL-1β in 
response to H.pylori may regulate gastric acid secretion (Beales and Calam 
1998). Increased abundance of proinflammatory cytokines can be a driver for 
cancer development. For instance, increased IL-1 expression is associated with 
increased risk of upper gastrointestinal cancer (El-Omar, Carrington et al. 2001).  
 
Macrophage migratory inhibition factor (MIF): Macrophage migration inhibitory 
factor (MIF) is also known as glycosylation-inhibiting factor (GIF), L-dopachrome 
isomerase, or phenyl pyruvate tautomerase. It was discovered in activated T-
lymphocytes as an inhibitor of the migration of peritoneal cells (David 1966). 
Later, it was shown that macrophages possess a receptor for MIF (Remold and 
David 1971) and associated with this was inhibition of macrophage migration 
(Rocklin 1976). Now it is well known that MIF interacts through CD74 and its 
activation regulates recruitment of CD44 (Bernhagen, Calandra et al. 1993) The 
recruitment of CD44 then activates non-receptor tyrosine kinases leading 
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ultimately to extracellular signal-regulated kinase phosphorylation (Shi, Leng et al. 
2006). It plays a vital role in proinflammatory signalling in the control of local and 
systemic immune responses. In H. pylori induced gastritis and gastric cancer 
there is increased MIF which enhances gastric epithelial proliferation (Xia, Lam et 
al. 2005; He, Yang et al. 2006). In addition, MIF indirectly promotes angiogenesis 
in ESCC by stimulating tumour cells to produce angiogenic factors, such as IL-8 
and VEGF (Ren, Law et al. 2005). Moreover, it was recently shown that MIF 
transduces inhibitory signals via CD74 regulating MSC migration (Barrilleaux, 
Phinney et al. 2009). Amongst specific downstream targets of MIF is activation of 
MAPK pathways, e.g. ERK1/2 which depends on activation of protein kinase A 
(PKA) and protein kinase C (PKC) (Mitchell 2004); there is also down-regulation 
of the expression of the tumour-suppressor protein p53 (Hudson, Shoaibi et al. 
1999).  
 
1.8.4 Chemokines 
Chemokines are defined as chemotactic cytokines vital for infiltration of immune 
cells and MSCs. They are also involved in cancer metastasis. The expression and 
regulation of chemokines and their receptors is widely modulated in chronic 
inflammation. The inflammatory chemokines recruit neutrophils, inflammatory 
cells, and stimulate neoangiogenesis. In general, chemokines bind to soluble and 
cell membrane-bound GAGs. The interaction with GAG has varying 
consequences; thus binding to soluble GAG impairs chemokine activity whereas 
immobilised membrane GAGs increases their local availability (Kuschert, Coulin 
et al. 1999). Chemokine receptors undergo oligomerization or dimerization and 
interact with chemokine-GAGs complexes to stimulate cancer cell migration and 
angiogenesis (Folkman and Shing 1992).  Broadly, the chemokines expressed in 
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cancer belong to inflammatory group. Inflammatory chemokines are induced or 
upregulated by pro-inflammatory stimuli e.g. TNF-α. This group of chemokines, 
e.g. CXCL10, CCL5 attract immune and inflammatory cell to the site of damage. 
The other group, homeostatic chemokines, includes members regulating the 
normal recruitment of neutrophils e.g. CXCL12 and CCL14. The inflammatory and 
homeostatic groups consist of various classes of chemokines which can be 
characterised on the basis of their structure, namely the spacing of their first two 
cysteine residues i.e. CXC, CC, C and CX3C. 
 
CXC Family. The α-chemokines, i.e. CXC, consist of 17 members that can be 
further classified depending on the presence or absence of a glutamine-leucine-
arginine (ELR) motif ie ELR+ or ELR- chemokines. The interaction of ELR+ or 
ELR- CXCs with their cognate G-protein-coupled seven trans-membrane (GPCR) 
receptors (CXCR) is essential for paracrine or autocrine signalling. In addition, 
growth-related oncogenes (GROs) (GROα, GROβ, and GROγ) of the ELR+ CXC 
group are potent promoters of cell proliferation and angiogenesis via interactions 
with CXC chemokine receptor 1 or 2 (CXCR1 or CXCR2). Autocrine signalling via 
GROβ/CXCR2 interaction increases ESCC proliferation by stimulating ERK1/2 
(Wang, Hendricks et al. 2006). In breast cancer, CAM-derived CXCL12/SDF-1 
interacts with CXCR4 on cancer cell enhancing their invasion (Orimo, Gupta et al. 
2005) and stimulating angiogenesis (Luker and Luker 2006). 
 
CC Family. The β-chemokines, ie CC,  consist of 28 members that act via CCRs 
which are mostly of the GPCR type (Murphy 2002). Two different studies in 
gastric cancer showed increased CC family members, CCL7 and CCL21 (Hwang, 
Lee et al. 2012) and their receptor, CCR7 (Mashino, Sadanaga et al. 2002), 
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associated with cancer cell invasion and metastasis. CCL5 derived from CD4+ T 
blockade significantly impaired gastric cancer progression and has been shown to 
induce apoptosis of CD8+ T cells (Sugasawa, Ichikura et al. 2008). Oesophageal 
cancer cell derived MCP-1 stimulates both infiltration of immune cells and 
secretion of angiogenic factors such as VEGF suggesting role in angiogenesis. 
Further, there is a significant correlation of MCP-1 expression by cancer cells and 
CCR2 via infiltrating stromal cell macrophages (Koide, Nishio et al. 2004) thereby 
suggesting cancer and stromal interactions that are important in tumour growth. 
 
C Family: A small family of chemokines with two members named, XCL1 
(lymphotactin-α) and XCL2 (lymphotactin-β). These ligands are expressed by 
immune cells and act as chemo-attractants for T cells via binding to XCR1 e.g. G-
protein receptor 5 (GPR5)(Kroczek and Henn 2012) as well as modulating cancer 
growth (Cairns, Gordon et al. 2001). 
 
CX3C Family: This subgroup of chemokines consists of single member called 
fractalkine (or CX3CL1). It exists in soluble form and in an immobilized form on 
cell membranes (Bazan, Bacon et al. 1997). Fractalkine supports adhesion and 
migration of stromal cells, e.g. monocytes and endothelial cells via the Gαi 
coupled receptor CX3CR1(White and Greaves 2009) 
 
1.8.5  Adipocytokines 
As the name suggested these are cytokine-like molecules secreted from 
adipocytes, also known as adipokines. The well-known members include 
chemerin, PAI-1, retinol binding protein 4 (RBP4), visfatin, and leptin. The most 
abundant and well-studied adipokine is leptin which may also be produced in 
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gastric chief cells and D1 cells in stomach (Bado, Levasseur et al. 1998). 
Similarly, other adipokines such as visfatin and chemerin may be derived from 
non-adipocytes including macrophages, neutrophils and fibroblasts (Moschen, 
Kaser et al. 2007; Albanesi, Scarponi et al. 2009). Generally, the adipokines are 
involved in energy metabolism, obesity and insulin resistance (MacDougald and 
Burant 2007; Rabe, Lehrke et al. 2008). However, recent evidence has identified 
a link to cancer (MacDougald and Burant 2007). Leptin exerts a mitogenic effect 
in oesophageal cancer cells (OE33) via PI3K/Akt and p38 MAPK (Beales and 
Ogunwobi 2007; Kendall, Macdonald et al. 2008). In contrast, adiponectin 
inhibited ERK1/2 and Bcl-2 expression, and increased Bax abundance, in OE19 
cells thereby exerting anti-proliferative and pro-apoptotic effects (Konturek, Burnat 
et al. 2008).  
 
1.9 Intracellular Signal Transduction Pathways  
Multiple different types of ligand-activated receptors have been defined that can 
be conveniently classified as (1) receptor tyrosine kinases (RTK) e.g. EGFR, (2) 
ligand gated ion channels, e.g. nicotinic cholinergic receptor, (3) the G-protein 
coupled receptors, GPCRs, e.g. CXCR4 and chemR23 and (4) nuclear receptors 
e.g. receptors for oestrogen, corticosteroids, thyroxin.  
 
Receptor tyrosine kinases. Members of the RTK family have a single 
transmembrane domain and typically act in dimers. They can be grouped into 20 
different classes including for example EGF receptors, IGF and PDGF receptor 
families respectively. The EGFR family illustrates some of the general issues and 
is linked to a well-defined intracellular signalling cascade. The members of the 
family are ErbB 1 to ErbB4 (or HER1-4). They are widely expressed in epithelial, 
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mesenchymal, and neuronal-derived cells where they influence cell proliferation 
and differentiation. The extracellular binding of ligand causes RTK receptor 
dimerization (Lemmon and Schlessinger 2010). Auto-phosphorylation of specific 
intracellular tyrosine residues creates binding sites for Src homology 2 (SH2) 
domain- and phosphotyrosine binding (PTB) domain-containing proteins (Pawson 
1995). The recruitment of Src causes downstream activation of a signal 
transduction pathway (Pawson 1995) in which isoforms of Raf (Raf1, A-Raf or B-
Raf) interact with Ras to activate MEK1/2 followed ERK1/2 (Roberts and Der 
2007) (Figure 1.4). In addition conformational changes in Ras transduce signals 
by PI3 kinase and Ral guanine nucleotide exchange factors (RalGEFs) (Hamad, 
Elconin et al. 2002; Yin, Pollock et al. 2007) (Figure 1.4). The loss of ErbB 
signalling results in failure of organ development and embryonic death (Miettinen, 
Berger et al. 1995). Mutations in Ras family members are common being found 
up to 40% of upper gastrointestinal cancers (Arber, Shapira et al. 2000; Lord, 
O'Grady et al. 2000). There may also be mutations in erbB receptors which, since 
they are upstream of Ras, can lead to constitutive activation of Ras/Raf/MEK in 
cancer (Roberts and Der 2007). Constitutive activation of Ras can also be result 
of germline mutation either in Ras itself or Raf isoforms. Mutations found in 
human cancers include Ras residues G12 (glycine to valine mutation at residue 
12), Q61 and infrequently at G13. In the case of Raf, V600E (valine substitution 
by glutamate at position 600) occurs in high proportion of cancers (Garnett and 
Marais 2004; Tan, Liu et al. 2008). Signalling through the MAPK cascade is 
transduced by GTP loading of Ras leading to the activation of Raf kinase;, 
constitutive activation of Ras is due to inhibition of GTPase activity that is longer 
be stimulated by GAP (Mitin, Rossman et al. 2005).  
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G-Protein coupled receptors. The GPCRs are a family of approximately 800 
receptors characterised by 7-transmembrane domains and exhibiting sequence 
homology and functional similarity; they can be grouped into 6 different classes 
(A-F). The binding of ligand to a GPCR causes a conformational change and 
regulates G-protein/guanine nucleotide-binding protein signals via the exchange 
of GDP to GTP on the alpha (α) subunit of a heterotrimeric G-protein complex; 
the other components of the complex are beta (β) and gamma (γ) subunits 
(Hurowitz, Melnyk et al. 2000; Krumins and Gilman 2006). Gα exists in different 
forms each possessing unique function: Gαs is linked to activation of adenylate 
cyclase and increased production of cyclic adenosine monophosphate (cAMP) 
while Gαi inhibits the production of cAMP from  adenosine-5'-triphosphate (ATP); 
Gαq/11 stimulates membrane-bound phospholipase C beta, and Gα12/13 are involved 
in Rho family GTPase signalling and control cell cytoskeleton remodelling and cell 
migration (Etienne-Manneville and Hall 2002; Vega and Ridley 2008). The major 
pathways resulting from GPCR activation are therefore stimulation of cAMP and 
phosphatidylinositol (PI) (Figure 1.4) (Gilman 1987). The increase of cAMP acts 
as secondary messenger to induce downstream events via kinases such as PKA. 
In the case of phospholipase C (PLC) (Boyer, Waldo et al. 1992), there is 
digestion of phosphatidylinositol 4,5-bisphosphate (PIP2) to generate inositol 
1,4,5-trisphosphate (IP3) which increases intracellular Ca
2+
, and diacylglycerol 
(DAG) which activates protein kinase C (Takai, Kishimoto et al. 1979).  
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Figure 1.4  Receptor Tyrosine Kinases (RTK) and G-protein Coupled Receptor 
(GPCR) signal transduction pathways.  
Ligand binding results in activation by phosphorylation of tyrosine residues and 
recruitment of docking proteins. Ras proteins then become activated, resulting in the 
activation of Ras kinase, which initiates the phosphorylation cascade of MEK and 
MAPK. The activation of phosphatidylinositol 3 kinase (PI3K) and Ral guanine 
nucleotide exchange factors (RalGEFs) also mediate MAPK signalling. GPCR 
activation leads to G-protein dependent activation of phospholipase C (PLC) or cyclic 
adenosine monophosphate (cAMP). The Ras-Raf-MEK-MAPK/ERK pathway can also 
be activated by GPCR agonists. 
 
 
Regulators of G protein signalling (RGS), guanine nucleotide exchange factors 
(GEF), switch on GPCR activity, while β-arrestin, G protein-coupled receptor 
kinases (GRK) and GTPase-activating proteins (GAP) all switch off GPCR 
signalling (Dohlman 2009). The GRKs have kinase activity and phosphorylate the 
intracellular domain of GPCRs at serine and threonine residues (Ribas, Penela et 
al. 2007). The phosphorylated residues serve as binding sites for β-arrestin and 
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disrupt conformation thereby inhibiting the reactivation of the signal transduction 
pathways (Gurevich and Gurevich 2006). GTPase-activating proteins (GAP) 
involved in hydrolysis of GTP regain the status of inactive G-protein-GDP 
complex causing inactivation. The regulation of RGSs is also important, and for 
instance GPCR activation releases PIP3, which itself binds to RGS4 GAP and 
causes temporary inactivation (Ishii, Fujita et al. 2005). Some GPCR regulatory  
mechanisms also involve PKC and PKA which may activate GRKs stop GPCR 
signalling (Lefkowitz 1998). The desensitised GPCR may be degraded via 
clathrin-associated receptor translocation to lysosomes (Hanyaloglu and von 
Zastrow 2008), but there is also recycling of internalised GPCRs to the cell 
surface. 
GPCR signalling is misdirected in various ways in cancer (Marinissen and 
Gutkind 2001). For instance, signalling via CXCL12/CXCR4 activates protein 
kinase B (PKB) associated with increased proliferation and decreased apoptosis 
in gastric cancer (Yasumoto, Koizumi et al. 2006).  
 
The ligand gated ion channel receptors. These are transmembrane receptors 
that regulate permeability to various ions such as Ca
2+
, Na
+
, K
+
, or Cl
- 
upon 
binding of appropriate ligands. The receptor class is named according to its 
ligand: for example, nicotinic acetylcholine receptors (nAChR), ionotropic 
glutamate receptors and ATP-gated channels (P2XR). The binding of ligands 
induces conformational changes in the receptors that allow the movement of ions. 
Receptor structure varies and for example nAChR is a complex pentamer 
structure, (ααβγδ), of which (α9)5 is expressed in epithelial and neuronal cells 
and shown to be overexpressed in cancer cells (Lee, Huang et al. 2010).  
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Nuclear receptors. The nuclear receptors (NRs) are typically localised in the 
cytosol in their inactive forms but on stimulation they move to the nucleus where 
they bind to DNA and change gene expression.  (Mangelsdorf, Thummel et al. 
1995).  The binding of lipophilic ligand to type I NRs activates them causing 
translocation from cytosol to nucleus and binding at specific hormone response 
elements (HREs) on DNA (Gronemeyer, Gustafsson et al. 2004). While type II 
NRs occur in the nucleus in the inactive state associated with the relevant HRE. 
The activation of type II NRs involves co-regulators (Aranda and Pascual 2001). 
The inactive state is maintained by a small protein called a co-repressor.  Co-
repressors directly associate with repressors and indirectly bind to DNA to limit 
gene transcription. In the presence of ligand the co-repressor is replaced by a co-
activator, a protein molecule recruited to DNA along with a transcriptional 
complex required for gene expression.  
 
Cross talk. Networking amongst different transduction pathways occurs widely in 
health and disease. Examples include the intracellular activation of signalling 
pathways by stimulation of neighbouring receptors collectively known as 
transactivation. Thus GPCR-mediated transactivation of tyrosine kinase receptors 
has been extensively studied. Transactivation includes ligand-dependent and 
independent activation of RTK pathways; for instance, prostaglandin E2 and 
endothelin act at their GPCRs to transactivate EGFR secondary to cleavage of 
HB-EGF or TNF-α with subsequent increases in phosphorylation of ERK2 and 
cell proliferation (Prenzel, Zwick et al. 1999; Pai, Soreghan et al. 2002; Ogunwobi 
and Beales 2008). Other relevant mechanisms include ligand-independent 
transactivation, for example GPCR activation of intracellular molecules such as 
Src and followed by autophosphorylation of EGFR (Hsieh, Sun et al. 2008).  
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1.10 Chemerin and ChemR23  
Chemerin is 18kDa chemokine/adipokine expressed in adipocytes and immune 
cells e.g. macrophages (Zabel, Zuniga et al. 2006). It is a potent chemoattractant 
that recruits macrophages, natural killer (NK) and dendritic cells via interacting 
with a GPCR, chemokine like-receptor 1 (CMLR1) also called chemerin receptor 
23 (chemR23) (Zabel, Zuniga et al. 2006; Yoshimura and Oppenheim 2008). 
Chemerin was originally identified in 3-D co-culture experiments of keratinocytes 
and fibroblasts from psoriatic skin using a subtraction hybridization approach 
(Nagpal, Patel et al. 1997).  The ligand was then confirmed to interact with 
chemR23 and two other putative receptors, G-protein-coupled receptor 1 (GPR1) 
and chemokine (CC motif) receptor-like 2 (CCRL2) (Nagpal, Patel et al. 1997; 
Bondue, Wittamer et al. 2011). Chemerin was subsequently isolated from 
haemofiltrates using HPLC followed by peptide analysis by MALDI-TOF-MS 
(Meder, Wendland et al. 2003; Wittamer, Franssen et al. 2003). The C-terminal 
sequence of full length chemerin (163 residues) is proteolytically cleaved to 
produce the active forms. Cleavage may be mediated by different proteases 
(Figure. 1.5). Elastase cleaves chemerin 163 between amino acids at positions 5 
and 6 from the C-terminus to give active chemerin-157 (Zabel, Allen et al. 2005). 
Similarly, processing at the C-terminus by cathepsin G produces active chemerin 
156 (Zabel, Allen et al. 2005); however cleavage by chymase of chemerin 157 
and chemerin 156 leads to the inactive chemerin 154 (Guillabert, Wittamer et al. 
2008; Du and Leung 2009).  
 
Various studies have determined chemerin or its transcripts in serum, media or 
cell extracts using ELISA,  Western blot, RT-PCR or gene microarray (Parlee, 
McNeil et al. 2012). In parallel, chemR23 expression has been studied in various 
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stromal cells, endothelial, macrophage, NK cells, dendritic cells using gene 
microarray, fluorescence-activated cell sorting (FACS), immunocytochemistry 
(ICC) and immunohistochemistry (IHC) (Albanesi, Scarponi et al. 2009; Kaur, 
Adya et al. 2010; Muruganandan, Parlee et al. 2011).  
 
 
Pro chemerin 163
Chemerin  155Chemerin 158
Chemerin 156
Chemerin 157
Chemerin  154
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Figure 1.5 Isoforms of chemerin.  
Schematic of proteolytic cleavage in the C- terminal region of full length prochemerin 
163 and subsequent chemerin derivatives. Solid arrows represent active chemerin, 
while black dotted arrows represent inactive isoforms of chemerin. 
 
Ligand-receptor interactions have been studied using calcium influx measurement 
in adipocytes and macrophages (Bondue, Wittamer et al. 2011) and decreased 
accumulation of cAMP using cell based FLIPR assays (Meder, Wendland et al. 
2003; Wittamer, Franssen et al. 2003). Chemerin binding to chemR23 also 
activates downstream signalling pathways involving p44-42, p38, JNK-II, Akt, 
PI3K, and NFκβ (Berg, Sveinbjornsson et al. 2010; Hart and Greaves 2010; 
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Kaneko, Miyabe et al. 2011) (Figure 1.5). Chemerin binding to GPR1 and CCRL-2 
does not activate intracellular signalling pathways but may increase the local 
availability of chemerin to chemR23 expressing cells (Barnea, Strapps et al. 2008; 
Zabel, Nakae et al. 2008). 
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Figure 1.6 Chemerin  mediated cellular functions.  
Shcematic representation of action of chemerin in activating signal pathways in 
varied cell types and subsequent cellular funcitons.  
 
Chemerin has been implicated in autocrine and paracrine signalling in maturation 
and differentiation of adipocytes (Roh, Song et al. 2007). The inflammation 
mediated by chemerin is associated with infiltration of macrophages and dendritic 
cells in inflamed tissues. Chemerin also increases lipolysis and insulin signalling 
in adipocytes (Goralski, McCarthy et al. 2007) and acts on endothelial cell to 
increase angiogenesis (Kaur, Adya et al. 2010).  
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The role of chemerin in arthiritis, liver fibrosis and obesity has attracted attention. 
Chemerin regulation of IL-6 and TNF-α, and vice versa, and also chemerin-
stimulated adiponectin, has indicated a role as anti-inflammatory cytokine (Cash, 
Hart et al. 2008). In contrast, it has been suggested that the ability of chemerin to 
stimulate TGFβ secretion (Cash, Hart et al. 2008) might be critical in liver fibrosis 
and chronic inflammation. In obesity, increased chemerin expression in mature 
adipocytes mediates insulin-dependent glucose uptake and cell metabolism 
(Takahashi, Takahashi et al. 2008) and chemerin concentrations in blood 
correlate with body mass index and plasma triglyceride levels (Zabel, Allen et al. 
2005).  Relatively little is known about possible roles of chemerin in cancer. 
However, previous findings in our group (Holmberg & Varro, unpublished 
observations) showed chemerin is increased in oesophageal CAMs from SC 
compared to ATMs. This raises the possibility of a role in oesophageal cancer. 
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1.11 Aims : 
This investigation focuses on the properties of myofibroblasts in oesophageal 
cancer and in particular on the mechanisms by which they communicate with 
cancer cells and with bone marrow derived MSCs. The specific aims were: 
 
1. To characterise myofibroblasts derived from ESCC and EAC (CAMs) and 
from adjacent tissue (ATMs) and to compare their properties with 
myofibroblasts from normal donor patients (NTMs). 
2. To investigate the role of chemerin in chemotactic responses of MSCs and 
oesophageal cancer cells and to define the signal transduction pathways. 
3. To determine the role of MIF in local modulation of the responses to 
chemerin. 
4. To establish mechanisms of transendothelial migration of MSCs and to 
validate the use of a chemR23 antagonist 
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2.1 Materials 
Oesophageal cancer cell lines (OE21, OE33 and OE19) were obtained from 
American type culture collection, ATCC, VA, US. Human mesenchymal stromal 
cells (MSC; MSC7F3914) and Human Umbilical Vein Endothelial Cells (HUVEC) 
were purchased from Lonza (Cambridge, UK). Cell culture materials namely 0.25 
% w/v trypsin-EDTA, Dulbecco's modified Eagle's medium (DMEM), Roswell Park 
Memorial Institute medium (RPMI)-1640, L-glutamine, non-essential amino acids, 
antibiotic-antimycotic solution, penicillin-streptomycin solution and phosphate 
buffered saline (PBS) were obtained from Sigma (Dorset, UK); Recovery
TM
 cell 
freezing medium came from Invitrogen (Paisley, UK). Fetal bovine serum (FBS) 
was purchased from Lonza. Cell culture reagents for MSCs and HUVECs i.e MSC 
Trypsin (0.25% w/v)-EDTA, Mesenchymal Stem Cell Growth Medium bulletkit, 
(MSCGM, includes basal medium and MSC growth supplement, MSCGS) and 
Endothelial Growth media (EGM) were purchased from Lonza Transfection kits, 
Amaxa™ Fibroblasts Nucleofector™ kit and AmaxaTM Human MSC 
Nucleofector® kit were also purchased from Lonza. Competent E. coli cells for 
plasmid amplification were purchased from Invitrogen. PKH67 membrane 
labelling reagent was purchased from Sigma. Chemerin silencing RNAs were 
obtained from Sigma and a chemerin overexpression plasmid from Origene, 
Rockville, USA. Macrophage migration inhibiting factor (MIF) siRNA was obtained 
from Invitrogen. Plasmid DNA extraction mini Kit and RNeasy kit were obtained 
from Qiagen (Manchester, UK). Protease Inhibitor cocktail set III, EDTA-free, 
phosphatase Inhibitor cocktail set III, EDTA free were obtained from Calbiochem 
(Darmstadt, Germany) and RIPA buffer was purchased from Cell Signalling 
(Hitchin, UK). Western blot reagents were obtained from Bio-Rad Laboratories 
(Hercules, CA, US) namely Immun-Star™ WesternC™ Chemiluminescence Kit, 
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Lowry DC protein assay, ChemiDoc XRS system and the nitrocellulose 
membrane came from Amersham Pharmacia (Biotech, Little Chalfont, UK). 
PageRuler
TM
 prestained protein ladder was purchased from Fermentas (York, 
UK). Bovine serum albumin (BSA) and 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) for immunocytochemistry were 
purchased from Jackson Immunoresearch (PA, USA) and Sigma, respectively. 
Vectashield with DAPI for nuclear staining was obtained from Vector laboratories 
(Peterborough, UK). The Click-iT EdU Alexa Fluor 488 Imaging kits were 
purchased from Invitrogen. Clonogenic reagent, (1, 9-dimethyl-methylene blue) 
was obtained from Sigma. Chemerin ELISA kits were obtained from Adipo 
Bioscience (Santa Clara, CA, USA) and MIF ELISA kits from R&D Systems 
Europe Ltd (Abingdon, UK). Boyden chamber control cell culture inserts and BD 
BioCoat™ Matrigel™ Invasion Chamber for migration and invasion assays were 
purchased from SLS (Nottingham, UK). The migration cell fixing and staining kit 
(DiffQuick) was from Dade Behring Inc (Newark, DE). Drugs including Ro320432, 
SB202190, SP600125, Uo126, ISO-1 were purchased from Calbiochem and 
LY294002 was obtained from Cell Signaling. Chemerin-9 was purchased from 
Genscript (Piscataway, NJ, USA). Chemerin was purchased from R&D Systems 
Europe Ltd (Abingdon, UK) and IGF-II from Calbiochem (Darmstadt, Germany). 
ChemoCentryx (Mountain View, CA, USA) provided the ChemR23 antagonist 
CCX-832 and a control compound (CCX-826). GeneChip©Human Genome U133 
plus 2.0 arrays was obtained from Affymetrix (Wycombe, UK).  
 
2.2 Human primary myofibroblasts  
Human primary myofibroblasts were obtained from resected oesophagael 
cancers and adjacent non-cancerous tissue during surgery for removal of tumours 
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at First Department of Surgery, University of Szeged, Szeged, Hungary. 
Myofibroblasts were prepared in the Department of Medicine, University of 
Szeged, Hungary as previously described (McCaig, Duval et al. 2006) and 
transported to University of Liverpool in liquid nitrogen and cryopreserved until 
use. Myofibroblasts were derived from four oesophageal squamous cancers and 
three Barrett's adenocarcinoma, recovered from the oesophagus and 
oesophagus/cardiac junction. From each patient, CAMs and ATMs were cultured. 
Also, 6 myofibroblast lines were obtained from the oesophagus of normal patients 
who were transplant donors (NTMs: 3 males, 3 females, mean average age 48.7 
± 5.8 yrs and 49.3 ± 2.7 yrs respectively). The details of tumour staging 
(pathology tumour size, lymph nodes, metastasis) and cancer classification are 
shown in Table 2.1.   
 
2.3 Tissue culture 
2.3.1 Human myofibroblasts  
Myofibroblasts were maintained in T-75 flasks in DMEM supplemented with 10% 
v/v FBS, 1% v/v penicillin-streptomycin, 2% v/v antibiotic-antimycotic and 1% v/v 
non-essential amino acids. This is referred to as "full medium” (FM) unless 
otherwise stated. Cells were grown at 37
o
C in a 5% v/v CO2 atmosphere and the 
medium was changed every 48 h.  
For passaging, cells at 80% confluence or above were washed twice with PBS 
followed by incubation for 5-8 min in 2ml 0.25 % w/v trypsin-EDTA. Trypsinised 
single cell suspensions were then added to 8ml of FM and 8x10
5 
to 10
6 
cells were 
re-plated in T-75 flasks. Aliquots of 10µl of cell suspensions were used for cell 
counting using a haemocytometer. The cells used in experiments were obtained 
from passages 5 to 15. 
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A 
Patient No. Age Gender Survival (months) Tumour Staging Tumour Location Classification Adjacent Tissue 
1 72 M 18 pT3N1M0 oesophagus Barrett adenocarcinoma Barrett’s 
2 64 M 19 pT2N3M0 cardia Barrett adenocarcinoma Barrett’s 
3 70 F >25 pT3N1M1 cardia Barrett adenocarcinoma Barrett’s 
4 56 M 34 pT3N1M0 oesophagus squamous carcinoma CIM, PAM (cardia) 
5 52 M 31 pT3N1M0 oesophagus squamous carcinoma normal 
6 49 M 35 pT2N1M0 oesophagus squamous carcinoma GERD 
7 69 M 14 pT3N1M0 oesophagus squamous carcinoma PAM (cardia) 
B 
 
Patient No. Age Gender Location 
8 44 F oesophagus 
9 45 M oesophagus 
10 52 F oesophagus 
11 60 M oesophagus 
12 52 F oesophagus 
13 41 M oesophagus 
 
 
Table 2.1 Characteristics of patients used to provide oesophageal myofibroblasts. A) Age, gender, post-operative survival (>, alive at time of 
submission), tumour staging, tumour localisation, tumour classification, and pathology assessment of tissue taken adjacent to the tumour for 
patients used to provide oesophageal CAMs and ATMs. Tumour staging is defined in terms of pathology of tumour (pT) where 0 defines no 
sign of tumour and 3 maximum size and/or extensions. Similarly, the involvement of local and metastasis to proximal lymph nodes is stated as 
N0 - N3 and metastasis severity by M0, no metastasis and M, distant metastasis. The gastro-intestinal junction tissue possessing the intestinal 
metaplasia and metastasis of pancreatic acinar cells are called cardiac intestinal metaplasia (CIM) and pancreatic acinar metaplasia (PAM) 
respectively in adjacent tissue, last column. B) Myofibroblasts isolated from 6 normal transplant donors tissue, NTMs (3 were males, 3 females 
mean average age 48.66 ± 5.78 yrs and 49.3 ± 2.66 yrs respectively). 
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2.3.2 Human mesenchymal stromal cells (MSC) 
Mesenchymal stromal cells were maintained in an undifferentiated state in T-75 
flasks in MSCGM containing 440ml basal medium and MSC growth supplements. 
Cells were maintained at 37
o
C in 5% v/v CO2 atmosphere. Every 3-4 days, media 
was aspirated and replaced with 20ml fresh media. Cultures were split and 
passaged at 80% confluence or over. Cells were detached with 2ml of trypsin 
(0.25% w/v)-EDTA for 2-3 min, and 8x10
5 
to 10
6 
cells were then added to 8ml FM 
and re-plated in T-75 flasks. The cells used in experiments were obtained from 
passages 5 to 12 and maintained their undifferentiated phenotype. 
 
2.3.3 Human Umbilical Vein Endothelial Cells (HUVEC) 
Human umbilical vein endothelial cells were maintained in T-25 flasks in EGM 
medium. Cells were maintained at 37
o
C in 5% v/v CO2 atmosphere. Every 2nd 
day, media was aspirated and replaced with 10ml fresh media. At 80% 
confluence cells were trypsinised with 1ml of trypsin (0.25% w/v)-EDTA for 2-3 
min, and then suspended in 4ml FM and re-plated in T-25 flasks at a density of 
1000-2000 cells/ml. The cells used in experiments were obtained from passages 
5 to 9. 
 
2.3.4 Human oesophageal cancer cell lines 
Oesophageal squamous cancer (OE21), adenocarcinoma (OE33), and Barrett's 
oesophagus (OE19) cell lines were cultured in RPMI-1640 supplemented with 
10% v/v FBS, 1% v/v penicillin-streptomycin, 2% v/v L-glutamine. Cells were 
maintained at 37
o
C in a 5 % v/v CO2 atmosphere, and media were changed every 
48-72 h. Confluent cells at 80% were washed twice with PBS, trypsinised using 
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0.25% w/v trypsin-EDTA and 8x10
5 
to 10
6 
cells added 8ml FM and re-plated in T-
75 flasks. 
 
2.3.5 Cryopreservation of cell lines 
Cells were trypsinised at 80% confluence, centrifuged at 800 x g for 7 min at 4
o
C 
and supernatants discarded. Pellets were resuspended in 1 ml recovery cell 
freezing medium and cell suspensions stored in 1.5 ml cryovials. These vials 
were placed in a plastic holder in a bath containing propane-1, 2,-diol and then 
transferred to a -80°C freezer overnight and then to liquid nitrogen for long-term 
storage. 
 
2.3.6 Recovering frozen cell lines 
Cells were removed from liquid nitrogen, thawed by hand or in a water bath at    
37
o
C and added to a T-75 culture flask with 19 ml FM and maintained 37
o
C in a 5 
% v/v CO2 atmosphere 
 
2.4 Preparation of condition media 
Myofibroblasts (1.5 x 10
6
 cells) were plated in T-75 falcon flasks and maintained 
at 37
o
C in a 5% v/v CO2 atmosphere for 24 h in FM. Cultures were then washed 3 
times with sterile PBS and incubated in 15ml serum free (SF) media (FBS 
excluded from FM) for 24 h. Conditioned media were collected in 20 ml Universal 
tubes and centrifuged for 7 min 800 x g, 4
o
C. Aliquots of 5 ml were stored at -
80
o
C until further use. 
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2.5 Immunocytochemistry 
Cells were cultured in T-75 flasks and trypsinised to yield single cell suspensions 
that were seeded at 10,000 cells per well on cover slips in 24 well plates. Cells 
were incubated for 24 h and fixed using 4% w/v paraformaldehyde for 30 min at 
room temperature (RT). Cells were then washed twice with PBS before 
permeabilisation with 500µl of fresh 0.2% Triton X-100 in PBS (PBS-T) for 30 min 
at RT. Cells were washed twice with PBS and incubated with 500µl of 5% w/v 
BSA for 30 min at RT. To prevent non-specific binding of secondary antibody, 
cells were incubated with 500 µl 10% v/v donkey serum for 1 h at RT. Cells were 
then washed with PBS twice and incubated with primary antibody diluted in PBS, 
overnight at 4
o
C in a humid atmosphere. Next day, the cells were washed with 
500µl 0.14M NaCl for 10 min, 0.5M NaCl for 10 min and 0.14M NaCl for 10 min. 
Secondary antibodies were prepared in HEPES. Slides were incubated with the 
appropriate secondary antibody for 1 h at RT in the dark. Cover slips were then 
washed in PBS for 10 min each and transferred to glass slides. Vectashield 
containing DAPI was added to cover slips that were mounted, sealed with nail 
varnish and kept overnight in the dark at 4
o
C. Staining was observed using 40 x 
magnification using a fluorescence Zeiss Axioplan-2 microscope and Axiovision 
software V 4.8.0. Images (MicrOptik, Deursen, Netherlands) were captured using 
a JVC-3 charged coupled device camera with KS300 software. Emissions of 
fluorescence (FITC) were captured with the XF22 filter (excitation 493 nm, 
emission 520 nm) and Texas Red was detected using the XF33 filter (excitation 
596 nm, emission 620 nm, Omega Optical, Essex, UK). Details of primary and 
secondary antibodies provided in Table 2.2. 
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Antibody Species Dilution Supplier 
Anti-α smooth muscle actin Mouse 1:100 Fitzgerald, USA 
Anti-vimentin Guinea pig 1:100 Fitzgerald, USA 
Anti-desmin Rabbit 1:100 Fitzgerald, USA 
Anti-chemR23 Rabbit 1:100 Millipore, UK 
Anti-GPCR GPR1 Rabbit 1:250 Abcam, UK 
Anti-CD105        Mouse 1:50 Bayport, USA 
FITC-conjugated donkey- 
anti-mouse Donkey 1:400 Jackson, USA 
Texas-Red-conjugated  
donkey-anti-guinea pig Donkey 1:400 Jackson, USA 
FITC-conjugated donkey- 
anti-rabbit Donkey 1:400 Jackson,  USA 
 
Table 2.2 Antibodies and their working dilution used in 
immunocytochemistry.  
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2.6 Bioassays 
2.6.1 Cell migration assays 
2.6.1.1 Boyden chamber-chemotactic migration assays 
 
Migration assays were applied to myofibroblasts, cancer cells and MSC following 
the manufacturer’s instructions. Cells were seeded in 500µl SF media on 
perforated polyethylene terepthalate (PET) membranes with 8.0 μm pores; the 
inserts were placed in wells containing 750µl of appropriate media. Cells were 
obtained by trypsinising 70% confluent cultures and resuspension in 5 ml of 
medium with 0.1% FBS. A 10 μL aliquot of the cell suspension was counted in a 
haemocytometer. Stimulants and inhibitors, conditioned media, cell types, 
seeding density and incubation times are described in the relevant sections. 
 
After incubation, migrated cells on the underside of the insert were stained with 
DiffQuick according to manufacturer's instructions. Cells on the upper side of the 
membrane were removed by scrubbing with a cotton bud and those on the lower 
side of the membrane were fixed, stained and counted under 10 x magnifications 
using a Zeiss 25 Axiovert Microscope (Carl Zeiss Microscopy, NY, USA). Cells 
were counted in five fields on a single membrane and means were calculated. 
 
2.6.1.2 In vitro scratch wound healing assays  
 
Cells were plated at 80% confluence in 6-well plates and incubated in 2ml FM 
until monolayers of cells were achieved. A single scratch was created across the 
monolayer in each well using a p2 pipette tip perpendicular to the surface and 
through the centre of the well. Experiments were performed in duplicates or 
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triplicates. Cells migrating across the wound were determined in one or two fields 
per well using time-lapse microscopy with Hamamatsu Orca ER Camera and 
Kinetic Imaging AQM-2001 software (Hamamatsu, Town NJ, USA). 
 
2.6.1.3 Transendothelial migration assays  
 
Mesenchymal stromal cells were labelled with 1µM PKH67 per 10
7
 cells following 
the manufacturer’s protocol. Transendothelial migration assays were applied to 
PKH67 labelled MSCs using BD BioCoat™ Matrigel™ Invasion Chambers 
according to manufacturer’s instructions. Endothelial cells, HUVEC were 
trypsinised and seeded at 10
6 
cells per insert and topped up with 500 µl of EGM. 
The HUVEC cells were incubated for 48 hr at 37
o
C in a 5 % v/v CO2 atmosphere 
to allow the formation of a monolayer. Subsequently the procedure used to study 
MSC migration was performed as described in section 2.6.1.1. Mesenchymal 
stromal cells were counted with green fluorescence for PKH67 for five fields on a 
single membrane and means were calculated.  
 
2.6.2  Cell proliferation assays 
2.6.2.1   EdU labelling 
 
Proliferating cells were labelled with 5-ethynyl-2´-deoxyuridine (EdU) and 
detected using the Click-iT
TM
 EdU Alexa Fluor 488 Imaging kit according to the 
manufacturer’s instructions. In 24 well plates, 10,000 cells/well were cultured on 
coverslips in 1ml FM for 24 h. Cells were washed twice with PBS and serum 
starved for 24 h to synchronize the cells at G0/G1 of the cell cycle. Fresh SF 
media (1ml) was added with 10µM EdU and stimuli or inhibitors for 24 h. Cultured 
cells were fixed in 4% PFA in PBS for 30 min at RT, then washed three times with 
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PBS followed by PBT (0.5% Triton X-100 in PBS) for 20 min at room temperature. 
Cells were incubated for 30 min with 3% 500µl of BSA. The Click-iT™ reaction 
cocktail was prepared freshly just before use by mixing 430 μL of reaction Click-iT 
buffer, 20μL of 100 mM copper sulphate (CuSO4),  1.2μL of Alexa Fluor dye, and 
50μL of reaction buffer additive solution in a final volume of 500 μL (sufficient for 
one well). Cells were washed three times with 3% 500µl of BSA and incubated 
with Click-iT for 30 min in the dark. Cover slips were then washed three times in 
PBS for 10 min each and transferred to a glass slide. Vectashield containing 
DAPI was added to the cover slips which was then mounted, and sealed with nail 
varnish, and kept overnight in the dark at 4
o
C until counting at 10x magnification 
using a Zeiss Axioplan-2 microscope. Alexa Fluor 488 light emission was 
captured with the XF22 filter (excitation 495 nm, emission 519 nm) and Axiovision 
software V4.8. Images were captured using a JVC-3 charged coupled device 
camera with KS300 software. 
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2.7 Gene expression arrays 
Myofibroblasts and MSCs were cultured as described in section 2.3.1 and 2.3.2 
respectively and RNA extracted by Dr. Islay Steele using the RNeasy kit. 
Similarly, the RNA was extracted from cultured oesophageal cancer cells, (OE21, 
OE19 and OE33) according to manufacturer's instruction. Samples were 
analysed using GeneChip©Human Genome U133 Plus 2.0 arrays at the Liverpool 
Genome Facility by Dr. Lucille Rainbow, according to the manufacturer's 
instruction. The GeneChip©Human Genome U133 Plus 2.0 array measures the 
expression of 47,000 transcripts. GeneChip® Scanner 3000 enabled high-
resolution scanning of the arrays. To provide stringent microarray assessments 
confirming reproducibility and avoiding the experimental artifacts, Microarray 
Suite 5.0 QC Metrics (MAQC) was used as a quality control. Further, the data 
were extracted using the software GeneSpring GX V.10. Data were normalised 
with a MAS5 algorithm and filtered using "flags present (P)", "marginal (M)", and 
"absent (A)". Statistical analysis was performed using student paired t-test, 
unpaired t-test and ANOVA within the GeneSpring software. For large datasets of 
differential gene expression (DE), the percentage of false positives among 
defined significant results, ie False Discovery Rate (FDR), was used. The 
expression of individual genes was reported relative to Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH). 
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2.8 Western Blots 
2.8.1 Preparation of whole cell lysates 
Cells were cultured in 10 cm Petri dishes at a seeding density of 10
6 
 cells and 
incubated for 24 h in FM. Cells were then washed three times with PBS and fresh 
10 ml SF media containing stimuli or inhibitors was added and incubated for 24 h. 
Media was then removed and 10ml sterile PBS added to the cells on ice. Cells 
were washed twice with 10ml PBS and recovered by 100µl RIPA buffer (25 mM 
Tris-HCL pH 7.6, 150 mM NaCl, 1% w/v NP-40, 1% w/v sodium deoxycholate and 
0.1% w/v sodium dodecyl sulfate), containing 1% v/v Protease Inhibitor cocktail 
set III, EDTA-free and 1% v/v Phosphatase Inhibitor cocktail set III, EDTA free. 
Cell suspensions were pipetted into clean labelled tubes, sonicated for 5 min and 
incubated on ice for 30 min. The extracts were then centrifuged at 12000 x g at 
4
o
C for 30 min and supernatants stored at -80
o
C. 
 
2.8.2 Protein quantification 
To ensure equal loading in Western blots, protein concentrations were quantified 
using modified Lowry DC protein assays. Bovine serum albumin standard (2 
μg/ml-0.125 μg/ml) was serially diluted in PBS and 5 μL was added in triplicate. 
Similarly, triplicates of 5 μL of sample diluted in RIPA lysis buffer (1:10) were 
added followed by the addition of 25 μL reagent A and 200 μL of reagent B. The 
samples were incubated for 30 min and absorbance was measured at 450 nm. 
  
2.8.3 SDS-poly-acrylamide gel electrophoresis 
Proteins were resolved by discontinuous SDS polyacrylamide gel electrophoresis 
(SDS-PAGE). A separating gel of 10% or 15% w/v SDS-poly-acrylamide was 
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layered with H2O-saturated iso-butyl alcohol. The chamber and gels were 
assembled as described in the manufacturer’s protocol. Each gel was loaded with 
5 μL of PageRulerTM Plus prestained protein ladder to provide molecular weight 
standards and to monitor electro-blotting. Cell extracts were denatured by pre-
heating for 5 min at 100
o
C with 5x loading buffer. Gels were run at a constant 
current of 100V for 1 h and were blotted once the bromophenol blue reached the 
lower end of the gel.  
 
2.8.3.1 Electrophoretic transfer 
Proteins were electotransferred onto nitrocellulose at a constant voltage of 100 V 
for 1 h at RT. Nirtocellulose membranes were then rinsed in Tris-buffered saline 
containing 0.1% Tween (TBS-T) three times for 10 min. Membranes were blocked 
for at least 1 h at RT with blocking buffer (TBS-T containing 5% W/V Marvel milk 
powder). Primary antibody diluted in 5 ml blocking buffer was applied to 
membranes overnight at 4
o
C. On the next day, membranes were washed four 
times in TBS-T and horseradish peroxidase (HRP)-conjugated secondary 
antibodies were applied for at least 1 h. Membranes were exposed using the 
Immun-Star™ WesternC™ Chemiluminescence Kit. 
 
2.8.3.2 Densitometry evaluation of band intensity  
Protein bands were quantified from captured blot images using a ChemiDoc XRS 
system (Bio-Rad, Hemel Hempstead, UK). The intensity of individual bands was 
quantified with the BioRad software version 2.3.1. The samples were normalised 
to Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) unless otherwise 
stated. 
 
 
  Materials and Methods 
 
58 
 
 
Antibody Species Dilution Source 
GAPDH Mouse 1:1000 Meridian Life 
Science, USA 
Chemerin Goat 1:250 R&D Systems, 
UK 
MIF Goat 1:200 R&D Systems, 
UK 
Phospho- p44/42 MAPK Rabbit 1:2000 CellSignal, USA 
Phospho-p38 MAPK Rabbit 1:1000 CellSignal, USA 
Phospho- SPAK/JNK-II Rabbit 1:1000 CellSignal, USA 
Total p44/42 MAPK Rabbit 1:2000 CellSignal, USA 
Total p38 MAPK Rabbit 1:2000 CellSignal, USA 
Total SAPK/JNK-II Rabbit 1:2000 CellSignal, USA 
Anti-Mouse Goat 1:20000 Sigma, UK 
Anti-Goat Rabbit 1:10000 Sigma, UK 
Anti-Rabbit Goat 1:10000 Sigma, UK 
Anti-Rabbit Goat 1:2000 Sigma, UK 
 
 
Table 2.3 Primary antibodies and secondary antibodies and their dilutions 
used for Western blot analysis.  
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2.9 Sandwich - enzyme linked immunosorbent assay 
(ELISA) 
Media samples were collected as mentioned in section 2.4 and were stored at -
80
o
C until use. Chemerin and MIF concentrations in media were measured using 
commercially available Chemerin ELISA Kits and Human MIF Immunoassays 
respectively.  
 
2.10 Amplification of plasmid DNA 
Chemically competent E. coli were used to amplify plasmids expressing DNAs of 
interest. A 50 μL aliquot of competent E. coli cells was thawed on ice, mixed with 
100 ng of plasmid DNA and then incubated for 30 min on ice, followed by 30 sec 
heat shock at 37°C and 2 min incubation on ice to induce uptake of DNA. The 
cells were allowed to recover by the addition of 250 μL of Luria broth (LB) 
medium in a shaking incubator at 37°C for 1 h. Two aliquots of the suspension 
(20 μL and 100 μL) were then plated onto pre-warmed (37°C) LB agar plates 
containing 100 μg/ml ampicillin. The plates were observed the next day after 
overnight incubation at 37°C for the antibiotic-resistant colonies. A single colony 
isolated from a fresh LB plate was used to inoculate 4 ml of LB medium 
containing 100 μg/ml ampicillin, the cells were then incubated at 37°C in a 
shaking incubator at 225 rpm for 4-8 h. Bacterial cultures were collected by 
centrifugation (6000 rpm for 5 min) and processed for plasmid DNA extraction 
using Qiagen Plasmid Mini Kit. DNA concentrations were measured by 
absorbance at A260, and the ratio of A260/A280 was used as an indicator of 
purity. When long-term storage of clones was needed, glycerol was added to an 
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aliquot of culture at a final concentration of 15% v/v, and the stocks were stored in 
required aliquots at -20°C. A small aliquot was kept at 4
o
C for usage till 6 months 
 
2.11  Transient transfection of myofibroblasts and MSCs 
 
Cells were cultured as described in section 2.3 and maintained at low passage 
number (<9) and 85% confluence before transient transfection. Amaxa™ 
Fibroblasts Nucleofector™ kits and AmaxaTM Human MSC Nucleofector® kits 
were used according to manufacturer’s instructions. Each transfection employed 
2 μg of DNA (5 x 105 cells) and 100 μL of complete nucleofector solution along 
with media. The required number of cells was centrifuged at 200 x g for 10 min 
and the supernatant was discarded. The pellet was resuspended at RT Human 
MSC Nucleofector Solution to a final concentration of 5 x10
5
 cells/100μL.  
Transfection was achieved by using the program U-23 (for high transfection 
efficiency) by adding 500 μL of the pre-warmed culture full medium to the cuvette 
and using the plastic pipette (provided in kits) and transfer sample to the T-75 
with 20 ml of freshly prepared FM.  
  
2.12 Statistics 
The final results were calculated as mean ± standard error of means (SEM). 
Student t-test and ANOVA were performed on the data as appropriate with 
significance at p≤0.05, unless otherwise stated. Experiments with standards 
included the assay efficacy, reliability, and calculation of unknown samples which 
were based on coefficient of regression, R
2
 and line equation, y= mx + c (where 
m= slope of line and c is the intercept at y-axis) 
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3.1 Introduction 
Myofibroblasts are often described as activated fibroblasts and are observed in 
the stroma of many, probably all, solid cancers. The isolation of myofibroblasts 
from tumours and their characterisation by morphology and function has been 
widely applied to studies of breast cancer, prostate cancer and gastric cancer 
(Ronnov-Jessen, Petersen et al. 1995; Tuxhorn, Ayala et al. 2002; McCaig, Duval 
et al. 2006; Holmberg, Quante et al. 2012). In oesophageal cancer, some studies 
have showed that fibroblasts influence tumour growth and development (Noma, 
Smalley et al. 2008; Grugan, Miller et al. 2010). However, in general little is 
known of how myofibroblasts obtained from oesophageal cancer (CAMs) differ 
from those obtained from neighbouring tissue (ATMs) or normal tissue (NTMs). 
Myofibroblasts share some markers, e.g. αSMA, vimentin with other stromal cells 
notably smooth muscle cells (Sappino, Schurch et al. 1990; Meran and Steadman 
2011). Some studies have therefore used a panel of positive (αSMA, fibroblast 
activated protein, fibroblasts secreted protein), and negative (pan cytokeratin, 
desmin) markers to distinguish myofibroblasts from epithelial cells and other 
stromal cells (Spaeth, Dembinski et al. 2009; Kidd, Spaeth et al. 2012). However, 
αSMA has been used in virtually every study characterising myofibroblasts and 
increased αSMA abundance is considered to be one of the strongest signatures 
of myofibroblasts. 
Recent studies of gastric myofibroblasts have shown clear differences between 
CAMs and ATMs with respect to proliferation and migration (Holmberg, Quante et 
al. 2012). To our knowledge, so far there has been no comparable study of CAMs 
and ATMs in oesophageal SC or AC. However, Zhang et al., 2009 compared  
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oesophageal fibroblasts from cancer and non-cancer tissue and confirmed 
increased proliferation using MTT assays. In the present study we used two 
different proliferation assays (EdU and clonogenic) and two different migrations 
assays (Boyden chamber and wound healing) to characterise oesophageal SC 
and AC CAMs and ATMs, and NTMs, and studied the responses of cancer cell 
lines (SC, OE 21 and AC, OE19 and OE33) to CM from these cells.  
 
3.1.1 Objectives 
 
Specific objectives were: 
1. To characterise CAMs and ATMs from SC and AC, and to compare with 
myofibroblasts from normal transplant donors (NTMs). 
2. To determine the effect of conditioned media from oesophageal CAMs, 
ATMs and NTMs on cancer cell proliferation and migration. 
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3.2 Material and Methods 
3.2.1 Cell culture 
 
Oesophageal SC and AC myofibroblasts (both CAMs and ATMs), and 
oesophageal NTMs, were cultured as described in sections 2.3, and 2.3.1. 
Oesophageal cancer cell lines (OE19, OE21, and OE33 cells) were cultured as 
described in section 2.3.3. 
3.2.2 Conditioned media 
Conditioned media were prepared from myofibroblasts as described in section 
2.4. 
3.2.3 Immunocytochemistry 
Myofibroblasts were seeded at a density of 10,000 cells/well in 24 well plates on 
cover slips (see section 2.3.1) and probed for each marker.  Approximately 500-
800 cells were counted for each marker and images were taken as described in 
section 2.5. 
3.2.4 EdU labelling 
To determine differences in proliferation between CAMs, ATMs and NTMs, cells 
were seeded at a density of 10,000 cells/well in 24 well plates on cover slips. The 
effect of myofibroblast CM was determined on OE19, OE21 and OE33 cells using 
EdU labelling as described in section 2.7.1. Myofibroblasts labelled with EdU 
were counted in 5-10 fields and cancer cells in 5 fields (100-200 cells/well). 
Images were taken as described in section 2.7.1. Data are presented as mean 
proliferating cells in 5 fields for cancer cells and 10 fields for myofibroblasts per 
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well; experiments were performed in triplicate and data expressed as mean ± 
S.E.M; significance was determined by ANOVA, p<0.05. 
3.2.5 Boyden chamber chemotactic migration assays 
Chemotactic migration assays were performed using Boyden chambers as 
described in section 2.6.1.1.  Inserts were seeded with 25,000 OE21 or OE33 
cells in 500µl 0.1% FBS in appropriate media. The bottom well contained 750µl 
CM from CAMs, ATMs or NTMs. The incubation time was 24 h. Cell staining and 
counting was performed as described in section 2.6.1.1. Data are presented as 
mean cells migrating in 5 fields/well; experiments were performed in triplicate and 
data expressed as mean ± S.E.M; significance was determined by student t-test 
or ANOVA as appropriate, p<0.05.  
3.2.6 Scratch wound assays  
Wound healing assays were performed in 6 well plates. Cells were allowed to 
form monolayers and subsequent steps were performed as described in section 
2.6.1.2. OE21 and OE33 cells were incubated for 8 h and 10 h respectively with 2 
ml myofibroblast CM after creating wound edges. Data analysis and presentation 
were performed as described in section 2.6.1.2. Thus, the distance between 
wound edges was measured at 5 equally spaced positions in each field and 
presented as mean percentage of wound healing/well; experiments were 
performed in triplicate and data expressed as means ± S.E.M; significance was 
determined by student t-test or ANOVA as appropriate, p<0.05. 
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3.3 Results 
3.3.1 Oesophageal myofibroblasts express α-SMA and vimentin 
The primary oesophageal tumours employed in this study exhibited increased 
numbers of myofibroblasts typically with disordered architecture and morphology 
compared to adjacent tissue or normal tissue. They also stained with α-SMA and 
vimentin and they were negative for the smooth muscle and pericyte marker 
desmin (Appendix, Figure 1; Data obtained by Dr Tiszlavicz, Szeged, Hungary). 
Initially, cultured myofibroblasts were examined for the expression of two 
characteristic markers, namely α-SMA and vimentin. Expression of α-SMA and 
vimentin was found in both SC and AC CAMs and ATMs, and in NTMs (Figure 
3.1 A, B). Distinct intermediate filaments were visible with vimentin staining while 
with α-SMA there was a network of immunopositive structures that were clustered 
within the plasma membrane (Figure 3.1 A). The majority (99%) of myofibroblasts 
were positive for α-SMA and vimentin, with no structural differences between 
CAMs, ATMs or NTMs. All oesophageal CAMs, ATMs, and NTMs were negative 
for desmin markers for pericytes.  
 
3.3.2 CAMs show increased proliferation compared to ATMs 
Myofibroblast characterization was then extended to include a search for 
functional differences between SC and AC CAMs, ATMs and NTMs. The 
incorporation of EdU was used to measure the proportion of CAM, ATM and NTM 
cultures that were entering S-phase of the cell cycle (Figure 3.2 A). In individual 
pairs of SC (n=4) and AC (n=3) cells, CAMs showed greater proliferation than 
their ATM counterparts (Figure 3.2 B & C). Taken together, the mean data reveal 
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significantly greater numbers of CAMs in S-phase compared to ATMs or NTMs 
(Figure 3.2 D & E). 
 
3.3.3 Optimisation of functional assays for oesophageal cancer 
cell lines, OE21, OE33 and OE19 
In order to study the effect of CM on oesophageal cancer cells it was first 
necessary to optimize assays of proliferation and migration for these cells. EdU 
incorporation assays showed full media significantly increased labeling of OE21, 
OE19 and OE33 cells by approximately 30% compared to SF conditions (Figure 
3.3 A & B). In wound healing assays, there was significantly increased migration 
of OE21 and OE33 cells in response to FM compared to SF conditions (Figure 
3.3 C). OE21 and OE33 cells both migrated as a layer of cells (Figure 3.3 D). 
There was poor adhesion of OE19 cells after wounding and serum starvation and 
so these cells were not included in wound healing assays.  
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Figure 3.1 Characterisation of cultured oesophageal myofibroblasts. A) Positive 
vimentin  (red) staining of cultured oesophageal myofibroblasts (arrow) from 
squamous cancer and normal oesophageal tissue (nuclear staining with DAPI, blue); 
top, CAMs; middle, ATMs; lower, NTMs. B) Positive α-SMA (green) staining in 
cultured oesophageal myofibroblasts (arrow) from squamous cancer and normal 
oesophageal tissue (nuclear staining with DAPI, blue); top, CAMs; middle, ATMs; 
lower, NTMs. C) Negative desmin staining in cultures oesophageal CAMs. Scale bar: 
20 μm.  
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Figure 3.2 Increased proliferation of cancer associated myofibroblasts. A) 
Representative data from EdU proliferation assays. Staining of CAM, ATM, and NTM 
nuclei with DAPI (blue, first column, arrow), EdU (green; middle, arrow) and merged 
(third column, arrow). B) Individual pair-wise comparison of EdU labelling in CAMs 
versus ATMs in 4 pairs of SC cells. C) Individual pair-wise comparison of EdU 
labelling in CAMs versus paired ATMs in 3 pairs of AC cells. D) Group mean of data 
in panel B; CAMs (n=4), ATMs (n=4) and NTMs (n=6). E) Group mean of data in 
panel C; CAMs (n=3), ATMs (n=3) and NTMs (n=6). Horizontal arrows mean p<0.05 
by ANOVA; Bars, SEM; Scale bar= 20µM.  
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Figure 3.3 Optimisation of EdU incorporation, and wound healing assays for OE19, 
OE21 and OE33 cells. A) Representative EdU incorporation assays. Staining of 
OE21 nuclei with DAPI (blue, first column), EdU (green; middle) and merged images 
(third column) of cells treated with serum free media (SF, control) and full media 
(FM). B) Mean EdU labeling of OE19, OE 21 and OE33 cells (10,000 cells/well, 2cm2) 
24 h in SF or FM. C) Wound healing assays of OE21 and OE33 cells, scored at 8 h 
and 10 h when the closure of the wounds was approximately 50%. D) Mean wound 
healing of OE 21 and OE33 cells 8 h in SF or FM. Horizontal arrows mean p<0.05 by 
ANOVA; Bars, SEM; Scale bar- 20µM.  
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3.3.4 Enhanced proliferation of OE21 and OE33 cells in response 
to CM from CAMs 
 
EdU incorporation was then used to measure the proliferation of OE21 and OE33 
cells in response to myofibroblast CM. In individual pair comparisons, CM from all 
4 SC CAMs (SC1- SC4) stimulated OE21 cell proliferation and CM from all 3 AC 
CAMs (AC1- AC3) stimulated OE33 cell proliferation compared to the relevant 
ATM CM (Figure 3.4 A & B). The group mean increase in OE21 cell proliferation 
in response to CAM CM was significant for SC (n=4) compared to either ATMs or 
NTMs (n=6) (Figure 3.4 C). However, CAM CM stimulated OE33 cell proliferation 
was significantly greater compared to NTM CM (n=6) but not ATM CM (Figure 3.4 
D). In addition, the increase in OE21 and OE33 cell proliferation was significant in 
response to CM from SC ATM and AC ATM respectively, compared to control 
(Figure 3.4 C & D). 
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Figure 3.4 Increased proliferation of OE21 and OE33 cells treated with CM from 
CAMs. A) EdU labelling of OE21 cells treated with CM from SC CAMs compared to 
the corresponding ATM CM. B) EdU labelling of OE33 cells treated with CM from AC 
CAMs compared to the corresponding ATM CM. C) Group mean data for EdU 
labelling of OE21 cells treated with CM from SC CAMs (n=4) compared to ATM CM 
(n=4) and NTM CM (n=6). D) Group mean data for EdU labeling of OE33 cells treated 
with CM from AC CAMs (n=3) compared to ATM CM (n=3). Horizontal arrows mean 
p<0.05 by ANOVA; Bars, SEM. 
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3.3.5 Wound healing assays show CAM CM induces greater OE21 
and OE33 cell migration 
 
In individual pairwise comparisons, CM from SC CAMs increased OE21 cell 
migration compared to CM from corresponding ATMs (Figure 3.5 A). Similar 
results were obtained for OE33 cells in response to CM from AC CAMs compared 
with ATMs (n=3) (Figure 3.5 B). The group mean data showed significant
 
increases in OE21 cell migration in response to CM from SC CAMs compared to 
the paired ATMs, or NTMs (Figure 3.5 C). Increase OE33 cell migration was also 
seen in response to CM from AC CAMs compared to the corresponding ATM CM. 
In addition, a significant increase in OE33 cell wound healing was seen in 
response to CM from AC ATM compared to control (Figure 3.5 D). 
 
3.3.6 CAM CM induces OE21 and OE33 chemotaxis 
 
Finally, studies of cell migration were extended to include a different type of assay 
namely chemotaxis in Boyden chambers. In individual paired comparisons, OE21 
cells treated with CM (in the lower chamber) from SC CAMs showed enhanced 
migration compared to CM from the corresponding ATMs (Figure 3.6 C). Similar 
results were obtained for OE33 cells in response to CM from AC CAMs compared 
with ATMs (Figure 3.6 D). The group mean data showed statistically significant
 
increases in OE21 and OE33 cell migration in response to CM from CAMs 
compared to ATMs or NTMs in both, SC and AC group (Figure 3.6 E & F). In 
addition, a significant increase in OE21 and OE33 cell migration was seen in 
response to CM from SC ATMs and AC ATMs, respectively, compared to control 
(Figure 3.6 E & F). 
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Figure 3.5 Increased migration in wound healing assays of OE21 and OE33 cells 
treated with CM from CAMs. A) Wound healing responses of OE21 cells treated with 
CM from SC CAMs versus corresponding ATMs. B) Wound healing responses of 
OE33 cells treated with CM  from AC CAMs versus corresponding ATM CM. C) 
Group mean wound healing data for OE21 cells treated with CM from SC CAMs 
(n=4), ATMs (n=4) and normal tissue myofibroblasts, NTMs (n=4). D) Group mean 
wound healing data for OE33 cells treated with CM from AC CAMs (n=3) and ATMs 
(n=3). Horizontal arrows mean p<0.05 by ANOVA; Bars, SEM.  
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Figure 3.6 Enhanced chemotaxis of OE21 and OE33 cells in response to CM from CAMs. A) 
Representative Boyden chamber migration assays of OE21 cells treated with CM from NTMs, 
ATMs, and CAMs (red arrow). B) Representative Boyden chamber migration assays of OE33 
cells treated with CM from NTMs, ATMs, and CAMs (red arrow). C) Boyden chamber 
migration assays of OE21 cells treated with CM from SC CAMs and corresponding ATMs. D) 
Group mean data of OE21 cell migration in response to CM from SC CAMs (n=4), ATMs (n=4) 
and NTMs (n=4). E) Boyden chamber migration assays of OE33 cells in response to CM from 
AC CAMs and corresponding ATMs. F) Group mean data of OE33 migration responses to CM 
from AC CAMs (n=3), ATMs (n=3) and NTMs (n=2). Horizontal arrows mean p<0.05 by 
ANOVA; Bars, SEM. 
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3.4 Discussion 
The main finding of these studies is that conditioned media from myofibroblasts 
increases the proliferation and migration of oesophageal squamous cancer i.e. 
OE21 cells and Barrett’s adenocarcinoma i.e. OE33, cells. The myofibroblasts 
used for these studies were characterised by positive staining for α-SMA and 
vimentin expression. In the case of both types of oesophageal cancer, the results 
indicate clear functional differences in proliferation in vitro between CAMs 
compared with ATMs or NTMs. Importantly, the functional differences also include 
an increased capacity for CM from SC and AC CAMs to stimulate the proliferation 
and migration of OE21 and OE33 cells compared to CM from ATMs or NTMs. 
Expression of α-SMA and vimentin are widely used as markers for myofibroblasts. 
In particular increased expression of α-SMA occurs when fibroblasts are 
transformed to myofibroblasts and is a marker for this transformation (Hinz, 
Celetta et al. 2001). The present data are therefore consistent with observations 
that myofibroblasts or CAFs from various other cancers such as lung, breast and 
pancreatic cancer also express α-SMA and vimentin (Serini and Gabbiani 1999; 
Micke and Ostman 2004; Surowiak, Suchocki et al. 2006; Brentnall, Lai et al. 
2012). However, expression of α-SMA also occurs in smooth muscle cells, and 
possible contamination of pericytes and epithelial cells might conceivably occur in 
myofibroblast cultures. This was tackled by showing positive co-staining for 
vimentin and negative staining for desmin and pan-cytokeratin thereby confirming 
that the myofibroblast cultures differ from smooth muscle cells pericytes or 
epithelial cells.  
 
Functional studies showed clear differences between CAMs versus ATMs or 
NTMs. In particular, SC and AC CAMs proliferate at greater rates than ATMs or 
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NTMs as indicated by EdU incorporation (which measures cells in S-phase). It 
would have been interesting to measure the apoptosis in myofibroblasts although 
previous studies have suggested no difference in cell death between gastric 
CAMs, ATMs and NTMs (Holmberg, Quante et al. 2012). Moreover, other work in 
the group has found no difference in apoptosis using cleaved caspase assays in 
these myofibroblasts (Holmberg, Quante et al. 2012). The present data are 
nevertheless consistent with previous studies using cell growth assays such as 
MTT (3-(4,5-dimethyethiazol-2-yl)-2,5-diphenyltetrazolium bromide) which show 
increased biomass of tumour fibroblasts, and flow cytometry to measure cells in 
the S and G2-M phases of the cell cycle which has confirmed increased tumour 
fibroblast proliferation compared with non-tumorous fibroblasts derived from 
oesophageal SC (Zhang, Fu et al. 2009). 
 
In view of the potential importance of myofibroblasts in regulating the tumour 
microenvironment and promoting cancer cell growth, the effect of myofibroblast 
CM was then studied on several different oesophageal cancer cell lines. For 
these studies CM from SC and AC myofibroblasts were applied to an SC cell line 
(OE21) or to AC cell lines (OE33 and OE19), respectively. Myofibroblast CM 
stimulated proliferation and migration of the cancer cell lines, and CAM CM was 
more potent than ATM CM.  Proliferation was measured as EdU incorporation into 
DNA of dividing cells. Unlike BrdU incorporation assays, EdU incorporation 
assays are rapid to perform and do not require DNA denaturation; in principle 
though, the two assay both measure cells in S-phase. In previous studies, 
oesophageal cancer cell proliferation has been measured by MTT and XTT 
(sodium3’-[1-phenylamino)-carbonyl]-3,4-tetrazolium]-bis(4-methoxy-6-nitro) 
benzene-sulfonic acid hydrate incorporation (Liu, Jamieson et al. 2005; 
O'Donovan, O'Sullivan et al. 2011). These assays measure tetrazolium salt 
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reduction in metabolically more active cells by mitochondrial dehydrogenase. 
Although convenient, they do not therefore measure cell proliferation directly. 
Moreover, the tetrazolium salt in the presence of PMS (phenozine 
methosulfate) is toxic and can result in unreliable assays. It is conceivable that 
increased proliferation could be accompanied by increased apoptosis in which 
case EdU incorporation might not indicate an increase in cell numbers. In 
response to CM from SC and AC CAMs, OE21 and OE33 cells exhibited both 
increased EdU incorporation and greater clonal expansion compared with ATM 
CM. Previously, other models have been used to study stromal-cancer cell 
interactions; for example co-culture studies suggest that direct contact of breast 
cancer cells, UACC-81 and MCF7 with fibroblasts is essential to induce cancer 
cells proliferation or migration (Maeda, Alexander et al. 2004; Samoszuk, Tan et 
al. 2005). Even so, studies using CM from myofibroblasts in CFU and Boyden 
chamber migration assays have shown enhanced cancer cell proliferation and 
migration, respectively, in human breast cancer and in gastric cancer (Gioni, 
Karampinas et al. 2008; Mi, Bhattacharya et al. 2011; Holmberg, Quante et al. 
2012). Hence, the data from multiple models supports the idea of functional roles 
for myofibroblasts driving cancer cell proliferation. 
The present study examined migration of cancer cells using two different assays: 
wound healing and transwell Boyden chamber assay. In wound healing assays 
the ability of cells to migrate in an open field is measured; this type of assay is 
suitable for cells that migrate as a sheet ie without loss of cell-cell contact. 
Boyden chamber assays also determine migration but in this case in response to 
a gradient of growth factor; they therefore measure chemotaxis. Moreover these 
assays are suitable for cells that migrate individually ie exhibit EMT. In response 
to CM from oesophageal SC and AC CAMs, both OE21 and OE33 cells showed 
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enhanced migration compared with CM from ATMs or NTMs. The migration of 
cancer cells in response to myofibroblast CM has previously been determined in 
several other studies, for example Holmberg et al., showed increased AGS cell 
migration in response to CM from gastric cancer CAMs and ATMs(Holmberg, 
Quante et al. 2012). 
In conclusion oesophageal myofibroblasts in culture express α-SMA and vimentin 
markers, which are important markers of their differentiation. However, there are 
important functional differences between CAMs, ATMs and NTMs: CAMs 
proliferate more than ATMs and NTMs. In addition CM from CAMs consistently 
induces more proliferation and migration of OE21 and OE33 cells compared to 
CM from paired ATMs, or from NTMs. One obvious mechanism to explain these 
observations would be the increased abundance of paracrine factors in CAM CM. 
In subsequent chapters, therefore, this possibility will be explored in order to 
define myofibroblast secreted factor(s) involved in stimulating oesophageal 
cancer cell proliferation or migration.  
3.5 Conclusion 
 
1. CAMs, ATMs, and NTMs exhibit a myofibroblast phenotype. 
2. CAMs are more proliferative than ATMs in both SC and AC. 
3. Conditioned media from SC and AC CAMs increased proliferation and 
migration of OE21 and OE33 cell, respectively, more than CM from ATMs, 
or NTMs. 
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4.1 Introduction 
Chemerin is a comparatively new protein that has emerged as a modulator of 
cancer growth. Its potential to recruit stromal cells, e.g. macrophages and 
dendritic cells has been studied in obesity (Landgraf, Friebe et al. 2012), insulin 
resistance (Takahashi, Takahashi et al. 2008) and inflammatory diseases 
(Landgraf, Friebe et al. 2012). In addition, recent findings have shown increased 
chemerin concentrations in ascites fluid resulting from ovarian and liver cancer 
(Wittamer, Franssen et al. 2003) although no functional relevance was attached 
to the observation. Other studies have shown increased chemerin in association 
with a good prognosis for non-small cell lung cancer (NSCLC) (Shen Zhao 2011), 
and suppression of tumorigenesis in melanoma (Pachynski, Zabel et al. 2012). 
Nevertheless, little attention has been given to chemerin interactions with its 
cognate receptors, chemR23 and GPR1, or to the activation of signalling 
cascades, in cancer. To our knowledge, so far nothing has been published 
relating chemerin to oesophageal cancer. 
Proteomic studies using iTRAQ analysis to compare the secretome of SC CAMs 
and ATMs have been performed by Dr C Holmberg (Holmberg 2009) The results 
revealed chemerin to be an upregulated chemokine in the media of CAMs relative 
to paired ATMs in all 4 SC patients examined (see Appendix 2). In the present 
study these observations were validated and the effect of chemerin on MSC, 
OE21 and OE33 cell migration was investigated, together with the role of the two 
putative chemerin receptors: chemR23 and GPR1. 
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4.1.1 Objectives 
 
The specific objectives were: 
1. To validate the expression and secretion of chemerin by myofibroblasts. 
2. To investigate the effect of chemerin on MSC, OE21 and OE33 cell 
proliferation and migration. 
3. To study ligand–receptor interactions and dissect the transduction 
pathways mediating chemerin-stimulated MSC migration. 
4. To identify targets of chemerin expressed by MSCs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                           Chemerin and Mesenchymal Stromal Cell migration
  
83 
 
4.2 Material and Methods 
4.2.1 Cell culture and condition media preparation 
 
Oesophageal SC and AC myofibroblasts (CAMs and ATMs), and oesophageal 
NTMs, were cultured as described in section 2.3.1. Conditioned media were 
prepared as described in section 2.4. Oesophageal cancer cell lines (OE19, 
OE21 and OE33 cells) and MSCs were cultured as described in sections 2.3.2 
and 2.3.3 respectively. 
4.2.2 Immunocytochemistry 
 
Expression of chemR23 and GPR1 in MSC was confirmed using ICC as 
described in section 2.5. Approximately 500-800 cells were counted in each case 
and images were taken as described in section 2.5. 
4.2.3 EdU labelling 
Proliferation was determined by EdU labelling as described in section 2.7.1. Cells 
were incubated in 1 ml SF media containing human recombinant chemerin at 
100ng/ml for 24 h. Labelled cells were counted in 5-10 fields (approximately 100-
200 cells/well) in triplicate. Images were taken as described in section 2.3. Data 
are represented as mean % EdU-labelled cells ± S.E.M, and significance 
determined by student t-test, or ANOVA as appropriate and considered significant 
at p<0.05. 
4.2.4 Boyden chamber- chemotactic migration assays 
 
Chemotactic migration assays were performed as described in section 2.6.1. 
Inserts were seeded with 10,000 cells in 500µl SF and the bottom well contained 
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either 750µl CM or SF media containing chemerin (4 - 100ng/ml) or other 
treatment, as appropriate. The effect of CM from myofibroblasts overexpressing 
chemerin or in which chemerin had been knocked-down was studied on MSC and 
OE21 cell migration as described in section 2.6.1.1. The effect of chemerin 
receptor (chemR23 and GPR1) knock down in MSCs was studied in response to 
CM or chemerin. Inhibitors of MAPK (SP600125, 50µM; UO126, 10µM; 
SB202190, 3µM), PKC (Ro320432, 2µM) and PI3K (LY294002, 50µM), were 
used.  Cell staining and counting were performed as described in section 2.6.1.2. 
Data are represented as mean of cells migrating in 5 fields/well in triplicate ± 
S.E.M and significance was determined by student t-test or ANOVA as 
appropriate and considered significant at p<0.05. 
4.2.5 Scratch wound assays  
The effect of chemerin (20ng/ml, 100ng/ml) on OE21, OE33 and MSC migration 
in scratch wound assays was studied in 6 well plates as described in 2.6.1.2.  
4.2.6 Western blot analysis 
 
Western blot analysis was used to validate expression of chemerin in 
myofibroblasts after overexpression and knockdown and to determine activation 
of MAPK pathways after chemerin and PMA stimulation, as described in section 
2.9.  
4.2.7 Gene Expression analysis 
Transcript profiles of myofibroblasts, MSCs and OE21 cells were analysed using 
GeneChip©Human Genome U133 Plus 2.0 arrays as described in section 2.8.  
4.2.8 Sandwich - enzyme linked immunosorbent assay (ELISA) 
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Chemerin concentrations in media from myofibroblasts, MSCs and oesophageal 
cancer cell lines were determined by ELISA as described in section 2.10.  
4.2.9 Transient transfection of myofibroblasts and MSCs 
Squamous cancer CAMs and ATMs were transfected with a chemerin 
overexpression plasmid (3µg) or with 3 different silencing RNAs (siRNA) (3µM) as 
described in section 2.11 and 2.12.  
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4.3 Results 
4.3.1 Gene arrays indicate reciprocal expression of chemerin and 
chemR23 transcripts in CAMs and MSCs 
In initial studies, the relative abundance of chemerin and chemR23 transcripts 
was examined using existing microarray datasets from oesophageal CAMs, 
ATMs, MSCs and cancer cell lines. The abundance of chemerin transcripts 
relative to GAPDH was highest in CAMs and ATMs (both SC and AC), followed 
by MSCs, OE19, OE21 and OE33 cells. A comparison between CAMs and ATMs 
from SC or AC showed no difference in chemerin transcript abundance. Similarly 
the abundance of chemerin transcripts, relative to GAPDH, in NTMs resembled 
that in CAMs and ATMs and was higher than in MSCs and cancer cells (Figure 
4.1 A). 
The abundance of chemR23 transcripts relative to GAPDH was significantly 
higher in MSCs than in myofibroblasts or cancer cells (Figure 4.1 A). There was 
no difference in chemR23 transcript abundance in the different types of 
myofibroblast. A microarray analysis was also performed for the other putative 
chemerin receptor, GPR1. The abundance of GPR1 transcripts relative to 
GAPDH was higher in MSCs than in CAMs, ATMs (either SC or AC), NTMs or 
cancer cells. There was no difference of GPR1 transcripts between CAMs and 
ATMs in AC, but in SC there was higher abundance in ATMs than CAMs.  
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Figure 4.1  Chemerin expression is higher in myofibroblasts while that of its putative 
receptors, chemR23 and GPR1, is higher in MSCs. Transcript abundance of 
chemerin, chemR23 and GPR1 relative to GAPDH in  OE19, OE21, OE33, MSCs, 
and different groups of myofibroblasts (CAMs, ATMs, NTMs). Horizontal arrows mean 
p<0.05 by ANOVA; vertical bars, SEM. 
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4.3.2 Increased chemerin expression in CAMs 
 
Given the microarray data, it was then considered particularly important to 
validate the observation by proteomic analysis of increased chemerin in CAMs 
using Western blot and ELISA. Western blot analysis of media and cell extracts 
from SC CAMs and ATMs showed greater expression of chemerin in CAMs than 
in ATMs (Figure 4.2 A and B). In contrast, cell extracts from MSC and OE21 cells 
showed either no, or barely, detectable expression of chemerin (Figure 4.2 C). 
The group mean data for densitometry analysis Western blots of SC cell extracts 
and media confirmed significantly increased chemerin expression in CAMs 
compared to ATMs (Figure 4.2 D and E).  
To further validate the findings, individual pairwise comparisons were then made 
of chemerin expression measured by ELISA of media from SC and AC CAMs 
compared to ATMs (Fig 4.3 A & C). The range of chemerin concentrations in 
CAM media was 200 to 3250 pg/ml compared with 90 pg/ml to 1450 pg/ml in 
ATMs. The group mean chemerin concentration in CAM media was significantly 
higher than in their paired ATMs for both SC and AC  (Figure 4.3 B & D).  
4.3.3 Chemerin receptor, chemR23 and GPR1, expression in MSC  
 
Since the gene array data suggested chemR23 and GPR1 were relatively well 
expressed in MSCs compared to myofibroblasts and cancer cells the expression 
of these was then validated by immunocytochemistry. Specific antibodies for each 
receptor showed strong chemR23 and GPR1 expression in MSCs (Figure 4.2 F). 
Approximately 90-95% of MSCs were positive for chemR23 and GPR1 
suggesting most cells expressed both receptors. Myofibroblasts and cancer cells 
showed weak chemR23 and GPR1 expression. 
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Figure 4.2 Increased chemerin expression in CAMs and ChemR23 receptor 
expression in MSCs. A) Western blots analysis of chemerin in media from SC CAMs 
and ATMs, and B) cell extracts. C) Western blots of chemerin in MSC and OE21 cell 
extracts. D) Quantitative analysis of chemerin abundance in SC CAM and ATM media 
by densitometry (n=4), and E) cell extracts (n=4). F) Immunohistochemical staining of 
ChemR23, and GPR1 in MSCs. Horizontal arrows p<0.05 by t-test; vertical bars, 
SEM; scale bar, 20µM; magnification, 40x.  
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Figure 4.3 ELISA indicates increased chemerin in media of CAMs compared to 
ATMs. A) Chemerin concentrations (pg/ml) in individual pairs of CAMs (filled bars) 
and ATMs (open bars) from SC. B) Mean chemerin concentration from SC CAMs and 
ATMs (n=4). C,D) Similar data for AC (n=3). Horizontal arrows,  p<0.05, paired t- test; 
vertical bars, SEM.  
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4.3.4 Chemerin increased EdU incorporation 
 
Next, the role of chemerin was investigated using human recombinant chemerin 
in cell proliferation assays, by EdU. EdU incorporation assays showed increased 
proliferation in MSC and OE21 cells in response to 100ng/m chemerin (Figure 4.4 
B & C). 
4.3.5 Chemerin in CM from CAMs stimulated MSC proliferation 
 
The role of chemerin released from CAMs was then studied by examining the 
effect of CM from SC myofibroblasts, and from NTMs, on MSC proliferation. Thus 
CM from CAM6 significantly increased MSC proliferation compared to CM from 
the corresponding ATM or from NTMs (Figure 4.4 D). The stimulatory effect of 
CAM CM on MSC proliferation was inhibited using chemerin neutralising antibody 
(Figure 4.4 E). 
4.3.6 Recombinant chemerin enhanced MSC, OE21, OE33 and 
myofibroblast chemotactic cell migration  
 
To study the effect of chemerin in chemotactic cell migration, Boyden chamber 
assays were performed. Chemerin increased MSC, OE33 and OE21 cell 
migration in these assays (Figure 4.5 A, B, C, D, & F). It also increased CAM and 
ATM migration significantly compared to SF media (Figure 4.5 G & H).  
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Figure 4.4 Increased proliferation of MSCs in response to chemerin. A) 
Representative image of EdU staining (arrow) of MSCs in response to chemerin, 100 
ng/ml. B) Dose dependent increase in EdU labelling of MSCs in response to 
chemerin. C) Similar data for EdU labelling of OE21 cells. D) Increased EdU labelling 
of MSCs in response to CM from CAMs, ATMs and NTMs. E) Chemerin immune-
neutralisation (Chem Ab) significantly decreased EdU labelling of MSCs treated with 
CM from CAM6. Horizontal arrows, p<0.05, ANOVA; vertical bars, SEM.   
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Figure 4.5 Chemerin stimulation of cell migration in chemotaxis assays. A) 
Representative image of migrating MSCs (red arrow). B) Dose-dependent MSC 
migration in response to chemerin. C) Representative image of OE21 migrating cells 
(red arrow). D) Dose-dependent OE21 migration in response to chemerin. E) 
Representative image of OE33 migrating cells (red arrow). F) OE33 cells migrated in 
response to dose dependent stimulation by chemerin. G) Chemerin (100 ng/ml) 
stimulated CAM1 and ATM1 and H) CAM6 and ATM6 migration (n=3). Horizontal 
arrows means p<0.05,  t- test; vertical bars,  SEM. Scale bar, 20 µm 
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4.3.7 Recombinant chemerin increased MSC, OE33 and OE21 cell 
migration in wound healing assays 
 
As a final step in characterising the biological properties of chemerin, its effects in 
a different cell migration assay, namely scratch wound healing, was studied. In 
these assays MSCs, OE33 and OE21 cells exhibited significantly more migration 
in response to chemerin at doses of 20 and 100 ng/ml compared to SF controls 
(Figure 4.6 A-F). 
 
4.3.8 Conditioned media from CAMs enhances MSC and OE21 
cell migration  
 
To study whether chemerin produced by myofibroblast increases MSC migration 
studies were performed using CM and a chemerin neutralising antibody. In 
Boyden chamber assays, CM from SC CAMs and ATMs increased MSC 
migration. Individual pairwise comparisons showed MSCs migrated more in 
response to CM from CAMs than the corresponding ATMs (Figure 4.7 A). The 
group mean data also showed CAM CM significantly increased MSC migration 
compared to either ATM or NTM CM (Figure 4.7 B). The effect of chemerin (100 
ng/ml) on MSC and OE21 cell migration was inhibited by a neutralising antibody 
(Figure 4.7 C & D). Moreover, the specificity of chemerin neutralising antibody 
was showed by no effect on IGF-II stimulated migration (100 ng/ml) (Figure 4.7 
C). Importantly, MSC and OE21 cell migration in response to CM from SC CAMs 
was significantly inhibited by chemerin neutralising antibody (Figure 4.8 E & F). 
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Figure 4.6 In wound healing assays, chemerin stimulated cell migration in a dose 
dependent manner. A) Representative images of MSCs migrating individually in 
scratch wound assays (red arrow) in response to chemerin stimulation. B) Dose 
dependent chemerin stimulation of MSC migration. C) Representative image of OE21 
cells migrating as a sheet. D) Dose dependent chemerin stimulation of OE21 cell 
migration. E) Representative image of OE33 cells in wound healing assay in the 
presence of chemerin. F) Chemerin has little or no effect on OE33 cell migration. n=3. 
Horizontal arrows, p<0.05, t-test; vertical bars, SEM. Scale bar, 20μm. 
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Figure 4.7 In Boyden chamber migration assays, SC CAM CM increased MSC and 
OE21 cell migration.  A) Comparison of MSC migration in response to CM from 
paired SC CAMs versus ATMs. B) Group mean data of MSC migration in response to 
CM from SC CAMs (n=4), ATMs (n=4) and NTMs (n=4). C)  Chemerin neutralising 
antibody inhibited MSC migration in response to chemerin (100 ng/ml) but not IGF-II 
(100 ng/ml). D) Chemerin stimulation of OE21 cell migration is decreased by 
chemerin immuno-neutralisation (Chem Ab). E) Stimulation of MSC migration by 
CAM4, CAM5, CAM6 and CAM7 CM was inhibited by chemerin neutralising antibody 
(n=3). F)  OE21 migration in response to CAM5 CM treatment was partially inhibited 
by chemerin immuno-neutralisation. Horizontal arrows, p<0.05, ANOVA; vertical bars, 
SEM. 
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4.3.9 Chemerin neutralisation inhibits CM stimulated OE21 
wound healing  
 
In wound healing assays, chemerin (100ng/ml) and CM from CAM4 significantly 
increased OE21 cell migration compared to SF media (Figure 4.8 A & B). The 
stimulatory effect was significantly inhibited by chemerin neutralising antibody 
(Figure 4.8 A & B).  
 
4.3.10 Knock-down of chemerin inhibits and overexpression 
increases cell migration  
 
In addition to the neutralising antibody approach, knock-down and overexpression 
of chemerin were used to confirm a role in cell migration. Chemerin knock-down 
in CAMs using siRNA was confirmed by Western blots (Figure 4.9 A). MSCs 
showed significantly reduced migration in response to CM from CAMs treated 
with silencing RNA compared to control CAM CM (Figure 4.9 B). In the case of 
OE21 cell migration, there was a significant reduction by CAM4 and CAM7 CM 
after chemerin knock-down (Figure 4.9 D).  
Overexpression of chemerin after transfection with an expression vector of CAM4 
and ATM7 cells was confirmed by Western blot (Figure 4.9 A). The CM from 
myofibroblasts overexpressing chemerin significantly increased in MSC and 
OE21 cell migration relative to control (Figure 4.9 C & E). 
 
 
                                                                           Chemerin and Mesenchymal Stromal Cell migration
  
98 
 
 
 
 
 
0
20
40
60
80
100
W
o
u
n
d
 h
e
a
li
n
g
 (
%
)
CAM4 CM  - +           +
Chem. Ab - +           +
*
0
20
40
60
80
100
W
o
u
n
d
 h
e
a
li
n
g
 (
%
)
Chemerin    - - +        +
Chem. Ab    - +         - +
*
 
Figure 4.8 In wound healing assays, chemerin immuno-neutralisation decreased 
OE21 migration.  A) Effect of immuno-neutralisation on OE21 migration stimulated by 
chemerin (100ng/ml). B) OE21 migration in response to CM from CAM4 was inhibited 
by chemerin neutralising antibody (n=3). Horizontal arrows, p<0.05; ANOVA; vertical 
bars, SEM. 
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Figure 4.94 Chemerin knock-down decreased, and overexpression increased, MSC 
migration in Boyden chamber migration assays. A) Western blots showing chemerin 
knock-down in siRNA treated (Si1) CAM7 and (Si2 and Si3) CAM4 cells, and 
overexpression after chemerin plasmid transfection in CAM4 and ATM7 cells. B) 
MSC migration is decreased in response to CM from CAM4 and CAM7 transfected 
with chemerin silencing RNA, Si1 and Si3 respectively. C) Increased MSC migration 
in response to CM from CAM4 and ATM7 overexpressing chemerin. D) OE21 cell 
migration is decreased in response to CM from CAM4 siRNA transfected cells, and 
increased by CM from chemerin overexpressing ATM7 cells. E) In wound healing 
assays, CM from CAM4 cells overexpressing chemerin increased OE21 cell 
migration. Horizontal arrows, p<0.05, t- test; vertical bars, SEM.   
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4.3.11 ChemR23 knock-down in MSCs reduce the migratory 
response to CM and chemerin 
The data above indicate a role for chemerin in mediating the effect of 
myofibroblast CM on migration of several cell types including MSCs. The relevant 
receptors in MSCs were then examined by separate knock-down of chemR23 and 
GPR1. The knock-down of receptors by validated siRNAs was confirmed by 
immunocytochemistry (Figure 4.10 A & B). Scoring of chemR23 and GPR1 after 
knock-down indicated a reduction in immunoreactive cells by 80.7% and 75.9%, 
respectively, relative to control MSCs (Figure 4.10 C & D). In both cases, a 
negative control, vimentin, showed no change after treatment with siRNA for 
chemR23 and GPR1 confirming the specificity of the receptor suppression (Figure 
4.10 C & D). 
In response to CAM CM, MSCs treated with chemR23 siRNA showed significant 
decreases in migration compared to control cells (Figure 4.11 A, Left panel). 
Similar results were obtained in response to chemerin (Figure 4.11 B, Left panel). 
However, GPR1 knock-down in MSCs had only modest effect on migration in 
response to CM from CAM6 but no effect to chemerin (Figure 4.11 A & B, Top 
and bottom right panel respectively). 
 
4.3.12 Chemerin activation of chemR23 stimulates MAPK 
pathways 
Having established a functional role for chemR23 in mediating chemerin effects 
on MSCs, the next step was to determine the signal transduction pathways 
involved in cell migration. In response to chemerin, MSC cell extracts showed 
increased phosphorylation of p42-44, p38 and JNK-II kinases in Western blots 
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using phosphor-specific antibodies and in all cases this was decreased by 
chemR23 knock-down (Figure 4.12). 
 
4.3.13 Chemerin stimulated MSC migration via activating MAPK 
pathways 
 
The role of signalling pathways activated by chemerin was then studied using 
specific pharmacological inhibitors targeting p42-44, p38, JNK-II, and PKC 
pathways. Chemerin-induced MSC migration was significantly inhibited by 
SP600125 (JNK-II inhibitor), UO126 (p42/44 inhibitor), SB202190 (p38 inhibitor), 
Ro320432 (PKC inhibitor) but not LY294002 (PI3K inhibitor) (Figure 4.13 A). The 
PKC inhibitor showed the highest inhibition of chemerin-stimulated MSC 
migration. Combinations of inhibitors i.e. two or three together virtually abolished 
chemerin stimulated MSC migration (Figure 4.13 B).  
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Figure 4.5 Immunocytochemical validation of receptor expression after chemR23 and 
GPR1 knock-down. A) Representative images from MSCs stained for vimentin 
(positive control) and chemR23. B) Representative image from MSCs stained for 
vimentin (positive control) chemR23 and GPR1.  C) Quantitative data show 
decreased chemR23 expression after its knock-down and D) quantitative data 
showing GPR1 expression after its knock-down. Horizontal arrows, p<0.05, t-test; 
vertical bars, SEM. Scale bar, 20µm. 
 
 
 
C D 
A B 
                                                                           Chemerin and Mesenchymal Stromal Cell migration
  
103 
 
 
 
              
0
100
200
300
400
500
Cntrl Si 1 Si 2 Si 3
M
ig
ra
ti
n
g
 c
e
ll
s
 r
e
la
ti
v
e
 t
o
 
c
o
n
tr
o
l
Control
ChemR23 KD
0
100
200
300
400
500
Cntrl Si1 Si2 Si3
M
ig
ra
ti
n
g
 c
e
ll
s
 r
e
la
ti
v
e
 t
o
 
c
o
n
tr
o
l
Control
ChemR23 KD
Control
GPR1 KD
Control
GPR1 KD
Chemerin   +        +        +        +                   +      + 
Cntrl Si
Cntrl Si
CAM6 CM   +        +       +        +                   +      + 
 
 
Figure 4.61 In Boyden chamber migration assays chemR23 knock-down decreased 
MSC migration in response to chemerin (100ng/ml) and CM from CAMs. A) Effect of 
3 different chemR23 silencing RNAs (Si) (left) and a GPR1 validated siRNA (right) on 
MSC migration in response to CAM6 CM. B) MSC migration after chemR23 and 
GPR1 knock-down in response to chemerin. Horizontal arrows, p<0.05, t- test; 
vertical bars, SEM.   
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Figure 4.12 Chemerin stimulated p42/44, p38, and JNK-II in MSCs and the 
stimulation is reduced after chemR23 knock-down. A) Representative Western blot 
analysis of phospho- and total p42/44 kinase, p38 kinase, and JNK-II in MSCs 
treated with chemerin (100 ng/ml) for 0, 10, 20, 30 mins. B) Western blot of phospho 
and total p42/44 kinase, p38 kinase, and JNK-II expression in response to chemerin 
(Ch) (100 ng/ml) in control MSC cells and after chemR23 knock-down. 
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Figure 4.73 Chemerin stimulated MSC migration is mediated by several protein 
kinases. A) In Boyden chamber assays, chemerin stimulated MSC migration is 
inhibited by SP600125 (JNK-II inhibitor, 50µM), UO126 (p42/44 inhibitor, 10µM), 
SB202190 (p38 inhibitor, 3µM), Ro320432 (PKC inhibitor, 2µM) but not LY294002 
(PIK3 inhibitor, 50µM) (n=3). B) Chemerin stimulated MSC migration  is significantly 
inhibited by combinations of two of UO126, SB202190, and Ro320432, and by 
combination of three of SP600125, UO126, SB202190 and Ro320432 (n=3). 
Horizontal arrows, p<0.05, Anova; vertical bars, SEM. 
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4.3.14 PKC acts upstream of MAPK activation 
The observation that the strongest inhibition of chemerin-stimulated MSC 
migration was by the PKC inhibitor suggested the existence of signalling 
cascades downstream of PKC. This hypothesis was then investigated by using 
p42/44, p38, JNK-II inhibitors against PMA-stimulated MSC migration. MSCs 
showed a significant increase in migration in response to the PKC activator, PMA 
(Figure 4.14 A). The MAPK inhibitors SP600125, UO126 and SB202190 
significantly inhibited PMA-stimulated migration (Figure 4.14 A). The combination 
of all three inhibitors virtually abolished PMA stimulated MSC migration compared 
to control (Figure 4.14 A). In addition, Western blot analysis of cell extracts from 
PMA-stimulated MSCs showed increased phospho - p42/44, p38 and pJNK-II 
(Figure 4.14 B & C respectively) that was reduced by the PKC inhibitor Ro320432 
(Figure 4.14 C).  
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Figure 4.14.  PMA stimulated MSC migration is mediated by activation of p42/44 
kinase, p38 kinase, JNK-II, and PKC. A) PMA (100nM) stimulated MSC migration in 
Boyden chamber assay and was inhibited by SP600125 (JNK-II inhibitor, 50µM), 
UO126 (p42/44 inhibitor, 10µM), and SB202190 (p38 inhibitor, 3µM). B) 
Representative Western blot analysis of p42/44, p38 and JNK-II kinases from MSC 
cell extracts treated with PMA. C) Western blots analysis of p42/44,  p38 and JNK-II 
kinases from MSC cell extracts treated with Ro320432 (Ro, PKC inhibitor) and 
chemerin (100 ng/ml). Horizontal arrows, p<0.05, ANOVA; vertical bars, SEM.  
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4.4 Discussion 
The main finding of this chapter is that oesophageal SC CAMs are a source of 
increased chemerin expression compared with ATMs. Bone marrow derived 
MSCs strongly express the putative chemerin receptors, chemR23 and GPR1, 
and have a strong migratory response to chemerin. Knockdown and 
overexpression studies have confirmed that chemerin in CAM CM acts at 
chemR23 to induce MSC migration. The latter is mostly mediated by activation of 
PKC which in turn stimulates the p42/44, p38 and JNK-II MAPK pathways. 
In this study, the initial discovery of chemerin expression by myofibroblasts was 
made by iTRAQ proteomic analysis comparing CM from SC CAMs and ATMs. 
Chemerin was the only chemokine identified as upregulated in all 4 CAMs from 
SC patients. Interestingly, microarray studies did not show a difference in 
chemerin transcript abundance in CAMs versus ATMs emphasising the 
importance of validation of the proteomic data. Thus a combination of methods 
(ELISA and Western blot) was used to validate the increased chemerin 
abundance both in media and cell extracts of CAMs from oesophageal SC. These 
confirmed increased chemerin in CAM media. Presumably the different 
conclusions from microarray and protein studies indicate regulation of chemerin 
expression at a translational or post-translational level.  
Upregulation of chemerin in fibroblasts related to pathology (skin psoriasis 
compared to paired normal fibroblasts) has previously been reported using RT-
PCR (Albanesi, Scarponi et al. 2009). In addition, other studies have shown 
increased abundance of chemerin in plasma, media and cell extracts using ELISA 
and Western blot (Parlee, Ernst et al. 2010; Parlee, McNeil et al. 2012). However, 
the existence of various chemerin isoforms (Du and Leung 2009) limits the 
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interpretation of assays using a single antibody in ELISA or Western blot.  
Chemerin-9 (which has high bioactivity) was undetectable by the ELISA used 
here, emphasising the need for  further studies to precisely define the active 
forms of chemerin in CAM media; these in turn will depend on the use of multiple 
antibodies of different specificities. Nevertheless the combination of the two 
methods, taken together with the iTRAQ data, provides strong evidence of 
increased expression in CAMs. Consequently, for the first time, it has been 
possible to identify myofibroblasts as a source of elevated chemerin, at least in 
oesophageal cancer. 
The microarray data analysis showed that MSCs have greater chemerin receptor 
expression, both chemR23 and GPR1, compared to myofibroblasts followed by 
oesophageal cancer cells, OE21, OE19 and OE33 cells. Immunohistochemistry 
confirmed the expression of chemR23 and GPR1 in MSCs and showed weak 
staining for both receptors in CAMs and OE21 cells. Techniques such as RT-PCR 
and FACS have previously been applied to other cells eg adipocytes and 
macrophages, to establish chemR23 and GPR1 expression (Huang, Zhang et al. 
2010; Bondue, De Henau et al. 2012). In the present study, the finding of 
increased ligand (chemerin) in myofibroblasts and of receptor expression 
(chemR23) in MSCs provided a basis for further detailed functional studies, 
namely with regard to cell migration. 
Recent work has shown that MSCs are an integral part of the tumour 
microenvironment and are key factors for tumour growth and development (Feng 
and Chen 2009; Kidd, Spaeth et al. 2009). Undifferentiated MSCs can contribute 
to various stromal cell populations including potentially CAMs, as well as epithelial 
cells in oesophageal AC (Worthley, Ruszkiewicz et al. 2009; Hutchinson, 
                                                                           Chemerin and Mesenchymal Stromal Cell migration
  
110 
 
Stenstrom et al. 2011; Lecomte, Masset et al. 2012). It therefore becomes 
important to understand the mechanisms involved in recruitment of MSCs to the 
tumour microenvironment. In this context the chemotactic property of chemerin 
demonstrated in this study suggests a potential novel mechanism.  
Recombinant chemerin increased MSC migration and neutralising antibody to 
chemerin decreased MSC migration stimulated by CM from CAMs and ATMs 
indicating a role for the native protein. Chemerin is known to interact with 
chemR23 to induce trafficking of inflammatory cells and dendritic cells (Ernst and 
Sinal 2010; Bondue, Wittamer et al. 2011). In good agreement with this, siRNA 
knock-down of chemR23 decreased chemerin stimulated MSC migration. 
Albanesi et al., have used anti chemR23 antibody to inhibit chemerin stimulated in 
vitro transmigration of pDC thereby confirming the chemerin interaction with 
chemR23 in chemotaxis (Albanesi, Scarponi et al. 2009). However, the transient 
knockdown by siRNA was not 100% efficient and other reporter based in vitro 
assays, such as Tango assays, ought to be considered as an alternative 
approach in the future (Barnea, Strapps et al. 2008). The latter assay depends 
upon the exogenous ligand activation of receptor followed by protein-protein 
interactions subsequently activating the binding of protease to specific sites of 
cleavage in the fusion of a membrane receptor and transcriptional activator. The 
release of transcriptional activator amplifies the reporter gene and produces 
appropriate signals for quantification (Barnea, Strapps et al. 2008). This method 
might provide a further rigorous approach to define receptor specificity, and its 
activation by chemerin in our cell systems.  
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Other studies showed GPR1 has equal binding affinity to chemerin, however no 
signal transduction ability was observed suggesting of no functional significance 
(Ernst and Sinal 2010; Bondue, Wittamer et al. 2011). We investigated the 
functional significance of GPR1, and in agreement with previous studies GPR1 
knock-down had no effect on chemerin stimulated MSC migration.  
The action of chemerin on MSCs was shown to be mediated by activation of 
p44/42, p38, JNK-II and PKC signal transduction pathways. Furthermore, 
chemerin-mediated MSC migration was significantly reversed by a PKC inhibitor 
suggesting PKC as upstream of MAPK signalling pathways. Nevertheless many 
of the inhibitors used produced only partial inhibition of migratory responses. 
There are two components to interpreting these data First there is partial PKC-
dependent downstream activation of MAPKs signals (Figure 4.15). Second, 
chemerin chemotaxis might independently activate p44/42, p38 and JNK-II. It is 
known that chemerin activates Akt, and PI3K to facilitate macrophage adhesion to 
ECM (Hart and Greaves 2010). However, in our studies the PI3K pathway had no 
role to play in chemerin stimulated MSC migration. 
ChemR23
p42/44 , JNK-II,   p38
PKC        p42/44, JNK-II,  p38
Chemerin
Migration
Migration
 
Figure 4.15. The PKC activation partially activates downstream p44/42, p38, JNK-II 
pathways. In addition, individual activation of p42/44, p38 and JNK-II stimulates cell 
migration. 
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Although not studied in as much detail, we have also investigated and confirmed 
the effect of chemerin on cancer cells. In response to chemerin and CM from SC 
CAMs, OE21 cells showed increased proliferation and migration whereas OE33 
cells did not respond to chemerin. These observations suggest cancer-restricted 
tumour-stromal interaction mediated by chemerin.   
The results presented here raise the first indication of a role for chemerin in 
oesophageal cancer. Firstly, myofibroblasts in oesophageal SC are a major 
source of chemerin. Secondly, chemerin secreted from CAMs interacts with the 
putative receptor chemR23, expressed by MSC and cancer cells and stimulates 
their in vitro migration. Thirdly, the chemerin-chemR23 interaction regulates cell 
migration via activation of signalling pathways, notably PKC that is upstream of 
p44-42, p38, and JNK-II. Berg et al., and others have shown chemerin influences 
the secretion of TNF-α, interleukins and MMPs that further regulate the 
recruitment and migration of cells across stromal compartment (De Becker, Van 
Hummelen et al. 2007; Berg, Sveinbjornsson et al. 2010; Lecomte, Masset et al. 
2012). It is possible that there are comparable extracellular mediators in the 
present system and, if so, their identification will provide valuable insight in 
understanding molecular mechanism involving the tumour microenvironment and 
recruitment of cells to it. 
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4.5 Conclusions 
 
1. Oesophageal SC CAMs secrete chemerin and MSCs express the putative 
chemerin receptors, chemR23 and GPR1. 
2. Chemerin in CM stimulates the migration of MSCs via interaction with 
chemR23.  
3. Chemerin-stimulated chemotaxis is the result of activation of PKC followed 
by partial downstream activation of p-44/42, p38, and JNK-II MAPKs but 
not PI3K. 
4. Chemerin in CM also induces OE21 cell migration. 
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5.1 Introductions 
 
The findings in chapter-4 confirmed an increase of chemerin in myofibroblasts 
associated with oesophageal SC and showed its significance in enhancing MSC 
migration in vitro. In general, chemokines activate multiple paracrine signalling 
pathways regulating functions  such as migration and invasion (Wels, Kaplan et 
al. 2008).  For example, Zhiyong Mi et al., showed increased expression of CCL5 
in BM-derived MSCs along with their recruitment to a metastatic niche in 
response to distant osteopontin originating from breast cancer cells (MDA-
MB231) (Mi, Bhattacharya et al. 2011). In the present study, it was considered 
reasonable to suppose that chemerin might also activate paracrine signalling 
mechanisms in MSCs that were functionally significant.  
Proteomic studies in the group (Holmberg, Varro, unpublished observations) 
using SILAC-labelled MSCs identified increase MIF abundance in response to 
chemerin stimulation. It has been reported that MIF acts as a negative regulator 
of MSC migration at sites of tissue damage (Ozaki, Nishimura et al. 2007; 
Barrilleaux, Fischer-Valuck et al. 2010). It was therefore hypothesised that MIF 
might regulate MSC migration in response to chemerin. To our knowledge there 
have been no previous studies of the effect of chemerin on MIF release. Hence, 
the rationale for the studies in this chapter was to investigate and determine the 
role of MIF in MSC migration.  
 
 
Identification of MIF as a Chemerin Target in MSCs and its Functional Significance 
116 
 
5.1.1 Objectives 
The specific objectives of this chapter were: 
1. To study the effect of chemerin on MIF secretion from MSC and OE21 cells. 
2. To determine the functional significance of MIF on chemerin stimulated MSC 
migration. 
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5.2 Material and Methods 
 
5.2.1 Cell culture  
Myofibroblasts, MSCs, and oesophageal cancer cell lines were cultured as 
described in sections 2.3. 
5.2.2 Boyden chamber migration assays 
The effect of MIF on migration was investigated using Boyden chamber assays as 
described in sections 2.6.1.1 and 2.6.1.2. The bottom well contained 750µl 
serum-free media, with or without chemerin (4-100ng/ml), MIF (200ng/ml), IGF-II 
(100ng/ml) or ISO-1 (50µM).  
5.2.3 Transient transfection of myofibroblasts and MSCs 
MSCs were transfected with validated MIF siRNA (100µM) as described in 
sections 2.11 and 2.12 following the manufacturer’s instruction. 
5.2.4 Western blot analysis 
The expression of MIF in normal and transiently transfected myofibroblasts, 
MSCs and OE21 cells extracts and media was investigated by Western blot as 
described in section 2.9.  
5.2.5 Sandwich - enzyme linked immunosorbent assay (ELISA) 
The concentration of MIF in media from myofibroblasts, MSCs, OE21 and OE33 
cells was determined by ELISA as described in section 2.10.  
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5.3 Results 
 
5.3.1 Chemerin stimulated MSC expresses MIF 
Because proteomic studies using SILAC had shown increased MIF abundance in 
MSC media after 24 hr stimulation with chemerin, validation studies using ELISA 
and Western blot were undertaken to confirm this observation.  
The analysis of MIF by ELISA showed relatively low concentrations in media from 
unstimulated MSCs and increased abundance in response to chemerin and IGF-II 
(Figure 5.1 A). However, in OE21 cell media there were relatively high 
concentrations basally and no effect with IGF-II or chemerin (Figure 5.1 B). 
Similarly, the basal concentrations of MIF in control MSC media were relatively 
low in Western blots, but in response to stimulation by chemerin or IGF-II there 
was increased MIF; there was also increased MIF in MSC cell extracts after 
stimulation (Figure 5.1 C top panels). In contrast, chemerin and IGF-II had very 
modest effects on MIF detected by Western blot in OE21 cell extracts and media 
(Figure 5.1 C bottom panels). ELISA also showed the mean MIF concentration in 
ATM (ATM4-ATM7) media was significantly higher than in the corresponding 
CAM media (CAM4-CAM7) (Figure 5.1 E).   
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Figure 5.1 Increased MIF secretion in MSCs in response to IGF-II (100 ng/ml) and 
chemerin (100 ng/ml). A) ELISA showed MIF secretion in MSC (n=2) but not B) OE21 
media in response to IGF-II or chemerin (n=2). C) Representative Western blots 
showing secretion of MIF by MSCs (top panel) but not by OE21 cells (bottom panel) 
treated with chemerin or IGF-II for 15 min.  D) Myofibroblasts from squamous cancer 
(CAMs) secreted less MIF compared to ATMs (n=4).  Horizontal arrows, p<0.05, t-
test; vertical bars, SEM. 
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5.3.2 MIF inhibits chemerin and IGF-II stimulated MSC migration 
The role of MIF was then investigated with respect to cell migration in response to 
chemerin and IGF-II using Boyden chambers. Chemerin and IGF-II stimulated 
MSC migration was significantly inhibited by MIF (200ng/ml) (Figure 5.2 A). The 
inhibitory effect of MIF on chemerin-stimulated MSC migration was significantly 
reversed by ISO-1, a MIF antagonist, at 50μM (Figure 5.2 C). A role for 
endogenous MIF in modulating MSC migration was then indicated by the 
observation that ISO-1 dose-dependently increased migration in response to 
chemerin (Figure 5.2 B).  
 
5.3.3 MIF inhibits chemerin and IGF-II stimulated MSC migration 
Finally, knock-down studies were performed to further validate the role of MIF. 
Thus knock-down of MIF expression in MSCs using siRNA was confirmed by 
Western blot (Figure 5.3 A). In cells transfected with MIF siRNA there was a 
significant increase in migration in response to 4ng/ml chemerin compared to 
control (Figure 5.3 B); however, at 20ng/ml chemerin, which produced a stronger 
stimulation of MSC migration, there was no significant effect of MIF knockdown 
(Figure 5.3 B)  
Medium from chemerin-stimulated MSCs pre-treated with siRNA to knock-down 
chemR23 expression was then studied by ELISA to establish the role of 
chemerin-chemR23 interactions in MIF secretion. As expected, ELISA showed a 
significant decrease in MIF secretion in chemerin stimulated MSCs pre-treated 
with chemR23 siRNA compared to control MSCs (Figure 5.3 C). Interestingly, 
however, while MSC migration in response to chemerin (4 ng/ml) after chemR23 
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knockdown was, as expected, decreased (p<0.05) compared to control cells, 
ISO-1 strongly increased migration further supporting the idea that MIF plays a 
part in modulating responses to modest chemerin stimulation (Figure 5.3 D). 
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Figure 5.2 MSC migration in response to ISO-1 (50µM) treatment. A) MSC migration 
in response to chemerin or IGF-II (100 ng/ml) was inhibited by MIF (200 ng/ml). B) 
ISO-1 increased chemerin-stimulated MSC migration in a dose-dependent manner 
and C) ISO-I reversed the effect of MIF on chemerin-stimulated migration.  Horizontal 
arrows, p<0.05, ANOVA; vertical bars, SEM. 
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Figure 5.3 In Boyden chamber assays, MSC migration in response to chemerin was 
significantly increased by MIF knock-down. A) Western blots showing MIF knock-
down in MSC cell extracts after siRNA treatment. B) MSC migration in response to 4 
ng/ml, but not 20 ng/ml, chemerin was increased by MIF knock-down. C) ChemR23 
knock-down decreased MIF release in response to chemerin. D) MSC migration in 
response chemerin (4 ng/ml) was decreased after chemR23 knock-down in MSCs but 
was increased by ISO-1 (50µM).  Horizontal arrows, p<0.05, ANOVA; vertical bars, 
SEM. 
 
 
 
 
A 
B 
C D 
Identification of MIF as a Chemerin Target in MSCs and its Functional Significance 
124 
 
5.4 Discussion 
 
Initial proteomic studies using SILAC identified increased MIF in chemerin- 
stimulated MSC media. The main point of the work in this chapter was to validate 
this observation and explore its biological significance. Thus, studies using ELISA 
and Western blot confirmed an increase in concentration of MIF in media and cell 
extracts of MSCs after chemerin stimulation. Chemerin enhanced OE21 cell 
migration (chapter 3) but, in contrast to MSCs, it did not stimulate MIF secretion in 
these cells, although it should be noted that basal secretion of MIF is already 
relatively high in OE21 cells.  Using siRNA treatments and the antagonist ISO-1 
evidence was obtained to indicate that MIF significantly inhibited MSC migration 
in response to chemerin.  
Interestingly, the present findings indicated that MIF restrained the MSC migratory 
response to relatively low concentrations of chemerin (4ng/ml) but not higher 
concentrations (20ng/ml and 100ng/ml). Presumably, maximal secretion of MIF 
occurs at concentrations of chemerin lower than those that are maximal for 
migration so that relatively strong chemerin stimulation overwhelms MIF-inhibitory 
effects. This finding may be relevant in understanding MSC recruitment in cancer. 
Thus the high concentrations of chemerin in CAM CM promote MSC migration 
while in CM from ATMs and NTMs, where chemerin concentration is lower, MIF is 
able to act more effectively as an auto-inhibitor thereby restraining MSC 
recruitment to normal or preneoplastic tissues (Figure 5.4). 
The proposed role of MIF in the present system would appear to be novel. 
However, the existence of similar phenomena is known for other growth factors in 
cancer biology. Well known example of biphasic roles is TGF-β which at 
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physiological concentrations acts as a negative regulator of proliferation of 
epithelial cells (Blobe, Schiemann et al. 2000). 
 
 
           
Chemerin
MIF
MSC
Blood vessel
Cancer 
cells
Myofibroblasts
Migration
                            
 
Figure 5.4 MSC migration regulated by chemerin.  
Chemerin stimulated MSC migration and MIF secretion. The migration of MSCs was 
inhibited by autocrine release of MIF only at relatively modest chemerin 
concentrations. 
 
However, in cancer the neoplastic cells become insensitive to this inhibitory effect 
of TGF-β and simultaneously increased TGF-β expression promotes tumour 
growth via stimulating cancer cell invasion and metastasis (Maehara, Kakeji et al. 
1999).   
The present functional studies were made using both an antagonist for MIF, ISO-
1 (Dessein, Stechly et al. 2010) and siRNA, knock-down approaches. A 
hydrophobic pocket in MIF constitutes a catalytic domain which is important for its 
tautomerase action on substrates such as asp-hydroxyphenylpyruvic acid. The 
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binding of ISO-1 at the catalytic site abolishes MIF tautomerase activity and 
suppresses the production of cytokines, e.g. TNFα (Al-Abed, Dabideen et al. 
2005). Previously, it was shown that MIF inhibits migration of MSCs and that this 
was rescued by ISO-1 in vitro (Barrilleaux, Phinney et al. 2009), which is in broad 
agreement with the present findings. In addition, though, knock-down studies here 
using validated MIF siRNA also confirmed the inhibitory effect of MIF on MSC 
migration. Intriguingly, ISO-1 rescued chemerin-stimulated migration of MSCs 
pre-treated with chemR23 siRNA. This could suggest chemerin regulation of MIF 
through a mechanism independent of chemR23, for example via GPR-1 or 
CCLR2; or alternatively, it may reflect the fact that MIF is an effective inhibitor of 
MSC migration at low level chemerin stimulation (in this case achieved by 
receptor knock-down). Further studies to clarify this interpretation would be 
useful.  
The functional significance of MIF in oesophageal cancer is not well understood. 
However clinical studies showed increased MIF expression in cancer tissues 
compared to non-cancerous tissues in oesophageal SC by tissue staining and 
RT-PCR for mRNA expression. Moreover, ELISA has shown elevated levels of 
MIF in a SC cell line, Eca-109 (Xia, Zhang et al. 2005), while  MIF has been 
shown to regulate angiogenic factors in oesophageal cancer cells, HKESC-1, 
HKESC-2, such as VEGF and IL-8 suggesting positive regulation of tumour 
growth (Ren, Law et al. 2005).  The current findings using ELISA and Western 
blot suggest that MIF abundance in media and cell extracts from OE21 cells is not 
increased by chemerin. A possible explanation could be that expression levels of 
chemerin receptor, chemR23, that are sufficient to trigger the biological function 
are inadequate for effective regulation of MIF in OE21 cells. More plausible, 
however, is that MIF release is already close to maximal and chemerin stimulation 
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has little or no additional effect. In the future it would be useful to study other 
validated SC cell lines for MIF secretion such as HKESC-1, HKESC-2 (Ren, Law 
et al. 2005) and Eca-109 (Xia, Zhang et al. 2005) to determine whether the 
observations on OE21 cells are representative.  
The current findings suggest MSC responses to chemerin are modulated by 
autocrine effects of MIF and that the relative concentrations of chemerin and MIF 
determine the migratory response. It will now be necessary to establish the in vivo 
significance of these findings in order to better understand the role of chemerin in 
carcinogenesis. Nevertheless the data do raise the interesting possibility of an 
auto regulatory role for MIF production by MSCs that restricts recruitment when 
chemerin concentrations are relatively low (e.g. from normal and preneoplastic 
stromal cells) and which is overcome by high chemerin concentrations.  
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5.5 Conclusions 
 
1. Chemerin effect on MSC is release of chemokine, MIF. 
2. Chemerin stimulated MSC migration was inhibited by MIF. 
3. The regulatory effect of MIF in CM might depend on the relative abundance 
of chemerin to MIF in media. 
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Characterisation of chemerin-stimulated 
transendothelial migration using a 
ChemR23 antagonist 
 
haracterisation of chemerin-stimulated transendothelial migration using a ChemR23 
antagonist 
130 
 
6.1 Introduction 
 
The potential role of chemerin in MSC recruitment to oesophageal cancers was 
raised in chapter 4. Further, MIF expression by MSCs was identified in chapter 5 
as an effect of chemerin which was proposed to supress MSC recruitment to sites 
of moderate or low chemerin production. However, there remains the question of 
whether MSC recruitment by chemerin also includes stimulation of 
transendothelial migration (given that MSCs are presumably recruited from the 
circulation). While this study was in progress a chemR23 antagonist became 
available providing additional opportunities to study the role of chemerin in MSC 
migration and in transendothelial migration in particular. First, however, it was 
considered necessary to establish that the antagonist (CCX832) inhibited 
chemerin effects in the assays that had already been employed in this study.     
The extravasation of MSCs through endothelial monolayers is regarded as an 
integral part of recruitment to tumours. This process is thought to be regulated by 
several factors including MMP-2 and MMP-9 (Vande Broek, Asosingh et al. 2004; 
De Becker, Van Hummelen et al. 2007; Ries, Egea et al. 2007). Previous work in 
our group using SILAC-based proteomics (Holmberg & Varro, unpublished 
observations) identified increased MMP-2 secretion in IGF-II stimulated MSCs.  
IGF-II is a relatively well-established chemotactic growth factor secreted by CAMs 
(Holmberg, Quante et al. 2012), and was shown in chapter 4 to strongly stimulate 
MSC migration. It was therefore hypothesised that chemerin stimulated MSC 
transendothelial migration at least in part by a mechanism involving MMP-2.  
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The present studies made use of the chemR23 antagonist, CCX832, generated 
by a collaborator, Chemocentryx, who generously provided a sample 
(ChemoCentryx 2011). To the best of our knowledge there are, so far, no 
published studies of the effect of chemR23 antagonists in oesophageal SC. 
Hence, CCX832 was used firstly in validation studies employing assays used 
earlier and then secondly to directly study chemerin/ChemR23 interactions in 
MSC transendothelial migration.  
 
6.1.1 Objectives 
The specific objectives were: 
1. To characterise the action of the chemR23 antagonist CCX832 in inhibiting 
chemerin-stimulated MSC and OE21 cell migration in vitro. 
2. To use CCX832 to study the effect of chemerin and CM in stimulating 
transendothelial migration by MSCs using a Matrigel-coated invasion 
chamber.  
3. To determine the role of MMP-2 in transendothelial migration of MSCs in 
response to chemerin. 
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6.2 Material and Methods 
 
6.2.1 Cell culture  
MSCs and OE21 cells were cultured as described in sections 2.3.2 and 2.3.3 
respectively. 
6.2.2 Boyden chamber migration assays 
The effect of CCX832 (0.1nM - 1µM), and a control compound CCX826 (1 µM), 
on MSC and OE21 cell migration was investigated using Boyden chamber as 
described in section 2.6.1.1. The bottom well contained 750µl serum-free media, 
CM from CAM4, chemerin or chemerin-9 (6.25nM of chemerin-9 equivalent to 
100ng/ml chemerin) with or without CCX832 or CCX826.  
6.2.3 Scratch wound healing assays  
Wound healing assays were performed with OE21 cells to determine the effect of 
CCX832 (1 µM) on chemerin-9 stimulated migration (6.25nM) as described in 
sections 2.6.1.2 and 2.6.1.3. 
6.2.4  Labelling of MSCs 
MSCs were labelled using the fluorescent membrane dye, PKH67, and validated 
for functional studies. The labelling has been described in section 2.13.1.3.  
6.2.5 Transendothelial migration assays 
The effect of CCX832 (1µM) and CCX826 (1 µM) on transendothelial migration of 
labelled MSCs across a monolayer of HUVECs overlaid on Matrigel coated 
membrane was investigated using BD BioCoat™ Matrigel™ invasion chambers 
as described in section 2.6.1.3. Furthermore, chemerin-9 (6.25nM) and CAM4  
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CM-stimulated transendothelial migration of labelled MSCs was investigated 
using a chemerin neutralising antibody. The effect of human recombinant MMP-2 
in these assays was studied using specific inhibitor for MMP-2 (MMP-2 inhibitor I) 
(Holmberg, Ghesquiere et al. 2013).  
6.2.6 MMP activity assay 
Enzyme activity assays for MMP-2 were performed using the selective substrate 
MCA-Pro-Leu-Ala-Nva-Dpa-Ala-Arg-NH2 and CM from chemerin-stimulated MSCs 
as described in section 2.18. 
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6.3  Results 
 
6.3.1 The ChemR23 antagonist, CCX832, inhibits chemerin-
stimulated MSC and OE21 cell migration 
Initially, the action of CCX832 against both full length chemerin and its C-terminal 
active fragment chemerin-9 was evaluated in both Boyden chamber and scratch 
wound migration assays. In Boyden chamber assays, chemerin-9 (6.25nM) 
exhibited similar efficacy to the recombinant full length chemerin (100ng/ml) for 
stimulation of MSC migration (Figure 6.1 A). MSC migration in response to 
chemerin-9 was inhibited in a dose-dependent manner by CCX832 (Figure 6.1 B 
& C). At a concentration of 1µM (which was the highest concentration of CCX832 
used) the control compound CCX826 had no effect (Figure 6.1 D). Furthermore, 
CCX832 and AF2325 (chemerin neutralising antibody) also inhibited significantly 
CAM CM-induced MSC migration (Figure 6.1 E). Chemerin-9 stimulation of OE21 
cell migration in Boyden chamber assays was also reversed in a dose-dependent 
manner by CCX832 (Figure 6.2 A & B). Moreover, CCX832 (1µM) and chemerin 
neutralising antibody, AF2325, inhibited CAM CM-stimulated OE21 cell migration 
(Figure 6.2. C). In wound healing assays, CCX832 (1µM) inhibited also OE21 cell 
migration in response to C-9 while the control compound, CCX826, had no effect 
(Figure 6.2 D) 
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Figure 6.1 In Boyden chamber migration assays, the chemR23 antagonist CCX832 
significantly inhibited MSC migration. A) Chemerin-9 (C-9) and mature chemerin-157 
(chemerin) similarly stimulated MSC migration. B) Dose-dependent inhibition of MSC 
migration in response to chemerin-9 by CCX832 (0, 0.1nM, 1nM, 10nM, 100nM, and 
1µM) (n=3). C) Data from panel B with basal subtracted. D) CCX832 (1µM) 
significantly inhibited chemerin-9 stimulation of MSC migration while the control, 
compound CCX826 (1 µM) did not (n=3). E) CCX832 (1µM) and chemerin 
neutralising antibody, AF2325, inhibited MSC migration in response to CAM CM while 
the control compound, CCX826 (1 µM), did not. Horizontal arrows, p<0.05, t- test; 
vertical bars, SEM.   
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Figure 6.2 The chemR23 antagonist, CCX832, significantly inhibited OE21 cell 
migration in Boyden chamber and scratch wound assays. A) Dose-dependent 
inhibition of OE21 migration in response to CCX832 (0, 0.1nM, 1nM, 10nM, 100nM, 
and 1µM). B) The data from panel A with basal subtracted. C) CCX832 (1µM) and 
chemerin neutralising antibody, AF2325, inhibited OE21 migration in response to CM. 
D) In wound healing assay, CCX832 (1µM) inhibited OE21 migration while the control 
compound CCX826 (1 µM) did not. Horizontal arrows, p<0.05, t- test; vertical bars, 
SEM.   
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6.3.2 Chemerin stimulates transendothelial migration of MSCs   
via ChemR23 
MSCs labelled with the membrane-inserting dye, PKH67 (Figure 6.3 A) were then 
used to investigate the ability of MSCs to migrate through a HUVEC monolayer 
(transendothelial migration). First, we confirmed using Boyden chamber assays 
that migration in response to chemerin-9 was similar for labelled and unlabelled 
cells (Figure 6.3 B). Chemerin-9 and CM from CAM4 stimulated transendothelial 
migration of MSCs and in both cases the response was significantly inhibited by 
both CCX832 (1µM) and chemerin neutralising antibody, AF2325 (Figure 6.3 C, D 
& E) while the control compound, CCX826, had no effect (Figure 6.3 D & E).  
6.3.3 Chemerin stimulated transendothelial migration of MSCs 
requires MMP-2 
Previous data indicated expression of MMP-2 by MSCs and increased abundance 
in the media after growth factor stimulation (IGF-II). We considered the possibility 
that chemerin might stimulate MMP-2 release that was required for MSC 
transendothelial migration. Initially, then, enzyme activity was shown to be 
significantly increased in the medium in response to chemerin and IGF-II 
stimulation of MSCs (Figure 6.4 A). Human recombinant MMP-2 was then shown 
to stimulate MSC transendothelial migration and the response was inhibited in a 
dose-dependent manner by a selective MMP-2 inhibitor (MMP-2 inhibitor I) 
(Holmberg, Ghesquiere et al. 2013). Since the MMP-2 inhibitor at 60.18 µM was 
found to have no further inhibitory effect compared to 20.16 µM in human MMP-2 
stimulated MSC migration. (Figure 6.4 B) we used this concentration in further 
studies. Chemerin and IGF-II stimulated MSC transendothelial migration was 
significantly inhibited by the MMP-2 inhibitor at this concentration (Figure 6.4 C).  
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Figure 6.3 The chemR23 antagonist, CCX832, significantly inhibited MSC 
transendothelial migration. A) Representative fields from transendothelial MSC 
migration experiments showing migrating unlabelled (left panel) and labelled MSCs 
(right panel). B) Membrane labelling did not effected MSC migration in response to 
chemerin-9 (C-9) compared to unlabelled MSCs. C) CCX832 and chemerin 
neutralising antibody, AF2325, inhibited MSC transendothelial migration stimulated 
by chemerin-9 D) The inactive compound CCX826 (1 µM) did not affect chemerin-9 
stimulated MSC transendothelial migration. E) Conditioned media (CM) from CAMs 
stimulated MSC transendothelial migration and this was significantly inhibited by 
CCX832 (1µM) but not CCX826 (1 µM). Horizontal arrows, p<0.05, t- test; vertical 
bars, SEM.   
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Figure 6.4 MMP-2 is released by chemerin and stimulates transendothelial migration 
of MSCs.  A) IGF-II and chemerin significantly increased MMP-2 enzyme activity in 
MSC media detected by the selective substrate MCA-Pro-Leu-Ala-Nva-Dpa-Ala-Arg-
NH2. B) MMP-2 stimulates transendothelial migration and there is dose-dependent 
inhibition by an MMP-2 selective inhibitor (MMP-2 inhibitor I). C) An MMP-2 inhibitor 
significantly inhibited IGF-II and chemerin stimulated MSC transendothelial migration. 
Horizontal arrows, p<0.05, t- test; vertical bars, SEM.  
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6.4 Discussion 
In chapters 4 and 5 chemerin-regulated MSC migration was characterised. Since 
circulating MSCs presumably gain access to tissues after crossing the 
endothelium, an assay was then established to study transendothelial migration of 
these cells in vitro. Both chemerin and CM were shown to stimulate 
transendothelial migration of MSCs. Transendothelial migration involves MMP-2, 
and in addition chemerin was shown to stimulate MMP-2 secretion suggesting a 
molecular mechanism for MSC extravasation. Characterisation of a chemR23 
antagonist, CCX832, confirmed the role of chemerin/chemR23 interactions in CM 
and chemerin-stimulated MSC and OE21 migration, and this compound was then 
used to establish a role for these interactions in MSC transendothelial migration. 
The data presented here are the first of their kind to study chemR23 function 
using CCX832 in oesophageal cells and in MSCs. The validation of CCX832 in 
these systems provides a basis for future in vivo studies.   
Transendothelial migration of MSCs requires protease activity for passage of the 
cells across the endothelial barrier. The activity of MMP-2 in MSC media was 
measured using a selective fluorogenic substrate, MCA-Pro-Leu-Ala-Nva-Dpa-
Ala-Arg-NH2, (Holmberg, Ghesquiere et al. 2013) and shown to be increased in 
response to chemerin. Others have previously demonstrated increased MMP-2, 
MT1-MMP and MMP-9 levels in MSCs in response to inflammatory cytokines, 
TNF-α and IL-1β (Ries, Egea et al. 2007). Moreover, these proteases, along with 
protease inhibitor, TIMP-3 regulate the chemotaxis of BM-derived MSCs to the 
matrix environment (De Becker, Van Hummelen et al. 2007; Ries, Egea et al. 
2007). Our findings are in agreement with previous studies showing MMP-2 
induce MSC transendothelial migration (De Becker, Van Hummelen et al. 2007; 
Ries, Egea et al. 2007). Chemerin also increases MMP-2 and MMP-9 in 
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endothelial cells (Kaur, Adya et al. 2010). In the future it will be necessary to 
expand the present studies including, for example, using gelatin zymography to 
determine the ability of chemerin to activate other gelatinases (eg MMP-9) in 
MSCs. There is also a need for Western blots to probe active and inactive MMP-
2, and other MMPs, in both cell extracts and media in response to chemerin.  
In chapters 4 and 5, chemerin-stimulated cell migration was studied using 
knockdown and overexpression approaches. Although the findings were robust 
and reproducible, these approaches do not lend themselves to future studies in 
vivo. However, the use of a chemR23 antagonist, CCX832, suggests a novel 
method to target chemerin-chemR23 interactions involving MSC function in vivo. 
Previously, CCX832 has been used in studies of psoriasis (ChemoCentryx 2011) 
but so far no studies of the compound in cancer have been published. 
Nevertheless the use of other antagonists targeting GPCRs in cancer is well 
established; for example, a recognised target in prostate cancer is the 
gonadotropin releasing hormone receptor (GnRH) which regulates testosterone 
and dihydrotestosterone and can be blocked by antagonists resulting in impaired 
cancer cell proliferation (Cook and Sheridan 2000; Pommerville and de Boer 
2010). Other examples include studies associated with increased chemokine 
CCL5 expression in breast cancers and targeting the receptor, CCR5, by the 
antagonist maraviroc which attenuates invasion of breast cancer cell in vitro and 
in vivo (Velasco-Velazquez, Jiao et al. 2012). In these cases, the targets were 
cancer cells themselves, rather than the tumour microenvironment. 
Our results have shown for first time that blocking chemR23 decreases 
transendothelial migration of MSCs in vitro and clearly it will now become 
interesting and important to devise experiments to test the effects in vivo.  
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The present studies have shown chemerin-stimulated OE21 cell migration was 
also inhibited by CCX832. These findings therefore suggest a potential paracrine 
signalling pathway in oesophageal cancer cells involving myofibroblasts that 
might be exploited therapeutically. Other studies in oesophageal cancer cells that 
involve targeting of GPCRs include the findings of EGF/EGFR transactivation of 
β-adrenoceptors (Liu, Wu et al. 2008) and in particular the demonstration that 
EGF stimulated oesophageal SC cell (HKESC-1) proliferation was inhibited by 
Atenolol and ICI 118,551 which are antagonists of β-adrenoceptor (Liu, Wu et al. 
2008). Although not extensively studied, increased OE21 cell proliferation was 
observed in response to chemerin (data not shown). Thus it would now be 
interesting to study the blocking effect of CCX832 on OE21 cell proliferation in 
response to chemerin. 
These present findings confirm the role of chemR23 in MSC and OE21 cell 
migration and they extend these findings by demonstrating a role in 
transendothelial transit. It now becomes important to ascertain whether chemerin-
stimulated cancer cell migration, or recruitment of MSCs to the oesophageal 
cancer niche, is important in vivo. Xenograft studies in mice using various 
strategies to track MSCs (Kang, Shin et al. 2012) and by targeting ligand-GPCR 
axis or biomolecules modulation may help here (De Becker, Van Hummelen et al. 
2007; Placencio, Li et al. 2010). Moreover, the in vitro validation of CCX832 
provides a platform for future xenograft experiments to study chemR23 more 
generally in tumour growth. These studies are now underway. Potentially the data 
from such studies will indicate whether this is an appropriate candidate for cancer 
drug development.  
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6.5 Conclusions 
 
1. Chem23 antagonist, CCX832, inhibited chemerin-stimulated MSC and OE21 
cell migration. 
2. Chemerin-stimulated transendothelial migration of MSCs was inhibited by 
CCX832. 
3. Chemerin-stimulated secretion of active MMP-2 from MSCs was required for 
MSC transendothelial migration.   
 144 
 
 
 
 
 
 
 
 
7 Chapter 7 
 
 
 
Final Discussion 
Final Discussion 
145 
 
7.1 Overview 
The main findings of this thesis are that (a) oesophageal CAMs are functionally 
distinguishable from their paired ATMs in both SC and AC, (b) conditioned media 
from oesophageal CAMs increases cancer cell migration and proliferation 
compared to CM from ATMs, (c) there is increased chemerin abundance in SC 
CAMs compared to their respective ATMs and (d) chemerin stimulates migration 
of chemR23- expressing MSC and OE21 cells. The migration of MSCs is 
mediated through chemerin-chemR23 dependent activation of PKC, p44/42, p38 
and JNK-II pathways. In addition, (e) chemerin increases MIF secretion by MSCs 
which tends to reduce the migratory response at low chemerin concentrations and 
(f) migration of MSCs across a monolayer of endothelial cells was also stimulated 
by chemerin and required induction of MMP-2. The effect of chemerin MSC 
transendothelial migration was reversed by a chemR23 antagonist, CCX832, 
which provides a basis for future in vivo studies.  
 
7.1.1 Myofibroblasts and the tumour microenvironment 
 
7.1.1.1 CAMs are functionally distinct from ATMs 
 
Morphology and expression of markers such as α-SMA and vimentin confirmed 
the CAMs and ATMs used in the present studies as myofibroblasts.  These are 
phenotypically different from other stromal cells and are considered to be subset 
of fibroblasts (Gabbiani, Ryan et al. 1971). Previously, heterogeneity of 
myofibroblasts has been associated with a role in tissue organisation (Powell et 
al., 1999). The present study on oesophageal myofibroblasts, and previous 
studies of gastric, breast and oesophageal myofibroblasts have shown CAMs to 
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be more aggressive than their corresponding ATMs, or myofibroblasts from 
normal tissue (Holmberg, Quante et al. 2012) (Noma, Smalley et al. 2008; Peng, 
Zhao et al. 2013).. The differences are evident both in vitro, for example with 
respect to proliferation and migration, and in vivo when xenografts composed of  
co-injected cancers cells and myofibroblast/CAMs are studied (Quante, Tu et al. 
2011).  
 
What mechanisms account for the differences between CAMs, ATMs and NTMs? 
Previously, hypomethylation was identified in gastric CAMs which might account 
for differences in gene expression (Jiang, Gonda et al. 2008) and in protein 
secretion (Balabanova 2012). In addition, the profiling of miRNA in gastric 
myofibroblasts showed differential regulation in CAMs which might change protein 
expression (Wang, 2013). At the phenotypic level, the activation of proteolytic 
systems (Bernstein, Twining et al. 2007; Holmberg, Ghesquiere et al. 2013),  
differences in NHE1 activity (Czepan, Rakonczay et al. 2012) and in IGF-II 
secretion (Grotendorst, Rahmanie et al. 2004) could all contribute to increased 
myofibroblast proliferation and migration. 
 
Because myofibroblasts critically influence the microenvironment it seems 
possible that they are rate limiting factors in determining disease progression via 
their rich pool of extracellular secreted proteins involved in autocrine and 
paracrine signalling (Powell, Mifflin et al. 1999; Kalluri and Zeisberg 2006; Hinz, 
Phan et al. 2007). In addition, the recent recognition of polyclonal tumour origins 
was hypothesised to be due to paracrine signalling from secreted factors such as 
Wnt-1 from myofibroblasts (Thliverisa A. T. et al. 2013). Collectively, these 
signalling mechanisms control the growth and invasiveness of cancer cells, 
infiltration of MSCs, and differentiation of various cells including myofibroblasts 
Final Discussion 
147 
 
themselves (Hinz, Phan et al. 2007; De Wever, Demetter et al. 2008; Quante, Tu 
et al. 2011). 
 
7.1.1.2 Differential secretory profile of CAMs vs ATMs: chemerin is a 
novel example 
 
Proteomic analyses of CM from oesophageal myofibroblasts (Holmberg & Varro, 
unpublished data) have revealed an impressive array of secreted proteins. The 
list includes families of proteases, chemokines and inflammatory cytokines that 
could play crucial roles in cancer progression. Other studies have shown 
increased SDF-1 in CAMs that might encourage angiogenesis and tumour growth 
as well as MSC recruitment (Orimo, Gupta et al. 2005; Quante, Tu et al. 2011; 
Jung, Kim et al. 2013). Similarly, compared to NTMs increased Wnt-2 was 
reported in oesophageal CAMs and shown to regulate the invasiveness of cancer 
cells (Fu, Zhang et al. 2011). The present validation of a novel target in the 
oesophageal CAM secretome, chemerin, should therefore be seen as a further 
(previously unsuspected) example of differential expression of signalling 
molecules. Interestingly, there was no marked difference in chemerin transcripts 
observed in microarray datasets suggesting the existence of post transcriptional 
mechanisms regulating expression, possibly due to differential miRNA expression 
(Wang 2013). There is extensive evidence of post-translational processing of 
chemerin that determines biological activity. The precise processing mechanisms 
in myofibroblasts have not yet been addressed and this question should now be 
resolved. However, prochemerin is known to be processed by various enzymes, 
such as elastase, tyrptase, and plasmin at least some of these may also be 
produced by myofibroblasts indicating that the machinery for post-translational 
processing is present in these cells (Du and Leung 2009). Interestingly, chemerin 
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was not detected in adenocarcinoma myofibroblasts despite the presence of gene 
transcripts. This might be attributed to its complete enzymatic degradation in AC 
and studies of these are now required. 
 
7.1.2 Biological outcomes of chemokine-ChemR23 interactions 
 
7.1.2.1 Chemokine-ChemR23  
 
Recruitment of inflammatory cells and MSCs is an important step in inflammation-
driven cancers and is orchestrated to a large extent by chemokines. Chemokines 
such as SDF-1/CXCL12 (Levesque, Hendy et al. 2003) and MCP-1 to MCP-4 
(Uguccioni, D'Apuzzo et al. 1995) are recognised as potent chemoattractants. 
Studies have also demonstrated chemokine (C-C motif) ligand 2 (CCL-2)/MCP-1 
(Lin, Chuang et al. 2012) and SDF-1/CXCL12 derived from CAMs (Orimo, Gupta 
et al. 2005) could interact with epithelial and other stromal cells in 
microenvironment, macrophages and endothelial cells. The interaction is crucial 
for triggering cell proliferation, angiogenesis and downstream activation of other 
chemokines, cytokines and proteases (Balkwill 2004).  
 
In this study, chemerin was confirmed to be approximately equally efficacious as 
IGF-II as a chemoattractant for MSCs and cancer cells. Nevertheless the function 
of chemokines is not restricted to chemotaxis. Indeed, chemerin has been shown 
to be responsible for cell differentiation and proliferation as well (Muruganandan, 
Roman et al. 2010; Yang, Li et al. 2012). For example, chemerin induces 
adipocyte differentiation, clonal expansion, and basal proliferation of bone marrow 
MSCs (Muruganandan, Roman et al. 2010; Muruganandan, Parlee et al. 2011). 
Stimulation of proliferation was not studied in detail, but chemerin shown in pilot 
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experiments to increase cancer cell proliferation. In addition, differentiation of 
MSCs into adipocytes was confirmed in response to chemerin (data not shown). 
In addition, in response to CAM CM and chemerin, the specific marker study of 
osteogenic (Alizarin Red staining), chondrogenic (Alcian Staining) and adipogenic 
(Oil Red O) differentiation of MSC might suggest chemerin inducing differentiation 
capability. However, the relevance of this findings remains uncertain given that in 
oesophageal cancer adipocytes in the stromal environment are unlikely to be 
functionally important, in contrast to some other cancers notably breast cancer 
(Dirat, Bochet et al. 2011).  
 
The GPCRs, chemR23 and GPR1, have previously been shown to interact with 
chemerin in various cell types (Barnea, Strapps et al. 2008; Huang, Zhang et al. 
2010). Other studies showed chemerin also binds efficiently to CCLR2 (Zabel, 
Nakae et al. 2008; Otero, Vecchi et al. 2010). In this study, chemR23 and GPR1 
expression was confirmed at the transcript level, and also by 
immunohistochemistry, in MSCs and oesophageal cancer cells. However, the 
functionally significant chemerin interaction was shown to be with chemR23. 
Although interactions with the two receptors might have varying biological 
significance the current findings indicate that chemerin stimulation of MSC 
migration requires only chemR23. Other studies also confirmed the 
chemerin/chemR23 axis is primary to transduce signals and to execute the cell 
functions (Huang, Zhang et al. 2010). Despite equal binding affinity to GPR1 and 
CCLR2, it may be that these only amplify the preceding effects on chemotaxis for 
example by increasing local availability of chemokine to cells expressing primary 
receptors (Zabel, Nakae et al. 2008; Otero, Vecchi et al. 2010). 
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7.1.2.2 Chemerin signalling in migration 
 
The various downstream pathways involved in chemokine signalling include 
activation of PKC, PI3K/Akt, MAPK, Src, and Jak/STAT and activation of Rac and 
Rho GTPase (Raftopoulou and Hall 2004; O'Hayre, Salanga et al. 2008). 
Chemerin triggers p44/42 and Akt in chrodocytes (Berg, Sveinbjornsson et al. 
2010), and p44/42, p38 and Akt in fibroblast-like synoviocytes (Kaneko, Miyabe et 
al. 2011); it also increases calcium influx and inhibits cAMP in endothelial cells 
(Hart and Greaves 2010) all linked to cell motility. Here, chemerin induced MSC 
cell migration via increased phosphorylation of p44/42, p38 and JNK-II, while  
PI3k/Akt was not crucial for chemotaxis notwithstanding the finding that PI3K and 
Akt are considered key signalling mediators in adhesion of macrophages (Hart 
and Greaves 2010). Chemerin increases calcium influx and triggeres MAPKs 
pathways via Gi family members regulating dendritic cell chemotaxis (Wittamer, 
Franssen et al. 2003). It would be worth examining the role of calcium influx in 
MSCs in the future. The activation of p44/42, p38 and JNK-II was presumably part 
of a cascade following PKC activation as occurs  in various other cell functions 
including migration (O'Hayre, Salanga et al. 2008). Pharmacological inhibitors 
showed partial PKC-dependent downstream MPAKs activation, but there also 
seems to be PKC independent responses that sustain activation. This raises the 
possibility of cross talk following transactivation of RTK downstream of GPCR 
activation which should be further studied. In this context, and based on earlier 
studies of chemokine/GPCR interaction, it would be useful to determine whether 
there is activation of proteases such as ADAM’s that cleave and release active 
EGF ligands to trigger intracellular pathways via EGFR (Gschwind, Zwick et al. 
2001).  
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7.1.2.3 Chemerin, cytokines and proteases 
 
Chemerin is known to enhance chondrocyte chemotaxis via increased secretion 
of TNF-α, interleukin-6 and interleukin 8 (Berg, Sveinbjornsson et al. 2010). Other 
studies have confirmed TNF-α and IL-6 strongly stimulate MSC migration (Fu, 
Han et al. 2009; Anton, Banerjee et al. 2012). Chemokines such as osteopontin 
have also been shown to induce MSC-derived CCL5 to enhance migration and 
increased cancer cell invasion (Mi, Bhattacharya et al. 2011). In the present 
study, chemerin was shown to target MIF and MMP-2 in MSCs, which has not 
been previously demonstrated (Figure 7.1).   
The inflammatory cytokine, MIF, exerts a dual role both intracellular and 
extracellular which are considered to be anti- and pro-tumorigenic, respectively 
(Verjans, Noetzel et al. 2009). This is reminiscent of the dual function of TGF-β 
which inhibits cell migration in normal tissue, but in cancer it acts as a tumour 
enhancer (Derynck, Akhurst et al. 2001).  The present in vitro findings indicated 
that MIF inhibition of MSC migration was exhibited only at moderate chemerin 
concentrations. This suggests the strength of the stimulus provided by chemerin 
decides the degree to which MSCs are recruited.  
It is well-known that for cells to cross the endothelial monolayer (either in 
recruitment or in metastatic migration) there is a requirement for MMP activity 
(Przybylo and Radisky 2007). Chemerin was shown to induce MMP-2 secretion in 
MSCs, which extends studies showing stimulation of MMP-1, MMP-3, MMP-8 and 
MMP-13 (Berg, Sveinbjornsson et al. 2010) and MMP-9 (Kaur, Adya et al. 2010) 
in other cells. 
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Previously MMP-2 and also MMP-14 were shown to be crucial for MSC migration 
in vitro (De Becker, Van Hummelen et al. 2007; Lu, Li et al. 2010). MMP-2 targets 
laminin and collagen which are constituents of BM and ECM (Giannelli, Falk-
Marzillier et al. 1997). Moreover, the co-localisation of MMP-2 with integrin has 
been shown at the leading edge of the migrating cells (Ogier, Bernard et al. 
2006). A similar mechanism is considered to control the MSC migration across 
endothelial monolayers and suggests a mechanistic target for in vivo MSC 
homing in microenvironment. The existence of other proteases in this process 
cannot be ruled out. For example, MMP-9 and MMP-14 shown to increase cell 
migration via interacting with integrin (Egeblad and Werb 2002; Sabeh, Ota et al. 
2004).  
Chemerin
MSC
Cancer cells
Myofibroblasts
Migration
MIF
MMP-2
Blood vessel
 
 
 
 
Figure 7.1 Novel stromal cell signalling for MSC migration.  
Schematic showing cancer associated myofibroblasts secretion of chemerin and 
stimulation of MSC migration via chemR23. The chemerin/chemR23 interaction 
activates PKC and MAPKs pathways. Chemerin targets in MSCs include MIF and 
MMP-2 which enhance transendothelial migration. 
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7.1.2.4 Targeting chemerin-ChemR23 interactions 
 
The identification of chemokine-receptor interactions opens up the prospect of 
therapeutic intervention. For example the antagonist maraviroc for CCR5 
decreases tumour growth in response to CCL5 (Velasco-Velazquez, Jiao et al. 
2012). In this study, the chemR23 antagonist, CCX832, was shown to significantly 
inhibit chemerin stimulated MSC and cancer cell migration. Very recently, the 
supplier of CCX832, ChemoCentryx, have reported that this compound 
antagonises the effect of chemerin in stimulating human monocyte migration 
(Watts, Dorrance et al. 2013). The binding affinity of CCX832 was significantly 
higher for  chemR23 than GPR1 and CCLR2, (Watts, Dorrance et al. 2013) 
thereby confirming its specificity. Together these two studies provide a platform 
for future in vivo work. In particular it now becomes possible to address the 
specific question of whether chemerin acts as a chemoattractant for MSCs in 
vivo, as well as more generally to determine whether chemerin influences tumour 
progression.  
7.2 Methodology 
The strong positive correlation of increased CAMs and tumour growth has been 
established (Orimo and Weinberg 2006).  The use of primary cells in our research 
is considered to provide advantages over immortalised myofibroblasts and 
fibroblast cell lines (Pan, Kumar et al. 2009). There are limitations, however; using 
primary cells for research tends to be associated with small sample sizes and 
limited life span (passages) of the cells. There is also a concern that even primary 
myofibroblasts may have adapted to culture conditions. Nevertheless several 
studies have shown that co-injection of CAMs and cancer cells in mice stimulates 
xenograft growth supporting the idea that CAMs do indeed promote cancer 
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progression and that this property is retained when the cells are expanded in vitro 
(Hwang, Moore et al. 2008; Holmberg, Quante et al. 2012).  
 
The identification of chemerin abundance was by the robust proteomic technique 
of iTRAQ (Holmberg & Varro, unpublished observations). Further, Western blot 
and ELISA was used to validate chemerin abundance in cultured myofibroblast 
cell extracts and media. Other approaches, such as IHC for primary tumour 
tissues would provide data on protein expression in tissues. The exploitation for 
selective cell type from clinical samples for gene expression could provide better 
chances for prognostic and diagnostic markers. For studies of the expression of 
specific genes in a defined cell type in a clinical samples, it would be possible to 
use laser capture microdissection (Gillespie, Ahram et al. 2001).  This allows 
targeting of  cells with defined properties and that after microdissected can be 
processed for either gene microarray or RT-PCR (Bonner, Emmert-Buck et al. 
1997).  
 
The present study made extensive use of different in vitro assays for proliferation 
and migration of cells in response to CM. The proliferation was studied by 
labelling cells in S phase (EdU incorporation). Migration was studied both by 
Boyden chamber and by wound healing assays. The cell functions of proliferation 
and migration reflect integrative responses of host cells (Teoh and Anderson 
1997). However, it would be useful to extend this to the study of cells in ECM. 
Thus an in vitro 3D culture system might be an approach to investigate cell 
behaviour in response to environment mimicking the possible tissue 
physiology/pathology (Noma, Smalley et al. 2008; Kimlin, Casagrande et al. 
2013). 
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There is ample scope for further studies of in vivo tumour growth using imaging 
methods that might extend the current in vitro findings. Mice transgenic for GFP 
expressing bone marrow can be used to provide evidence of homing of BM-MSCs 
(Quante, Tu et al. 2011; Lecomte, Masset et al. 2012). Simultaneously, the 
tumour can be grown and accessed for increased cancer cell population by co-
injection of transfected cancer cells for red fluorescence e.g. (renilla luciferase-
monomeric red fluorescence reported gene) (Wang, Cao et al. 2009) and 
myofibroblasts. There are also future prospects for the use of knockout mice for 
chemerin and chemR23. In response to chemerin the recruitment of NK cells, and 
dendritic cell have been studied in chemR23
-/-  
mice for inflammation and tumour 
model (Luangsay, Wittamer et al. 2009; Pachynski, Zabel et al. 2012).  The 
mouse chemR23 expressing dendritic and macrophages were shown to respond 
to human and mouse chemerin  equally confirming the conserved chemerin and 
chemR23 cell signalling system homologous to human (Luangsay, Wittamer et al. 
2009). Double transgenic mice for chemR23
-/-  
and GFP-BM-MSCs would provide 
a strong tool to study the recruitment of MSC in response to tumours harbouring 
primary myofibroblasts. 
 
7.3 Future prospects 
In this thesis the ligand-receptor interaction identified in vitro provides a notion of 
homing of MSCs, with extended scope of specific receptor and ligand which might 
be a potential therapeutic target. Orthodox conventional chemotherapy using 
single cytotoxic agents were ineffective in oesophageal tumours, thereby, later 
combinational therapy was carried out. Such as a combination of Cisplatin/5-FU, 
and Epirubicin/Cisplatin/5-FU are recently being used in clinical trial stage II and 
III respectively in oesophageal squamous cell carcinoma (Ross, Nicolson et al. 
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2002; Nishimura, Hiraoka et al. 2012). The advancement in molecular 
oncogenesis provided better therapeutics opportunities by targeted therapy 
chemotherapy. Such example includes targeting receptors, e.g. EGFR, with 
monoloclonal antibodies and Gefitinib, however was not impressively effective 
against oesophageal SC in clinical trial II (Janmaat, Gallegos-Ruiz et al. 2006; 
Ilson 2008). Others examples of molecular targets are VEGF, HGF, and COX-2 in 
oesophageal SC with inhibitors in clinical trial phase I/II (Tabernero, Macarulla et 
al. 2005; Tew, Kelsen et al. 2005; Ilson 2008; Hong, Wo et al. 2013). The small 
molecule drugs and targeted therapy proved to be efficient and at least 
circumvent the conventional problem over using cytotoxic drugs. Hence, the novel 
target in oesophageal squamous cancer, chemerin-chemR23 axis with available 
small molecule drug, CCX832 might holds a great promise in oesophageal cancer 
treatment. However, in this research the significance of chemerin-chemR23 
interaction was established using small sample size. Heterogeneity in patient 
population and their individual response to treatment is always a challenge to 
benefit from specific treatments.  Therefore, large panel of pre-clinical and clinical 
studies are further required to introduce CCX832, as potent drug in the cancer 
treatment.  
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Figure 1. α-SMA staining identified myofibroblasts in increased numbers, and with 
disordered morphology in oesophageal  adenocarcinoma cancer and squamous 
cancer. Myofibroblasts in a oesophageal A) adenocarcinoma and B) squamous 
cancer. Myofibroblast morphology in adjacent tissue (ATM) from the same patients 
C) adenocarcinoma and D) squamous cancer. Arrows indicate α-SMA positive 
myofibroblasts (brown). E and F) Quantification of myofibroblast morphology, 
architecture and number in cancer, and adjacent tissue. The scoring system for 
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myofibroblast morphology was: 0, normal; 1, mildly distorted; 2, severely distorted. 
Myofibroblast architecture was scored: 0, restricted to periglandular or subepithelial 
localisation; 1, both in periglandular/subepithelial regions and elsewhere in the 
interstitium; 2, severe architectural damage with meshwork-like appearance. 
Myofibroblast number was scored: 0, as NTMs; 1, mild to moderately increased; 2 
substantially increased. For the histopathological assessment, myofibroblasts were 
defined as stellate/spindle-shaped cells with consistent α-SMA and vimentin 
coexpresssion. Smooth muscle fibers were excluded based on their characteristic 
morphology. * p<0.05, n=7. 
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Uniprot ID Name 
Relative change CAM vs ATM 
Patient  #1 Patient  #2 Patient  #3 Patient  #4 
Q99969
Chemerin (Retinoic acid 
receptor responder protein 
2)
1.66 4.63 1.83 4.7
A. MRRLLIPLAL WLGAVGVGVA ELTEAQRRGL QVALEEFHKH PPVQWAFQE
SVESAVDTPF PAGIFVRLEF KLQQTSCRKR DWKKPECKVR PNGRKRKCLA
CIKLGSEDKV LGRLVHCPIE TQVLREAEEH QETQCLRVQR AGEDPHSFYF
PGQFAFSKAL PRS
Red – identified in 4 patients
Green – identified in 1 patient
Table 1.
 
     
Table 1. iTARQ identified chemerin as upregulated in media in all 4 CAMs 
compared to ATMs.  A) Tryptic peptides in chemerin identified by iTRAQ in 4 
(red) and 1 (green) patients. 
 
 
 
 
Isobaric tagging for relative and absolute quantitation (iTRAQ) 
Myofibroblast media was concentrated to 500 µl and 80µg of protein was 
precipitated in cold acetone, reduced with 2µl 50mM tris-(2-carboxyethyl) 
phosphine (TCEP) at 60
o
C for one hour and alkylated with 1µl 200mM methyl 
methanethiosulfonate (MMTS) for 10 min at room temperature. Samples were then 
digested using 8 µg sequencing-grade modified trypsin overnight at 37
o
C. The 
iTRAQ tag reagents were prepared by adding 70 µl ethanol to the samples and 
incubated for 1 h at ambient temperature. Samples were then mixed and dried by 
vacuum centrifugation to less than 30 µl. Protein samples labelled by iTRAQ were 
diluted to 2 ml with 25% v/v ACN and pH adjusted to less than 3 with H3PO4. The 
sample was then loaded onto a PolyLC PolySULFOETHYL A (4.6 x 200mm i.d.) 
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cation exchange (CEX) column using an Agilent 1100 HPLC system. Fractions (27) 
were collected and dried by vacuum centrifugation. Samples were then 
resuspended in 5% v/v ACN, 0.05% w/v TFA and loaded onto a PepMap C18 
(75µm x 180 mm i.d.) reverse phase column with C18 Trap (300 µm x 5 mm i.d.) 
using an LC Packings Ultimate nano-LC system run in-line with an Applied 
Biosystems QStar Pulsar mass spectrometer via a nano-electrospray source head 
and 10µm inner diameter PicoTip (New Objective, Massachusetts, USA). Spectra 
from both MS and MS/MS were acquired using an information-dependant 
acquisition (IDA) in positive ion mode. Protein identification and quantification were 
performed using the ProteinPilot
TM
 v3.0.1 software (Applied Biosystems; MDS-
Sciex). The Paragon algorithm was selected as the default search program, with 
the digestion agent set as trypsin and cysteine modification as methyl 
methanethiosulfonate. Only proteins with an identification confidence of at least 
95% based on the assignment of at least two tryptic peptides, and a local FDR 
calculated using the PSPEP algorithm of <1%,  were reported. Differentially 
abundant proteins were defined as having a fold change of 1.5 or more, and an 
associated p-value of <0.05.  
 
